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Summary 
Secondary lymphoid organs, such as lymph nodes or spleen, are the only places in our body where 
primary adaptive immune responses are efficiently elicited. These organs have distinct B and T cell rich 
zones and T lymphocytes constantly migrate from the bloodstream into T zones to scan dendritic cells 
(DCs) for antigens they present. Specialized fibroblasts, the T zone reticular cells (TRCs), span the T zone 
in the form a three-dimensional network. TRCs guide incoming T cells in their migration, both 
chemically, by the secretion of the chemokines CCL19 and CCL21, and physically, by construction of a 
road system to which also DCs adhere. In this way TRCs are thought to facilitate encounters of T cells 
with antigen-bearing DCs and thereby accelerate the selection of rare antigen-specific T cells. The 
resulting T cell activation, proliferation and differentiation all take place within the TRC network. 
However, the influence of TRCs on T cell activation has so far not been elucidated with the possible 
reasons being that TRCs represent a relative rare cell population and that mice devoid of TRCs have not 
been described. 
To circumvent these technical limitations, we established TRC clones and lines to have an abundant 
source to functionally characterize TRCs. Both the clones and lines show a fibroblastic phenotype, 
express a surface marker profile comparable to ex vivo TRCs and produce extracellular matrix molecules. 
However, expression of Ccl19, Ccl21 and IL-7 is lost and could not be restored by cytokine stimulation. 
When these TRC clones or lines were cultured in a three-dimensional cell culture system, their 
morphology changed and resembled that of in vivo TRCs as they formed networks. By adding T cells and 
antigen-loaded DCs to these cultures we successfully reconstructed lymphoid T zones that allowed 
antigen-specific T cell activation. 
To characterize the role of TRCs in T cell priming, TRCs were co-cultured with antigen-specific T cells in 
the presence antigen-loaded DCs. Surprisingly, the presence of TRC lines and ex vivo TRCs inhibited 
rather than enhanced CD8+ T cell activation, proliferation and effector cell differentiation. TRCs shared 
this feature with fibroblasts from non-lymphoid tissues as well as mesenchymal stromal cells. TRCs were 
identified as a strong source of nitric oxide (NO) thereby directly dampening T cell expansion as well as 
reducing the T cell priming capacity of DCs. The expression of inducible NO synthase (iNOS) was up-
regulated in a subset of TRCs by both DC-signals as well as interferon- produced by primed CD8+ T 
cells. Importantly, iNOS expression was induced during viral infection in vivo in both lymph node TRCs 
and DCs. Consistent with a role for NO as a negative regulator, the primary T cell response was 
exaggerated in iNOS-/- mice. Our findings highlight that in addition to their established positive roles in T 
cell responses TRCs and DCs cooperate in a negative feedback loop to attenuate T cell expansion during 
acute inflammation. 
Résumé 
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Résumé 
Les organes lymphoïdes secondaires, comme les ganglions lymphoïdes ou la rate, sont les seuls sites dans 
notre corps où la réponse primaire des lymphocytes B et T est initiée efficacement. Ces organes ont des 
zones différentes, riches en cellules B ou T. Des lymphocytes T circulent constamment du sang vers les 
zones T, où ils échantillonent la surface des cellules dendritiques (DCs) pour identifier les antigènes qu’ils 
présentent. Des fibroblastes spécialisés – nommés ‘T zone reticular cells (TRCs)’ forment un réseau 
tridimensionnel dans la zone T. Les TRCs guident la migration des cellules T par deux moyens: 
chimiquement, par la sécrétion des chimiokines CCL19 et CCL21 et physiquement, par la construction 
d’un réseau routier en trois dimensions, auquel adhèrent aussi des DCs. Dans ce cas, on pense que la 
présence des TRCs facilite les rencontres entre les cellules T et les DCs chargées de l’antigène et accélère 
la sélection des rares cellules T spécifiques. Ensuite, l’activation de cellules T, ainsi que la prolifération et 
la différenciation se produisent toutes à l’intérieur du réseau des TRCs. L’influence des TRCs sur 
l’activation des cellules T n’est que très peu caractérisée, en partie parce que les TRCs représentent une 
population rare et que les souris déficientes dans les TRCs n’ont pas encore été découvertes. 
Pour contourner ces limitations techniques, nous avons établi des clones et des lignées cellulaires de TRC 
pour obtenir une source indéfinie de ces cellules permettant leur caractérisation fonctionnelle. Les clones 
et lignées établis ont un phénotype de fibroblaste, ils expriment des molécules de surface similaires aux 
TRCs ex vivo et produisent de la matrice extracellulaire. Mais l’expression de Ccl19, Ccl21 et Il-7 est perdue 
et ne peut pas être rétablie par stimulation avec différentes cytokines. Les clones TRC ou les lignées 
cultivées en un système tridimensionnel de culture cellulaire, montrent une morphologie changée, qui 
ressemble à celle de TRC ex vivo inclus la construction de réseaux tridimensionnels.  
Pour caractériser le rôle des TRC dans l’activation des cellules T, nous avons cultivé des TRCs avec des 
cellules T spécifiques et des DCs chargées avec l’antigène. Etonnamment, la présence des TRC (lignées et 
ex vivo) inhibait plutôt qu’elle améliorait l’activation, la prolifération et la différenciation des lymphocytes 
T CD8+. Les TRCs partageaient cette fonction avec des fibroblastes des organes non lymphoïdes et des 
cellules souches du type mésenchymateux. Dans ces conditions, les TRCs sont une source importante 
d’oxyde nitrique (NO) et par ce fait limitent directement l’expansion des cellules T et réduisent aussi la 
capacité des DCs à activer les cellules T. L’expression de l’enzyme NO synthase inductible (iNOS) est 
régulée à la hausse par des signaux dérivés des DCs et par l’interféron- produit par des cellules T de type 
CD8+ activées. Plus important, l’expression d’iNOS est induite pendant une infection virale in vivo, dans 
les TRCs et dans les DCs. Par conséquent, la réponse primaire de cellules T est exagérée dans des souris 
iNOS-/-. Nos résultats mettent en évidence qu’en plus de leur rôle positif bien établi dans la réponse 
immunitaire, les TRCs et les DCs coopèrent dans une boucle de rétroaction négative pour atténuer 
l’expansion des cellules T pendant l’inflammation aigüe pour protéger l’intégrité et la fonctionnalité des 
organes lymphoïdes secondaires.  
Abbreviations 
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Abbreviations 
2D Two dimensional 
3D Three dimensional 
AICD Activation induced cell death 
Aire Autoimmune regulator 
BAFF B-cell activating factor 
BCR B cell receptor 
BEC Blood endothelial cell 
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CCR Chemokine (C-C-motif) receptor 
CD Cluster of differentiation 
CTLA-4 Cytotoxic T lymphocytes associated antigen 4 
CXCL Chemokine (C-X-C-motif) ligand 
DC Dendritic cell 
DEAF-1 Deformed epidermal autoregulatory factor 1 
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MW Molecular weight 
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OT Ovalbumin transgenic 
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1. Introduction: the immune system 
Our health is constantly threatened by a large variety of pathogens. To protect the body against these 
threats we possess a sophisticated weapon: the immune system. The first lines of defense are the epithelial 
surfaces of our body, the skin and the internal epithelial surfaces such as in the gastro-intestinal tract or 
the lung. Epithelial cells are tightly connected and provide an effective physical barrier for pathogens. 
Furthermore, they are reinforced by other mechanisms such as the mucus flow that prevents adherence 
of pathogens or the production of antimicrobial peptides (Hornef et al., 2002; Gallo et al., 2002). The 
second line of defense is the so-called innate immunity, which consists of different cells, such as 
neutrophils, macrophages and dendritic cells (DCs). Part of these cells are constantly monitoring 
peripheral tissues as well as blood for potential dangers. Conserved molecules expressed by pathogens, 
but not host cells, are recognized by ‘pattern recognition receptors’ on the surface of innate immune cells. 
If pathogens succeed to enter the body, patrolling innate immune cells arrive rapidly at the side of 
infection, where they engulf microbes and process them. In addition, chemokines and pro-inflammatory 
cytokines are secreted, which recruit more immune cells to the place of infection and alert the adaptive 
immune system, our third line of defense (Kawai and Akira, 2011; Takeda et al., 2003; Coombes and 
Robey, 2010; Junt et al., 2008). Macrophages and DCs are called antigen-presenting cells (APCs), as they 
present processed antigen in the context of MHC (major histocompatibility complex) class II molecules 
on their surface to T cells. This is crucial to activate them and therefore macrophages and DCs bridge 
innate and adaptive immunity. Besides T cells also B lymphocytes are activated during an adaptive 
immune response (Junt et al., 2008; Randolph et al., 2008; Coombes and Robey, 2010). 
In contrast to the innate immune response, the activation the adaptive immune cells, with the main 
players being B and T lymphocytes, is slow. Each single T or B cell recognizes only one specific antigen, 
with the naïve T cell precursor frequency for a given antigen being in the range of 20-2000 T cells. In the 
case of infection, these rare antigen-specific T cells are spread over all secondary lymphoid organs; have 
to first find the APC in order to be activated. Secondary lymphoid organs, such as lymph nodes, function 
as a meeting point to bring these cells together (Junt et al., 2008). Once lymphocytes productively interact 
with APCs including proper co-stimulation, they expand enormously and differentiate into effector cells. 
The result of a protective immune response is the generation of plasma cells secreting high-affinity 
antibodies, CD4+ T helper cells producing cytokines and CD8+ T cells with cytotoxic activity, which 
together in most cases effectively eliminate the cause of infection. Importantly, during the adaptive 
immune response some lymphocytes differentiate into memory cells. This immunological memory makes 
the adaptive response to secondary infections with the same pathogen faster and more efficient. The 
achievement of good immunological memory and high antibody titres are the goal of most vaccines 
(Williams and Bevan, 2007; Junt et al., 2008; Zhu et al., 2010; Batista and Harwood, 2009; Phan et al., 
2009; Laemmermann and Sixt, 2008). 
Secondary lymphoid organs: structure and function 
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1.1. Secondary lymphoid organs: structure and function  
The organs of the immune system are divided into primary and secondary lymphoid organs. Leukocytes 
are constantly produced in the primary lymphoid organs: the bone marrow (BM) generates B cells and 
innate immune cells and the thymus T cells. Mature, naïve lymphocytes leave the BM or the thymus after 
the completion of their maturation and then migrate constantly between secondary lymphoid organs 
(SLO) by using the bloodstream and lymph (Junt et al., 2008; Cyster, 2005). These organs, such as lymph 
nodes (LNs) or the spleen, serve as meeting points for antigen, APCs and lymphocytes and are the only 
places, where adaptive immune responses are efficiently mounted. This was demonstrated in mice with 
the spontaneous alymphoplasia (aly/aly) mutation, which leads to the complete lack of LNs and Peyer’s 
Patches as well as disturbed splenic architecture. These mice show a severely impaired capability to mount 
efficient adaptive immune responses. Furthermore, reduced SLO integrity in various other mouse models 
was shown to correlate with weaker immune reactivity against viral infection (Karrer et al., 1997; Junt et 
al., 2008; Cyster, 2005).  
SLO are strategically placed in the body and constantly monitor the body fluids for pathogens, thus 
allowing them to sample and concentrate antigen. The spleen surveys blood, LNs filter lymph and 
mucosal-associated lymphoid tissues monitor intestinal and respiratory mucosal surfaces (Cyster, 2005; 
Bajenoff et al., 2007; Junt et al., 2008). All SLO show a similar micro-architecture: They are highly 
compartmentalized and several distinct zones can be distinguished, including the B cell rich B zone (B-
follicle, cortex) and the T cell rich T zone (paracortex) (figure 1.1 right). As most of this thesis is focused 
on LNs, only these will be described in detail.  
Lymphocytes enter the LN via specialized blood vessels, the high endothelial venules (HEV), located 
mostly in the outer T zone. From here B and T cells are attracted by constitutively expressed chemokines 
towards their respective zones: CXCR5+ B cells are attracted to the CXCL13 rich B zone, while CCR7+ T 
cells are retained within the CCL21 and CCL19 rich T zone (figure 1.1 right and 1.6 left) (Cyster, 2005; 
Junt et al., 2008). T and B cells are moving with an average speed of 8-11µm (T cells) or 6µm (B cells) per 
minute and constantly scan the LN for antigen (Mueller and Germain, 2009; Batista and Harwood, 2009). 
If their respective antigen is not presented, they will leave after 12-18h (T cells) or 24h (B cells) through 
efferent lymphatic vessels in the medulla. The exit from SLO is mediated via sphingosine 1-phosphate 
(S1P), which is present in the lymph and interacts with the S1P-receptor 1 that is highly expressed on 
naïve T and B cells (Cyster, 2005) Lymphocytes in the efferent lymphatic vessels will be transported back 
to the bloodstream via the thoracic duct and continue their search for antigen in other SLO 
(Laemmermann and Sixt, 2008; Mueller and Germain, 2009). 
1.2. Stromal cells in secondary lymphoid organs 
The structural backbone of lymphoid organs is made up of radio-resistant non-hematopoietic stromal 
cells (figure 1.1, left). For a long time, these cells were thought to be only of structural importance.  By 
Introduction 
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contrast, various recent reports demonstrated them to create a specific and dynamic microenvironment, 
which is functionally influencing the immune response (Mueller and Germain, 2009; Laemmermann and 
Sixt, 2008; Junt et al., 2008). Besides the endothelial stromal cell populations, different subtypes of 
fibroblastic stromal cells were characterized in various SLO compartments: B zone stromal cells, T zone 
stromal cells as well as the recently identified marginal reticular cells (figure 1.1 right) (Roozendaal and 
Mebius, 2011; Mueller and Germain, 2009). 
 
Figure 1.1: Different LN microenvironments are formed by distinct stromal cells 
Consecutive pLN sections were stained for the hematopoietic compartment (B cells in red; T cells in green) (left) 
allowing to distinguish B cell follicles (B), the T zone (T) and the medulla (M). Labelling with stromal cell markers 
(gp38 in red and CD31 in green) (right) identifies 5 different stromal cell populations: gp38+ CD31+ LECs in the 
medulla and subcapsular sinus (SCS), gp38- CD31+ HEVs mainly in the T zone, gp38+ CD31- TRCs in the T 
zone, gp38+ CD31- MRCs below the SCS and gp38+ CD31- activated FDCs in the B zone. (Picture courtesy from 
S. Favre) 
1.2.1. Endothelial cells 
LNs are connected to both the blood and lymph circulation. Afferent lymphatic vessels draining 
peripheral tissues end in the subcapsular sinus (SCS) surrounding the LN (figure 1.3 left). The lymph 
contains a variety of molecules, such as cytokines or antigen, but also cells such as DCs (Laemmermann 
and Sixt, 2008; Randolph et al., 2008). Lymphatic endothelial cells (LECs) are identified by a combination 
of different surface molecules: CD31, gp38 (glycoprotein38 = podoplanin), Prox-1 (prospero homeobox 
protein 1) and LYVE-1 (lymphatic vessel endothelial hyaluronan receptor). In addition, they typically 
produce the chemokine CCL21 which attracts DCs and promotes their entry into lymphatic vessels 
(Randolph et al., 2008; Laemmermann and Sixt, 2008). Lymph cannot freely enter the LN and is mainly 
canalled around it before being collected in efferent lymphatic vessels localized in the medulla. However, 
part of the lymph enters small microchannels in the T zone, called conduits, which will be discussed 
below.   
Blood vessels present in the LN are mostly the above-mentioned specialized HEVs. Compared to normal 
venules they display special features: they consist of a blood endothelial cell (BEC) layer with plump 
morphology, surrounded by a thick basal lamina and a prominent perivascular sheath or channel (Gretz et 
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al., 1997; Miyasaka and Tanaka, 2004). In addition, several chemokines are displayed by HEVs, some 
constitutively produced by BECs themselves, such as CCL21, while others, such as CCL19 or CXCL12, 
are produced by other cell types and transported to the HEV followed by transcytosis and luminal display 
(Miyasaka and Tanaka, 2004). HEVs in peripheral LN (pLN) express the L-selectin (CD62L) ligand 
PNAd (peripheral-node addressin), while HEVs of mucosal associated SLO, such as mesenteric LN 
(mLN), express the 47 integrin ligand MAdCAM-1 (mucosal vascular addressin cell adhesion molecule 
1). Both play a role in the entry of lymphocytes into the LN, which is mediated by a cascade of events 
(figure 1.2): engagement of CD62L induces slow rolling of lymphocytes on the vessel. In pLN this is 
mediated by CD62L - PNAd interactions, while in mLN by CD62L- and 47 - MAdCAM interactions. 
In the next step, CCL21 on HEV triggers CCR7 on lymphocytes and induces firm adhesion on the vessel 
wall, mostly mediated by LFA-1 – ICAM-1 interactions, which is followed by transmigration of 
lymphocytes into the T zone (Mueller and Germain, 2009; Miyasaka and Tanaka, 2004) 
 
Figure 1.2: A cascade of events is necessary for lymphocyte entry in LN via HEV 
Interactions of CD62L (pLN) and 47 integrin (mLN) with PNAd and MAdCAM, respectively, induce rolling of 
lymphocytes on the vessel wall. In the next step, triggering of CCR7 and/or CXCR4 by CCL21 and CXCL12 leads 
to activation of integrins followed by the firm adhesion mediated by LFA-1 – ICAM-1 interactions eventually 
leading to transmigration across the endothelial barrier. Based on (von Andrian and Mempel, 2003; Miyasaka and 
Tanaka, 2004). 
 
1.2.2. B zone stromal cells 
Follicular dendritic cells (FDCs) are the most studied and most prominent B zone stromal cells (Figure 
1.3 right). They can be identified by the expression of the complement receptor CR-1 (CD35) and -2 
(CD21), ICAM-1 (intracellular adhesion molecule), VCAM-1 (vascular cell adhesion molecule), 
MAdCAM-1, FDC-M1 and -M2 and LTR (lymphotoxin beta receptor) (Allen and Cyster, 2008; Batista 
and Harwood, 2009). In the course of T-dependent B cell responses, some B cells generate germinal 
centres (GCs) in which affinity maturation and class switching takes place (figure 1.6 right). Activated 
FDCs in GCs were shown to up-regulate ICAM-1 and VCAM-1, which was demonstrated to be 
implicated in the survival of GC-B cells (Vinuesa et al., 2010). A unique feature of FDCs is their ability to 
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trap intact antigen in the form of immune-complexes (IC), which can be composed of antigen-antibody, 
antigen-complement or antigen-antibody-complement. ICs are trapped on FDCs by either CD21/35 or in 
a complement-independent way by the Fc receptor FcRIIb (CD32) and are then presented to both, 
naïve and activated B cells (Allen and Cyster, 2008). Interestingly, non-cognate B cells were shown to 
capture IC from SCS macrophages and deliver them to FDCs (Phan et al., 2007). The presentation of IC 
to naïve cognate B cells leads to their activation, though the importance of IC-presentation on FDCs in 
vivo is still debated (Allen and Cyster, 2008; Cyster, 2010). ICs presented by FDCs in germinal centres are 
thought to provide a long-term source of antigen, which plays a role for positive selection and 
competition of B cells while they undergo affinity maturation in germinal centres (Vinuesa et al., 2010; 
Batista and Harwood, 2009; Allen and Cyster, 2008; Tew et al., 2001). Furthermore, FDCs were shown to 
be the main source of CXCL13 in the B zone, which attracts B cells via the chemokines receptor CXCR5 
and possibly also enhances their motility (Allen and Cyster, 2008; Allen et al., 2007)(figure 1.3 right). In 
addition, B zone stromal cells (not only FDCs) are a source of BAFF (B-cell activating factor), a B cell 
trophic factor important for maintaining B cell homeostasis, but also B cell proliferation and 
differentiation (Batista and Harwood, 2009).  
 
 
Figure 1.3: Schematic overview of the cellular composition of the lymph node B zone 
CCR7+ DCs migrating to the LN via afferent lymphatic vessels arrive in the SCS, leave the lymph by migrating  
across the lymphatic cell boundary into the T zone, attracted by the chemokines CCL19 and CCL21. The SCS is 
lined by SCS macrophages, which capture antigen from the lymph and present it to B cells or transfer it into the B 
zone. Furthermore CXCL13 producing MRCs are found underneath the SCS. The B zone itself is spanned by a 
network of CXCL13 producing FDCs. CXCR5+ B cells enter the LN via HEV, travel on the TRC network (not 
shown) to the CXCL13+ B zone in which they migrate along the FDC network and search for antigen.(Cyster, 
2010; Junt et al., 2008; Bajenoff et al., 2006) 
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1.2.3. T zone stromal cells 
The T zone is spanned by a three-dimensional network formed by T zone reticular cells, also called T 
zone fibroblastic reticular cells (TRCs or T-FRCs) (Figure 1.4a). These cells express high levels of gp38 
(podoplanin), ICAM-1, VCAM-1, LTR, PDGFR and . TRCs have myofibroblastic features as shown 
by desmin and SMA (alpha smooth muscle actin) expression as well as their ability to contract collagen-I 
(Link et al., 2007; Tomei et al., 2009b). TRCs are the main source of the homeostatic chemokines CCL21 
and CCL19 in LN which trigger the chemokine receptor CCR7 and thereby attract and compartmentalize 
naïve T cells but also DCs within the T zone (Luther et al., 2000) (Figure 1.4 a,b and 1.5). Furthermore, 
both chemokines were demonstrated to enhance the T cell motility in the T zone and to provide a 
retention signal for migrating lymphocytes (figure 1.5) (Cyster, 2005; Worbs et al., 2008; Pham et al., 2008; 
Mueller and Germain, 2009). In addition, CCR7 triggering was shown to enhance dendrite formation by 
DCs and to positively influence DC maturation (figure 1.5) (Sanchez-Sanchez et al., 2006).  
Link and colleagues demonstrated that TRCs are the main source of IL-7 in LN, with IL-7 being a critical 
survival factor for circulating naïve T cells (Figure 1.4 and 1.5) (Link et al., 2007). But TRCs not only 
influence the hematopoietic compartment in SLO, as in a study from Chyou and colleagues, TRCs were 
shown to produce VEGF (vascular endothelial growth factor), thereby regulating the LN vasculature in 
homeostasis but also inflammation (Chyou et al., 2008).  
TRCs secrete several extracellular matrix (ECM) molecules and this is enhanced in in vitro co-cultures of 
TRC lines with activated lymphocytes or TNF and LT3 (Katakai et al., 2004). In vivo the TRCs 
produced ECM molecules form a unique channel system in LNs, the so-called conduits. These are small 
micro-channels consisting of a collagen I core surrounded by a microfibrillar zone and a basal membrane, 
which are enwrapped by TRCs (Sixt et al., 2005)(Figure 1.4a,b). Conduits connect the SCS with the HEVs 
in the T zone and are thought to act as an information highway for small molecules. First tracer studies 
from Gretz and colleagues demonstrated that high molecular weight (MW) molecules are excluded from 
the LN cortex and are only found in the SCS and the medullary sinuses. In contrast, small molecular 
weight molecules (MW < 40kDa), enter the paracortex and highlight the reticular network (Gretz et al., 
2000). Several chemokines were shown to be rapidly transported to the HEV via the conduits after 
subcutaneous injection. This was confirmed for endogenously produced chemokines, such as MCP-1 
(Gretz et al., 2000; Palframan et al., 2001; Roozendaal et al., 2008; Laemmermann and Sixt, 2008). Most 
of the conduit system is enwrapped by TRCs, but gaps exist, which are mostly occupied with LN-resident 
DCs. It was shown that these DCs can extend protrusions through the basal membrane into the conduit 
and sample antigen from it (Figure 1.4b) (Sixt et al., 2005). Taken together, the conduit system is thought 
to serve as an information highway, which alerts the LN in the case of an infection. Thus, allowing the 
LN to rapidly prepare for the initiation of an immune response (also see 1.3) (Roozendaal et al., 2008). 
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Figure 1.4: Schematic overview of the cellular composition of the lymph node T zone including the 
conduit network 
(a) TRCs in the T zone form an extensive three-dimensional network including the conduit system. The latter are 
micro-channels containing small molecules (MW < 40kDa), such as cytokines or antigen derived from the lymph. 
This allows the rapid transport of these small molecules from the SCS to the HEVs in the T zone. DCs are 
associated with the TRC network and T cells entering the LN via HEVs migrate along the TRC network, thereby 
passing the DCs. (b) TRCs produce the chemokines CCL19 and CCL21, which attract both T cells and DCs. 
Furthermore, CCR7 triggering enhances T cell motility but also increases dendrite formation of DCs and positively 
influences DC maturation. LN resident DCs cover TRC-free spaces on the conduits and extend protrusions into 
these micro-channels, allowing them to sample antigen. In addition, TRCs produce IL-7, which is an important 
survival signals for naïve T cells expressing IL-7 receptor. All three cytokines may be bound to extracellular 
proteoglycans and therefore be spatially restricted close to the source (not shown)(Link et al., 2007; Mueller and 
Germain, 2009; Turley et al., 2010; Lindquist et al., 2004; Sanchez-Sanchez et al., 2006; Sixt et al., 2005; 
Laemmermann and Sixt, 2008). 
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Based on the histological analysis of LN, Gretz and colleagues proposed already in 1996 that the unique 
three-dimensional sponge-like network built by TRCs in the LN might serve as a scaffold to guide 
lymphocyte migration (Gretz et al., 1996, 1997). In 2006 this was experimentally confirmed by Bajenoff 
and colleagues. Using intravital microscopy, migrating lymphocytes were demonstrated to crawl along 
TRC fibres in a random migration. While T cells remain associated with the TRC network and stay in the 
T zone, B cells cross the T-B zone border and ‘jump’ onto the FDC network, which guides their 
migration in the B zone (Bajenoff et al., 2006) 
 
 
Figure 1.5: Summary of TRC influence on T 
cells and DCs 
TRCs are a main source of IL-7 in the LN, which 
is an important survival signal for circulating T 
cells. In addition, TRCs produce the chemokines 
CCL19 and CCL21, which attract and enhance 
the motility of both, T cells and DCs. In 
addition, both chemokines have been implicated 
in survival of T cells and DCs. CCR7 triggering 
in T cells was shown to retain them in the T 
zone, enhancing the time they spend to search 
for antigen. Also maturation, endocytosis and 
dendrite formation of DCs is positively 
influenced by CCL19 and CCL21. (Link et al., 
2007; Pham et al., 2008; Sanchez-Sanchez et al., 
2006; Worbs et al., 2008; Mueller and Germain, 
2009) 
 
1.2.4. Marginal reticular cells 
Katakai and colleagues recently identified marginal reticular cells (MRCs) as a unique mesenchymal 
reticular cell type located underneath the SCS of LNs. As TRCs MRCs express gp38, ICAM-1, VCAM-1, 
LTR and PDGFR, but in addition constitutively express MAdCAM-1, TRANCE and CXCL13. Unlike 
FDCs MRCs are negative for CR1 and FcRII/III. MRCs share some features with stromal organizer 
cells, which are crucial to drive the SLO organogenesis during embryonic development but their precise 
function remains to be elucidated (Katakai et al., 2008; Roozendaal and Mebius, 2011). 
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1.3. The initiation of an adaptive immune response in the LN 
The LN structure was shown to change dramatically following infection. Pro-inflammatory mediators, 
such as MCP-1, produced at the place of infection are rapidly transported via the lymph to the draining 
LN. Using the conduit system in the T zone they quickly reach the HEVs, which is important for 
monocyte recruitment from the blood (Palframan et al., 2001). DCs, that encountered antigen in the 
periphery and are activated by ‘danger’ signals (e.g. TLR stimulation), travel to the draining LN using the 
lymphatics (figure 1.6a) (Randolph et al., 2008). Furthermore, the vessel diameter widens leading to 
increased blood flow. Together with the up-regulated CCL21 expression this increases lymphocyte influx 
into the LN. At the same time, egress of lymphocytes from the LN is shut down. Therefore, a huge 
number of naïve lymphocytes accumulate in the LN, which enhances the probability that antigen-specific 
lymphocyte finds the corresponding APC (Junt et al., 2008).  
1.3.1. Antigen sampling in the LN 
 LNs are very effective in sampling and concentrating antigen, with antigen being delivered by different 
routes: either as soluble antigen passively transported in the lymph or actively carried by cells, such as 
DCs (Randolph et al., 2008; Junt et al., 2008). Soluble antigen in the lymph is transported to the SCS, 
which inner surface is lined by SCS CD169+ macrophages and CD11b+ DCs that both efficiently take 
up antigen. The filtration of the lymph by SCS macrophages was shown to be a crucial event to prevent 
spreading of pathogens into the blood or in the case of vesicular stomatitis virus (VSV) infection into the 
brain (Iannacone et al., 2010; Junt et al., 2007). SCS macrophages can process antigen and directly present 
it to lymphocytes, but were also shown to efficiently shuttle intact antigen from the SCS into the B zone 
by surface mediated molecular transport (Junt et al., 2007; Cyster, 2010). MRCs were proposed to play a 
role in this route of antigen delivery as well, based on their prominent localization below the SCS (Katakai 
et al., 2008). Furthermore, SCS macrophages were shown to capture immune-complexes, which are 
transferred into the B zone and finally displayed by FDCs (Junt et al., 2008). Small molecular weight 
molecules contained in the lymph can enter the LN cortex via the conduit system, as described above. 
LN-resident DCs associated with the conduit system sample this antigen and present it to lymphocytes 
(Sixt et al., 2005). 
The second way of antigen delivery to the LN is the transport by cells, such as DCs. DCs, which are 
known to be the most effective APCs are present in peripheral tissues and ‘stand guard’ to immediately 
catch intruders in the body. In case of an infection DCs will engulf the pathogen, process it and present 
antigen in the context of MHC molecules at its surface. This in combination with pro-inflammatory 
signals leads to the maturation of DCs: the surface expression of MHCI, MHCII and co-stimulatory 
molecules such as CD80 or CD86 are induced, while the capacity for phagocytosis decreases. In addition, 
the chemokine receptor CCR7 is up-regulated allowing maturing antigen-bearing DCs to travel through 
afferent lymphatic vessels to the LN (Randolph et al., 2008). Once in the LNs they first accumulate in 
proximity to HEVs in the outer T zone, but later disperse throughout the whole T zone, where they settle 
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down on the TRC network (figure 1.6) (Lindquist et al., 2004). While DCs are rather sessile cells, their 
dendrites are constantly moving and probing their environment. Due to that DCs were calculated to 
contact approximately 5000 T cells per hour (Miller et al., 2004a). 
 
 
Figure 1.6 Cellular interactions in the LN that lead to the initiation of an adaptive immune response 
(a) Naive recirculating lymphocytes enter the LN via HEVs, then CCR7+ T cells (T) scan the CC21 and CCL19 rich 
T zone for antigen, while CXCR5+ B cells (B) migrate to the CXCL13 rich B zone. Antigen-bearing CCR7+ DCs 
enter through afferent lymphatic vessels and migrate into the T zone via interfollicular regions. SCS lining 
macrophages (M) capture antigen (ag) from the lymph and transport it to the follicles. In addition, conduits 
transport soluble antigen into the T zone and the follicle. (b) After antigen encounter and the appropriate co-
stimulatory signals, T cells start to proliferate and differentiate into effectors cells. Cytotoxic T cells (Tc) migrate to 
medulla, leave the LN through the efferent lymphatics and travel to the place of infection using the bloodstream. 
While some T helper cells (Th) also migrate to the site of infection, others up-regulate CXCR5 and migrate to the T-
B zone border. B cells encounter antigen in the follicles, subsequently up-regulate CCR7 and localize to the T-B 
zone border, where they interact with primed ag-specific T helper cells. Productive interaction with T helper cells 
induces the differentiation of activated B cells into short-lived plasmacells (P) that localize in the medulla. Only few 
primed B cells seed and establish the GCs, where they proliferate and undergo affinity maturation as well as class 
switching to become long lived high affinity antibody producing plasma cells. (Cyster, 2005; Shapiro-Shelef and 
Calame, 2005; Junt et al., 2008; Cyster, 2010). 
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1.3.2. T cell priming 
As described above, naïve T cells are constantly entering the LN via the HEV and scan the LN for 
antigen-bearing DCs (figure 1.4a and 1.6). Multiple signals are needed for T cell priming: the first is the 
triggering of their T cell receptor (TCR) by MHC-peptide complexes and the second is co-stimulation by 
surface receptors and cytokines. The best characterized co-stimulatory pathway is the interaction of 
CD28, expressed on the T cell with CD80 (B7.1) and CD86 (B7.2), which are both up-regulated on 
activated DCs. In addition, cytokines such as type I IFN influences the outcome of T cell priming and 
this will be discussed in detail below (Williams and Bevan, 2007). The use of high resolution imaging of T 
cell APC interactions in vitro revealed the concept of the so-called immunological synapse (IS) formation. 
The IS is a supra-molecular complex consisting of a central TCR-peptide-MHC cluster (cSMAC = central 
supramolecular activation complex), surrounded by a peripheral SMAC (pSMAC) characterized amongst 
others by LFA-1 - ICAM-1 clusters (Fooksman et al., 2010). However, the formation of IS in vivo is still 
under debate (Sumen et al., 2004; Henrickson and von Andrian, 2007). In a first attempt to study T cell 
priming in a more physiological context Gunzer and colleagues used a three-dimensional collagen matrix 
to study T cell priming. Surprisingly, though T cells were efficiently activated, only short-lived and 
transient T - DC interactions could be observed, but rarely stable interactions or IS formation (Gunzer et 
al., 2000). The authors proposed the ‘serial encounter model’: T cells accumulate and integrate activating 
signals during short-lived interactions with APC and are only fully activated after having passed a certain 
threshold (Gunzer et al., 2000; Friedl and Gunzer, 2001). However, the physiological relevance of this 
model was heavily debated, as within SLO collagen fibres are almost completely sheathed from T cells 
(Dustin and de Fougerolles, 2001). As another interpretation of these results Dustin and colleagues 
proposed collagen to be a negative regulator of IS formation. This interpretation could explain why 
collagen and other ECM in LNs are typically not exposed to lymphocytes, but enwrapped by TRCs, in 
contrast to most other tissues (Dustin and de Fougerolles, 2001; Dustin et al., 2001).  
The recent technical development of intra-vital microscopy finally allowed to directly observe T cell 
priming in real time in vivo (Bousso, 2008; Germain et al., 2008). Mempel and colleagues showed that T 
cell activation after subcutaneous injection of peptide-pulsed DCs can be divided into three distinct 
phases: First, T cells and DCs form short-lived interactions, which lead to the up-regulation of the 
activation markers CD69 and CD44 on the T cells. This is followed by the second phase in which T cells 
and DCs from long-lived conjugates leading to interleukin-2 (IL-2) and interferon- (IFN) production by 
primed T cells as well as the up-regulation of CD25. In the third phase T cells dissociate from DCs and 
rapidly proliferate until they leave the LN (Mempel et al., 2004; Henrickson and von Andrian, 2007). 
Depending on the experimental way of antigen-delivery different results could be observed: while antigen 
presented by migratory DCs from the skin induced short-lived and transient interactions, direct targeting 
of LN resident DCs resulted in immediate long-lived interactions (Mempel et al., 2004; Sumen et al., 
2004; Miller et al., 2004b; Shakhar et al., 2005). Overall, a positive correlation seems to exist between the 
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stimulation strength (antigen availability, antigen affinity, co-stimulatory molecules etc.) and the induction 
of long-lasting T-DC interactions (Henrickson and von Andrian, 2007; Bousso, 2008; Germain et al., 
2008). The first phase of short-lived transient interaction could be interpreted as time in which T cells 
gather information about the context of the infection: antigen-density, antigen-affinity, number of APCs 
and other features. This would give T cells the possibility to integrate all these information and might be 
essential for the induction of an immune response versus tolerance. One report using explanted LN 
showed that long-lasting T-DC interactions occurred in immunizing but not tolerizing conditions 
(Hugues et al., 2004). This could not be confirmed in a second study (Shakhar et al., 2005) in which the 
authors used the same system of antigen-delivery as the first report but the imaging was performed in the 
intact LN of the live mouse. 
1.3.2.1 Role of T zone stroma in T cell priming 
Several evidences suggest an influence of TRCs on T cell priming. As described, TRCs physically guide T 
cells in their migration, while DCs are associated with the TRC network (Lindquist et al., 2004; Bajenoff 
et al., 2008). In this way the TRC network ‘forces’ incoming naïve T cells to scan TRC-associated DCs for 
antigen (Luther et al., 2011). In addition, they produce the homeostatic chemokines CCL19 and CCL21, 
which not only influence T cell migration (as described earlier), but also act as co-stimulatory signals in T 
cell activation (Flanagan et al., 2004; Friedman et al., 2006). As described, CCR7 stimulation of DCs 
enhances their maturation, promotes dendrite formation, thereby increasing their surface for antigen 
presentation, and protects the cells from apoptosis (Sanchez-Sanchez et al., 2006; Mueller and Germain, 
2009). During the course of an immune-response the expression of CCL19 and CCL21 appears to be 
down-regulated. This goes along with the down-regulation of the CCR7 receptor on activated T cells. The 
regulation of homeostatic chemokines in the immune response by TRCs might influence the balance 
between retention and egress of activated T cell from the LN (Mueller and Germain, 2009). In addition, 
lymphoid stroma was shown to influence the quality of the immune response. TRCs in mLN but not 
pLN express the vitamin A metabolite retinoic acid which induces on T cells primed in mLN the 
expression of the gut-homing receptors CCR9 and 47 (Hammerschmidt et al., 2008). 
1.3.2.2 T zone stroma as target of viral infection 
Several intracellular pathogens were shown to infect TRCs, a prominent example being lymphocytic 
choriomeningitis virus (LCMV) (Mueller et al., 2007). In this context two different strains of LCMV have 
been examined: LCMV WE leads to acute infection which is effectively cleared, and LCMV clone 13 that 
establishes a chronic infection and generalized immunosuppression (Mueller et al., 2007). Both strains 
infect TRCs but only LCMV WE infection leads to cytotoxic T cell mediated destruction of the TRC 
network, which is inhibited by PD-L1 up-regulation on TRCs in the case of LCMV clone 13 infection 
(Mueller et al., 2007; Scandella et al., 2008). The loss of the splenic TRC network following LCMV WE 
infection was shown to lead to infection-associated immunodeficiency against secondary infections 
(Scandella et al., 2008). This illustrates the likely importance of an intact TRC network for the induction 
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of efficient immune responses. Other pathogens shown to infect TRCs include Leishmania donovani, 
Leishmania major, Simian immunodeficiency virus, Ebola virus, Marburg virus, Lassa virus and murine 
cytomegalovirus (Mueller and Germain, 2009; Junt et al., 2008). One could speculate that destruction of 
the TRC network might be one mechanism exploited by some pathogens to prevent the rapid induction 
of an adaptive immune response.  
1.3.3 T cell differentiation  
Although both CD8 and CD4 T cells need TCR triggering and co-stimulation to be primed, their 
requirement for full activation are distinct. Only short exposure to antigen is sufficient for CD8 T cells to 
initiate their proliferation and differentiation, while CD4 T cells need longer antigen-mediated stimulation 
for sustained proliferation (Williams and Bevan, 2007; Haring et al., 2006; Kaech et al., 2002).  
1.3.3.1. Cytotoxic T cell differentiation 
Naïve antigen-specific CD8 T cells expand dramatically after activation - up to 10.000 fold - (Haring et al., 
2006) before differentiating into cytotoxic T cells. Interestingly, already within the first 1-3 days following 
acute infection, the expansion of cytotoxic T cells, their acquisition of effector function as well as 
memory development are programmed (Williams and Bevan, 2007; Haring et al., 2006). Optimal 
development of cytotoxic T cell responses need the presence of a third signal, besides TCR triggering and 
co-stimulation. This signal can be IL-12, IFN/ or IFN (Williams and Bevan, 2007; Haring et al., 
2006). There is an on-going debate about the need of CD4 T cell help for CD8 T cell responses. There 
exists a negative correlation between high levels of inflammation and the need of T cell help. So far most 
evidence suggests that CD4 help is dispensable for acute CD8 responses in an inflammatory setting, but is 
critical for robust memory formation (Williams and Bevan, 2007; Castellino and Germain, 2006). 
Differentiated cytotoxic T cells leave the inflamed LN and travel to the side of infection. When cytotoxic 
T cells recognize peptide-MHCI complexes on pathogen-infected cells, their cytoskeleton is rearranged 
and a cytotoxic IS with the target cell is formed. As lytic granules are only released in the cleft of the 
cytotoxic IS, killing by cytotoxic T cells is highly specific to infected cells and leaves healthy neighbouring 
cells unaffected (Russell and Ley, 2002; Dustin and Long, 2010). Besides the secretion of effector 
cytokines, such as IFN or TNF, cytotoxic T cells, use two different modes of eliminating target cells: 
Ca2+- dependent perforin/granzyme release or Ca2+-independent FasL (CD95-ligand) mediated killing. 
Both pathways induce apoptosis of the target cells (Russell and Ley, 2002; Barry and Bleackley, 2002; 
Dustin and Long, 2010). After completion of their task – ideally with the pathogen being cleared from the 
body – most cytotoxic effector cells undergo apoptosis, while a small pool of memory cells persists and 
mounts rapid responses following re-exposure to the pathogen (Williams and Bevan, 2007)  
1.3.3.2. T helper cell differentiation 
The differentiation of naïve CD4 T cells into effectors cells is much more complicated than that of CD8 
T cells, as they can differentiate into several distinct T helper (TH) subsets - TH1, TH2, TH17, follicular T 
Initiation of an adaptive immune response 
 
25 
helper cells (TFH) - or into induced regulatory T cells (iTreg). Different subsets produce distinct ‘signature’ 
cytokines and in this way control adaptive immune responses to different pathogens (figure 1.7): TH1 are 
important to control intracellular pathogens, while TH2 are critical for extracellular pathogens, for example 
helminthes. TH17, which were originally identified due to their role in autoimmune diseases, such as 
experimental autoimmune encephalomyelitis (EAE), are also important in the protection against 
microbial challenges, such as extracellular bacteria and fungi. (Zhu and Paul, 2008; Zhu et al., 2010). In 
contrast to the other subsets, CXCR5+ TFH are resident in the B follicle where they provide B cell help. 
They are essential for the generation of plasma cells producing high affinity antibodies and memory B 
cells (Crotty, 2011). iTreg are important for maintenance of self-tolerance as well as for the regulation of 
immune responses and will be discussed in detail below. 
 
Figure 1.7: Naïve T cells differentiate into distinct subsets 
TCR triggering and co-stimulatory signals lead to the expansion and differentiation of naïve T cells. (a) For optimal 
CD8 T cell responses (expansion, differentiation and memory formation) an additional third signal is needed, which 
can be delivered by IL-12, IFN or IFN/. Fully differentiated CD8+ cytotoxic T cell travel to the place of 
infection, where they induce apoptosis in target cells either by the release of lytic granules (containing granzymes 
and perforin) or mediated via the Fas-Ligand pathway. In addition, they secrete cytokines such as IFN or 
TNF/. (Williams and Bevan, 2007; Haring et al., 2006; Russell and Ley, 2002; Barry and Bleackley, 2002) (b) 
Naïve CD4+ T cells have the potential to differentiate into at least 5 different subsets: TH1, TH2, TH17, TFH or iTREG 
dependent on the cytokines present during priming, for example IL-12 and IFN induce TH1 differentiation. For 
each of the subsets master transcription factors have been described, for example T-bet and Stat4 are essential for 
TH1. Recent evidences suggest Blimp-1 to have similar function in CD8 differentiation, however also the 
transcription factors T-bet, Eomes and BCL-6 are important (Belz and Kallies, 2010; Kallies et al., 2009). Each TH 
subset expresses ‘signature’ cytokines, for example IFN production by TH1, and is important in the clearance of 
distinct pathogens (Zhu and Paul, 2008; Zhu et al., 2010; Crotty, 2011). 
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The differentiation into a distinct CD4 subset depends among other factors on the cytokine environment 
during priming, which induces a specific ‘master’ lineage transcription factor determining the fate of a 
primed CD4 T cell (Figure 1.7). However, the differentiation into the CD4 effector lineages is not 
irreversible, as considerable plasticity between the different subsets was described (Murphy and 
Stockinger, 2010). 
1.3.4. B cell activation and differentiation 
The B cell receptor (BCR), in contrast to the TCR, binds intact antigens in their native form.  Different 
cell types were shown to present antigen to B cells: SCS macrophages, DCs and FDCs (Cyster, 2010). 
Two types of B cell antigens exist: T-cell dependent and T cell independent antigens. The latter are 
antigens which cross-link the BCR leading to B cell activation and differentiation into IgM-producing 
plasma cells (Shapiro-Shelef and Calame, 2005). When the BCR recognizes T-dependent antigens in the 
follicle, the B cell up-regulates CCR7, while CXCR5 expression levels remain high (Figure 1.6b). This 
leads to the re-localization of B cells to the T-B border where they encounter primed  antigen-specific T 
helper cells that have up-regulated CXCR5 after TCR triggering (Cyster, 2005). The majority of B cells 
directly differentiates into short lived plasma cells, which localize to the medulla while a fraction of 
activated B cells establishes GCs. During the GC reaction B cells strongly proliferate, accompanied by 
affinity maturation and immunoglobulin class switching, for which the help from TFH is essential (Crotty, 
2011). During the GC reaction long-lived plasma cells producing high-affinity-antibodies are generated 
that leave the LN via efferent lymphatic vessels and home via the bloodstream to the BM and mucosal 
surfaces, where they can reside for years. A second result of the GC reaction are memory B cells (Cyster, 
2005; Shapiro-Shelef and Calame, 2005). 
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1.4. Control of immune responses and tolerance induction  
Antigen receptors of lymphocytes (B and T cell receptor) are generated in a random fashion by V (D) J 
recombination. This process generates specific receptors against millions of potential antigens but at the 
cost of producing self-reactive lymphocytes as well. To prevent autoimmune disease, self-reactive T and B 
cells must be eliminated or silenced. The immune system has developed several ways to ensure this. 
Typically two types of tolerance induction are distinguished: central and peripheral tolerance. Central 
tolerance is established in the BM (B cell tolerance) and the thymus (T cell tolerance). As the work of this 
thesis is mostly focused on T cells, only establishment of T cell tolerance will be discussed in more detail. 
In the thymus T cell precursors that have rearranged their TCR undergo a positive and negative selection 
process. First, they have to recognize self-peptide-MHC complexes with low avidity to be positively 
selected. Second, autoreactive T cells that recognize self-peptide-MHC complexes with high avidity are 
negatively selected (Anderson et al., 2006; Starr et al., 2003; Palmer, 2003). Medullary thymic epithelial 
cells (mTEC) and medullary DCs express a wide range of peripheral tissues-restricted antigens (PTA), a 
process called promiscuous gene expression. The expression of many but not all PTA is regulated by the 
transcription factor autoimmune regulator (Aire). As a consequence absence or mutations in Aire lead to 
the development of autoimmune disease (Anderson et al., 2007; Kyewski and Klein, 2006; Metzger and 
Anderson, 2011). Self-reactive thymocytes whose TCR recognizes these PTA presented by mTEC or 
DCs in the context of MHC molecules, are eliminated (= ‘negative selection’). Though central tolerance is 
quite effective, it is not complete and T cells expressing low-affinity TCR against self-antigen are found in 
the peripheral T cell pool (Kyewski and Klein, 2006). To avoid autoimmunity by these self-reactive T cells 
various peripheral tolerance mechanisms prevent their activation. 
1.4.1. Tolerance induction by T cell intrinsic mechanisms or mediated by DCs 
Early experiments in vitro showed that TCR triggering without co-stimulation leads to a state of 
unresponsiveness to antigen restimulation, termed anergy. More recent studies indicated that it is not only 
the absence of co-stimulation but rather signalling through different receptors, such as the CD28 
homologue CTLA-4 (cytotoxic T-lymphocyte-associated antigen 4) or PD-1 (programmed cell death 1) 
(Walker and Abbas, 2002; Allen et al., 2011; Bour-Jordan et al., 2011; Fife and Bluestone, 2008). In 
addition to anergy, also the induction of apoptosis serves to eliminate self-reactive T cells in a process 
called activation induced cell death (AICD). Experiments with knock out mice showed that among other 
molecules CD95 and IL-2 are crucial for AICD (Walker and Abbas, 2002). 
Dendritic cells play a major role in peripheral self-tolerance induction. DCs constantly capture antigen, 
for example from dying cells, and process it. The presentation of self-peptides as well as harmless 
environmental peptides on MHC molecules in steady-state was suggested to play a major role in 
peripheral tolerance induction. When apoptotic cells containing OVA were injected into mice, DCs took 
up OVA and presented it in the LN to T cells. Transferred OVA-specific T cells proliferated first but 
were then deleted from the mice showing that presentation of self-peptides acquired from dying cells and 
Introduction 
 
28 
presented by DCs in steady-state conditions induces tolerance (Liu et al., 2002; Steinman et al., 2003). 
Studies in which antigen was directly targeted to DCs with or without maturation stimuli indicated that 
the same DC can induce tolerance or immunity depending on its maturation status. These studies made 
use of the endocytosis receptor DEC-205 expressed by LN resident DCs. Antigen coupled to an anti-
DEC-205 antibody is efficiently taken up by DCs and presented by them. Injection of antigen coupled to 
anti-DEC-205 leads to induction of tolerance by clonal deletion: antigen-specific T cells divide several 
times before they are eliminated. In contrast, co-injection of anti-CD40 antibody that induces DC 
maturation leads to a robust immune response (Turley et al., 2010; Steinman et al., 2003). Recently, 
evidence was provided for the existence of suppressive or regulatory DC subsets. These DCs can directly 
inhibit T cell activation by producing suppressive molecules, such as indoleamine 2,3-dioxygenase (IDO) 
or nitric oxide (NO), or indirectly by promoting the development of regulatory T cells (TREG). The 
regulation and development of the regulatory DC subsets is still not fully understood and remains to be 
elucidated (Steinman et al., 2003; Turley et al., 2010; Svensson and Kaye, 2006). 
1.4.2. Regulatory T cells  
TREG are important players ensuring peripheral tolerance: depletion or disruption of TREG function leads 
to development of autoimmune disease in mice and men (Sakaguchi et al., 2008). Natural nTREG arise 
during T cell development in the thymus and are thought to represent a separated lineage to cytotoxic T 
cells and T helper cells. They constitutively express CD4, CD25, CTLA-4 and GITR (glucocorticoid-
inducible tumor necrosis factor receptor). The transcription factor FoxP3 (forkhead box P3) and IL-2 
were shown to be essential for their development and function (Sakaguchi et al., 2008; Bluestone and 
Abbas, 2003; Belkaid and Rouse, 2005; Shevach, 2006). 
However, as described above, naïve peripheral T cells can be converted to so called inducible iTREG in a 
TGF (transforming growth factor beta)-dependent manner, which is greatly enhanced by retinoic acid 
(Allen et al., 2011; Sakaguchi et al., 2008). Though FoxP3 expression in mice correlates with suppressive 
T cell features, this is not uniformly the case in humans (Shevach, 2006). In addition FoxP3- CD4+ IL-10-
producing T cells have been identified (termed TR1), which exert suppressive activity.  In vitro TR1 can be 
generated by antigen stimulation in the presence of IL-10, while in vivo they are produced during certain 
infections (Shevach, 2006). 
TREG show different mechanisms to suppress immune responses: secretion of immune-suppressive 
cytokines, such as IL-10; cell-contact-dependent suppression, for example via CTLA-4; functional 
modification or killing of APC, for example stimulation of DCs to induce their expression of IDO 
(Sakaguchi et al., 2008; Vignali et al., 2008). Besides their role in peripheral tolerance, TREG are important 
to regulate excessive immune responses, thereby preventing tissue-destruction (Belkaid and Rouse, 2005). 
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1.4.3. Stromal cells in SLO as new member of peripheral tolerance promoting cell types 
Only in recent years, different LN stromal cell types were demonstrated to express and present PTAs. 
One of the first observations was made in a study from Lee and colleagues using the iFABP-OVA model, 
in which a truncated OVA form is expressed under the control of the small intestine specific iFABP 
(intestinal fatty-acid binding protein) promoter. Surprisingly, TRCs in non-draining LN showed OVA 
expression and transfer of OVA specific CD8+ T cells (OT-I T cells) led to their clonal deletion (Lee et 
al., 2007; Turley et al., 2010). Several studies showed that multiple PTA are expressed by TRCs under 
steady-state conditions (Turley et al., 2010). Interestingly, not only TRCs but also other LN stroma cells, 
such as LECs, BECs and epithelial cells within the gp38-CD31- population were described to express 
PTA (Fletcher et al., 2010, 2011b; Turley et al., 2010). Promiscuous gene expression by mTEC is in part 
controlled by the transcription factor Aire (Metzger and Anderson, 2011; Anderson et al., 2007; Kyewski 
and Klein, 2006). Though a rare subset of Aire expressing epithelial cells were found in the T zone of 
LNs (Metzger and Anderson, 2011), TRCs, LECs and BECs are negative for Aire but express Deaf1 
(deformed epidermal autoregulatory factor 1) which was shown to upregulate PTA expression. Similar to 
DCs LN stroma cells express TLR 3 but in contrast to DCs stimulation with its ligand led to reduced 
capacity in stimulating T cell proliferation (Fletcher et al., 2010).  
In addition, stromal cells from the spleen have been shown to promote the development of suppressive 
DCs. Svensson and colleagues showed that ex vivo isolated splenic stromal cells support the development 
of CD117+ Lin- precursor cells into IL-10 producing suppressive DCs (Svensson et al., 2004). In another 
report, Zhang and colleagues showed that LPS-activated bone-marrow derived DCs (BMDCs) co-
cultured with cell lines form neonatal splenic stroma induces suppressive DCs in a cell-cell contact 
dependent manner, which produce NO and suppress T cell responses (Zhang et al., 2004). In both 
studies, the splenic stromal cells were only poorly characterized and it is unclear whether these were 
FRCs-like cells or not. The in vivo counterpart of suppressive DCs was identified, though their 
dependency on SLO stromal cells in vivo remains to be elucidated (Zhang et al., 2004; Svensson et al., 
2004; Svensson and Kaye, 2006). 
1.4.4. Regulation of immune responses by mesenchymal stem or stromal cells 
Mesenchymal stem cells (MSCs) were originally described as plastic-adherent stromal cells isolated from 
the BM with the capacity to differentiate into multiple mesodermal lineages, including bone, fat and 
cartilage. Though MSCs show features such as self-renewal and multi-lineage differentiation, it is debated 
whether they truly are stem cells. Therefore it was suggested that the term multipotent mesenchymal 
stromal cells (abbreviation as well MSC) is more accurate (Nauta and Fibbe, 2007; Uccelli et al., 2008; 
Haniffa et al., 2009; Sato et al., 2010). 
In addition to BM, many other tissues contain MSCs, including adult adipose tissue, umbilical cord blood 
and several fetal tissues (Nauta and Fibbe, 2007). So far no unique surface markers for MSCs have been 
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identified, however, they are negative for classical hematopoietic (CD45) and endothelial markers (CD31), 
while they show expression of unspecific markers, such as CD105 or CD44 (Keating, 2006; Nauta and 
Fibbe, 2007; Uccelli et al., 2008). Experimentally, their identity is usually defined by plastic-adherence and 
the capacity to differentiate into osteocytes, adipocytes and chondrocytes (Nauta and Fibbe, 2007). In the 
last 20 years the immune-suppressive features of MSCs were established in many clinical studies, for 
example to suppress graft-versus-host disease (Haniffa et al., 2009; Sato et al., 2010). Different ways of 
MSC-mediated suppression have been described (figure 1.8).  
1.4.4.1. MSC-mediated modulation of DC function  
MSCs were shown to interfere with DC differentiation, maturation and function (figure 1.8b). Co-culture 
of DCs with MSCs decreased their expression of co-stimulatory molecules and pro-inflammatory 
cytokines and skewed their phenotype towards regulatory DCs producing IL-10. These effects are 
mediated by soluble factors, e.g. IL-6, M-CSF, PGE2 (Uccelli et al., 2008; Nauta and Fibbe, 2007). A 
recent report also showed that MSCs decrease the ability of DCs to form productive immunological 
synapses with T cells (Aldinucci et al., 2010). 
1.4.4.2. MSC-mediated suppression of T cell activation 
Numerous reports described the direct suppressive effect of MSCs on T cell activation (figure 1.8a). 
MSCs inhibit T cell proliferation induced by mitogens, anti - CD3/28 antibodies, allogeneic cells or 
antigen presented by APC. Interestingly, inhibition can be mediated by autologous and allogeneic MSCs 
(Uccelli et al., 2008; Nauta and Fibbe, 2007; Sato et al., 2010). Though the mechanism of suppression has 
been studied extensively, it is controversial and incompletely understood. The discrepancies in the 
mechanism of suppression may be due to the isolation of different MSCs types from various tissues as 
well as different culture and stimulation conditions. The lack of unique MSCs markers make it difficult to 
have a clear standard of MSC type, including its differentiation or activation state (Nauta and Fibbe, 2007; 
Uccelli et al., 2008; Sato et al., 2010; Keating, 2006). MSCs show high similarity to ‘ordinary’ fibroblasts 
and several reports showed that fibroblasts isolated from adult tissues indeed showed the same 
suppressive effect on T cell proliferation as MSCs (Haniffa et al., 2007, 2009; Jones et al., 2007). 
Transwell experiments indicate the involvement of cell-cell contact as well as soluble factors. Various 
molecules were shown to be produced by MSCs and to mediate suppression of T cell proliferation, such 
as TGF, IL-10, PGE2, hepatocyte growth-factor (HGF), NO, IDO and others (figure 1.8). Some of 
these factors are constitutively produced by MSCs, while the expression of others such as NO and IDO is 
triggered by soluble factors, such as IFN derived from activated T cells (Uccelli et al., 2008; Sato et al., 
2007; Keating, 2008; Sato et al., 2010). In a recent report MSCs were shown to express TLRs. 
Furthermore, MSC triggering via TLR3 and 4 was shown to reduce the suppression of T cell activation, 
thus suggesting a mechanism of dampening the suppressive capacity of MSCs during infections (Liotta et 
al., 2008). 
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However, blocking studies suggest that not a single factor produced by MSCs is responsible for 
suppression but rather the summary of several factors, though the exact contribution remains to be 
determined. (Uccelli et al., 2008; Nauta and Fibbe, 2007; Sato et al., 2010). Most studies used ex vivo 
expanded MSC, therefore, the physiological role of MSC mediated suppression is not really known. One 
hypothesis is that MSCs create an immune-privileged site in the BM to protect stem cells from potential 
harmful immune responses. In addition, as MSCs are found in the amniotic fluid, fetal blood, umbilical 
blood and other fetal tissues a role in fetal tolerance was suggested (Nauta and Fibbe, 2007).  
 
Figure 1.8: Mechanism of T cell suppression by MSCs 
Different mechanisms have been described that contribute to suppression of T cell activation by MSCs. (a) 
Suppressive factors by MSCs can directly act on the T cells. These factors are either constitutively expressed or 
induced, typically by IFN stimulation. The latter creates a negative-feedback loop, as IFN is produced by activated 
but not naïve T cells. In addition MSCs were implicated in inducing TREG development. (b) Suppressive factors by 
MSCs can indirectly act on T cells such as by altering DC maturation or activity. PGE2 produced by MSCs inhibits 
the differentiation of monocytes into DCs and together with other MSC-produced factors interferes with DC 
maturation. In addition it favours differentiation of immature DCs into regulatory IL-10 producing DCs (Uccelli et 
al., 2008; Nauta and Fibbe, 2007; Haniffa et al., 2009; Sato et al., 2010). 
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1.5. Three dimensional cell cultures as basis for the establishment of an artificial 
LN 
Most laboratories culture cells in conventional two-dimensional (2D) cell culture dishes. However, in vivo 
cells are embedded in a three-dimensional (3D) environment made by ECM molecules and resident 
stromal cells. To combine the advantages of in vitro culture, such as the ease of manipulation, with a more 
in vivo like environment, various 3D cell culture systems have been established (Pampaloni et al., 2007; 
Pedersen and Swartz, 2005; Haycock, 2011). Comparison of cells cultured in 2D or 3D revealed 
differences in morphology, matrix adhesion, cellular migration strategies, gene and protein expression 
(Pedersen and Swartz, 2005; Grinnell, 2003; Griffith and Swartz, 2006; Rhee, 2009). One simple approach 
to culture cells in 3D is to embed them in collagen gels, often mixed with other ECM molecules, such as 
the commercially available matrigel, that is a mix of basement membrane proteins produced by the tumor 
line EHS, such as laminin and collagen IV (Kleinman and Martin, 2005). However, matrix composition as 
well the physical properties such as the stiffness influence the cell behaviour. For example, depending on 
the matrix stiffness fibroblasts cultured in collagen gels show different cell morphology ranging from 
dendritic to bipolar appearance (Griffith and Swartz, 2006; Grinnell, 2003; Rhee, 2009; Kobayashi and 
Watanabe, 2010). 
The culture of cells in 3D systems is the basis for the development of artificial organs in vitro and in vivo. 
Reconstruction of lymphoid tissues in vitro is of great interest, as it would allow the study of 
haematopoiesis or immune responses in a tightly controlled environment. Furthermore, due to the 
simplicity of in vitro cultures they would allow the rapid screening of drugs and their influence on immune 
cells. Giese and colleagues reported in 2006 the establishment of a human artificial LN: They established 
a bioreactor allowing long-term culture of DCs with T and B cells embedded within an agarose matrix 
(Giese et al., 2006). In a second study, Giese and colleagues reported that immunization of this human 
artificial LN with a commercially available Hepatitis A vaccine leads to a rapid proinflammatory response, 
as measured by increased levels of TNF. Furthermore, after re-challenge with antigen TH2 cytokines are 
detected and plasma cells secreting antigen-specific antibodies are produced. In addition, the response to 
the vaccine could be abrogated by administration of an immune-suppressive drug. Therefore this human 
artificial LN is a valuable tool for testing immune function after vaccination in vitro (Giese et al., 2010). 
Currently, this system lacks the presence of stromal cells residing within a normal LN, which might 
influence the immune response.  
The establishment of artificial LN and their transplantation is of great interest for the application in 
medicine. For example such LNs could be used to boost immune responses in immune-deficient patients 
or to induce an anti-tumor response. In a study from Watanabe and colleagues, a collagen-sponge in 
which a thymus derived LT producing stromal cell line was embedded was transplanted under the 
kidney capsule. A few weeks after transplantation lymphocyte infiltrates in the transplants organized in 
distinct B and T cell areas and this was enhanced by the addition of activated DCs prior to 
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transplantation. Furthermore, the development of FDCs as well as the vascularisation of the transplants 
was observed (Suematsu and Watanabe, 2004). In a follow-up study, Okamoto and colleagues showed 
that these artificial LN supported adaptive immune responses which were maintained after 
transplantation into immune-deficient hosts, making the adaptation of this system for use in humans very 
attractive (Okamoto et al., 2007). 
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1.6. Aims of this thesis 
 
Establishment and characterization of TRC clones and cell lines in 2D and 3D culture 
Due to the lack of specific markers and efficient isolation protocols, TRCs were for a long time ignored 
by immunologists. These technical issues have been partially solved in the last years (Link et al., 2007), but 
TRCs represent rare cells (approximately 0.1% of the total LN population), making it difficult to isolate 
sufficient numbers to further characterize TRC function in vitro. Therefore, TRC clones and lines were 
established to obtain an abundant source of these cells. The surface marker profile of TRC clones and 
lines resembles closely that of ex vivo isolated TRCs and in addition they produce ECM molecules. 
However, the mRNA levels for Ccl19, Ccl21 and Il-7 are very low and could not be restored by stimulating 
the cells with different cytokines. To study TRC biology in a more physiological situation, a 3D culture 
system with TRC clones/lines was established and a more in vivo like cell morphology was observed, 
however CCL19, CCL21 and IL-7 levels remained low. When flow was applied to TRCs cultured in 3D, 
CCL21 levels were increased though not to physiological levels. In an attempt to reconstruct the 
lymphoid T zone in vitro, antigen-specific T cells and antigen-loaded dendritic cells were added to the 3D 
culture system and T cell activation could be observed, although it was reduced in presence of TRC. 
(Project described in results 2.1). 
Characterization of the precise role of TRCs in T cell priming 
Adaptive immune responses are initiated when T cells encounter antigen on dendritic cells (DCs) in T 
zones of secondary lymphoid organs. T zones contain a 3-dimensional scaffold of TRCs but currently it is 
unclear how TRCs influence T cell activation. Several evidences suggest TRCs as positive regulators of 
the immune response, but recently they were also implicated in peripheral tolerance induction. To define 
their precise role, we established a T cell activation assay in 2D culture, in which we studied T cell priming 
in presence or absence of TRCs. Surprisingly, TRCs attenuated CD8+ T cell proliferation and 
differentiation. This was confirmed with several distinct TRC lines and ex vivo isolated TRCs. Studies with 
pharmacological inhibitors and blocking antibodies identified iNOS (inducible nitric oxide synthase) -
responsible for NO production- and COX2 -responsible for prostaglandin production, including PGE2- 
as mediators of this suppression. In vitro IFN produced by activated T cells was shown to induce iNOS 
in TRCs, which was further enhanced in the presence of DCs. This observation was supported by the 
transient induction of iNOS expression in TRCs and DCs upon VSV (vesicular stomatitis virus) infection 
of WT mice. VSV infected iNOS knock out mice showed an exaggerated primary T cell response, 
consistent with the notion of iNOS being an attenuator of strong immune responses. (Project described 
in results 2.2). 
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2.1 Establishment and characterization of TRC clones and lines in 2D and 3D 
culture* 
 
 
Summary 
TRC represent are rare stromal cell population in the LN. To obtain an abundant source of these cells for 
their further functional characterization, TRC clones and lines were established. Both clones and lines 
show a fibroblastic phenotype, express a surface marker profile comparable to ex vivo TRC and produce 
extracellular matrix molecules. However, expression of Ccl19, Ccl21 and IL-7 was lost upon in vitro culture 
and could not be restored by cytokine stimulation. When TRC clones or lines were cultured in a three-
dimensional (3D) cell culture system, their morphology changed and successfully reproduced the 
networks seen for TRC in situ. 3D culture per se did not restore the cytokine production but adding fluid 
flow restored some of it.  
                                                      
* Partially based on: Tomei AA, Siegert A, Britschgi MR, Luther SA, Swartz MA (2009): Fluid flow regulates stromal 
cell organization and CCL21expression in a tissue-engineered lymph node microenvironment, Journal of 
Immunology 183, 4273-4283 
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2.1.1. TRC clones 
For a long time, stromal cells in the LN T zone have been neglected by immunologist, partially due to 
technical difficulties in working with these cells, notably the lack of isolation protocols and specific 
surface markers. After histological analysis of LN sections to identify reliable TRC marker combinations, 
A. Link established an isolation protocol and found a combination of markers (CD45- CD35- CD31- 
gp38+) allowing the identification of TRC in cell suspension. This allowed for the first time the detailed 
analysis of TRC on a single cells level (Link et al., 2007). However, with less than 0.5% of the total LN 
population, TRC represent a rare cell population, making it technically tedious to perform experiments 
with ex vivo isolated TRC. To this end, we have set out to generate cell clones and later lines (see 2.1.2) to 
have an abundant source of TRC.  
Before the start of my thesis work M. Britschgi and A. Link in our laboratory successfully established 
TRC clones from pLN of p53-/- and p19arf-/- mice (Tomei et al., 2009b) (partially unpublished). Both, 
p53 and p19, are tumour suppressor genes typically expressed in fibroblasts and we thought the lack of 
them will give the cells a first ‘hit’ with additional genetic modifications allowing their immortalization. To 
establish TRC lines, pLN were collagenase digested and the adherent cells cultured over several weeks. 
Surprisingly, in each case cells with a TRC-like phenotype outgrew the cultures. From some of these lines, 
TRC clones were established by limiting dilution.  
2.1.1.1. Several features are preserved in TRC clones, but Ccl19,  Cc l21 and I l -7  expression are 
lost 
M. Britschgi performed a first surface phenotype characterization of different TRC clones by flow 
cytometry (table 2.1.1). Here we will focus on two selected clones from pLN, the p53-/- clone H7. 2A10 
and the single p19arf-/- clone that express gp38 (podoplanin) but lack expression of the hematopoietic 
marker CD45. 
Surface marker ex v ivo  
TRC 
p53-/- 
clone 
p19arf-/- 
clone 
Surface marker ex v ivo  
TRC 
p53-/- 
clone 
p19arf-/- 
clone 
CD45 - - - BP-3 ++ - +/- 
CD19 - - - ICAM-1 (CD54) ++ + ++ 
CD11b - - - VCAM-1 (CD106) ++ +++ +++ 
PECAM (CD31)  - - - PDGF-R (CD140a) +++ ++ ++ 
CD35 - - - PDGF-R (CD140b) ++ + + 
CD105 (Endoglin) ++ + ++ LTR  ++ +++ +++ 
gp38 +++ +++ +++ TNF-R1 ++ ++ ++ 
Table 2.1.1: Surface phenotype of TRC clones from naive pLN 
Flow cytometric analysis of ex vivo TRC, the p53-/- TRC clone H7. 2A10 and the p19-/- TRC clone. ‘-’ = no 
expression; ‘+’ peak shift below 0.5 log; ‘++’ peak shift between 0.5 and 1 log; ‘+++’ peak shift above 1 log, 
all in relation to the no primary antibody control. (Analysis done by M. Britschgi and S. Siegert)(Tomei et al., 
2009b) 
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The two clones express ICAM-1 and VCAM-1, though expression levels are slightly higher for VCAM-1 
as compared to ex vivo TRCs and in the case of the p53-/- clone lower for ICAM-1. Furthermore, the 
expression of the mesenchymal cell markers PDGF-R and PDGF-R is preserved (figure 2.1.1a).  
 
Figure 2.1.1: TRC clone phenotype  
(a) Flow cytometric analysis of ex vivo isolated TRCs (upper panels) compared with the p53-/- TRC clone H7.2A10 
(lower panels). Comparable results were obtained with the p19arf-/- clone. After dead cell exclusion, cells were 
analyzed for CD45 versus gp38 expression (1st column), CD45- cells were then further analyzed for gp38 
(podoplanin) versus CD31 expression (2nd column). Histograms show the percentage of positive cells (± standard 
deviation) for the indicated markers on live CD45- CD31- gp38+ TRCs (Tomei et al., 2009a). (b) 
Immunohistochemical analysis of ECM production: The p53-/- clone was cultured for 3 days in chamber slides. 
After fixation of cells, laminin, fibronectin and collagen were labelled with antibodies (all shown in green). DAPI+ 
nuclei are shown in blue. Comparable results were obtained with the p19arf-/- clone. Scale bar 50µm. (c) 
Quantitative RT-PCR analysis of the two TRC clones (p53-/- and p19arf-/-) for Ccl21, Ccl19 and Il-7 transcripts. Bar 
graphs show the relative expression level relative to the average of two housekeeping genes (Hprt and Tbp). Ex vivo 
TRCs are as shown previously in (Link et al., 2007). 
 
In vivo TRCs are thought to be the major producers of ECM molecules and responsible for conduit 
formation. When TRC clones were cultured in chamber slides, laminin, fibronectin and collagen type-I 
proteins were detected by immunofluorescence (figure 2.1.1b). While laminin and fibronectin were part of 
intracellular as well as extracellular fibres, collagen-I was only found in intracellular compartments. This 
indicates that although collagen-I is produced it is not secreted. A main feature of TRCs in vivo is their 
expression of CCL19, CCL21 and IL-7; however this feature was lost in TRC clones (figure 2.1.1c). 
Together, these studies established that it is fairly easy to establish a TRC clone (or line) with a TRC-like 
surface phenotype and matrix production, but that additional factors are required to maintain other 
functions like cytokine expression. 
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2.1.1.2. Stimulation of TRC clone with recombinant cytokines does not restore Ccl19,  Cc l21  and 
I l -7  expression 
Cytokines such as TNF and LT are thought to regulate TRC development and activity in vivo 
including the induction of CCL19 and CCL21 expression (Cyster, 2005; Katakai et al., 2004; Schneider et 
al., 2004). Katakai and colleagues showed that stimulation of LN-derived TRC clones with TNF up-
regulates expression of CCL4, CCL5, CCL20 and CXCL10, but not CCL19 and CCL21. In addition, 
combined signalling via TNF-R and LTR was shown to enhance ER-TR7+ ECM network formation 
(Katakai et al., 2004). Our hypothesis was that the low expression of CCL19, CCL21 and IL-7 in our TRC 
clones might be due to the lack of positive regulators in vitro. To test this hypothesis, TRC clones were 
stimulated with different recombinant cytokines to see whether the CCL19, CCL21 and IL-7 expression 
can be restored. When transcripts of TRC clones were analysed after stimulation with cytokines or 
agonistic antibody (TNF, LT3, antiLTR, IL-1, IL-13, IL-6, TGF, IFN and PDGF-BB) for 
16h, no changes in CCL19, CCL21 and IL-7 could be detected (not shown). In addition to analysis of 
cytokine transcripts, flow cytometric analysis was performed to detect potential phenotypic changes. Only 
stimulation with TNF for 16 or 40h increased VCAM-1 expression (figure 2.1.2), while other tested 
markers (ICAM-1, CD31, CD35 and BP-3, as well as cell cycle analysis) remained unaffected (data not 
shown). Clones remained negative for MAdCAM-1, PNAd, CD35 and CD31 expression, even after 
cytokine stimulation. This suggests that TRC clones did not differentiate into other cell types, such as 
CD35+ FDCs or MAdCAM-1+ MRCs. Overall, the results indicate that simple re-stimulation of TRC 
clones with one cytokine at a time, including TNF or LT, was not sufficient to restore production of 
CCL19, CCL21 or IL-7.  
 
Figure 2.1.2: TNF  stimulation of TRC clone increases 
VCAM-1 expression 
The p53-/- clone H7.2A10 was stimulated with indicated 
cytokines for 16 or 40h, and then cells were analysed by flow 
cytometry. Histograms show VCAM-1 expression on living 
CD45-gp38+ cells. Used concentrations: 10ng/ml TNF, 
10ng/ml LT3, 10ng/ml TGF, 20ng/ml PDGF-BB, 
10ng/ml IFN, 10ng/ml IL-1, 25ng/ml IL-6, and 50ng/ml 
IL-13.  
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2.1.1.3. TRC clones cultured in a 3D culture system show in  v ivo  like morphology and reticular 
network formation 
Various cell types adopt a more in vivo like phenotype and function when grown in a 3D rather than 2D 
culture system (Pedersen and Swartz, 2005; Grinnell, 2003; Rhee, 2009). There are several different ways 
to culture cells in 3D. Most approaches use a gelatinous matrix to embed the cells, e.g. collagen, Matrigel 
(mixture of different ECM components) (Kleinman and Martin, 2005) or fibrin (Pedersen and Swartz, 
2005; Haycock, 2011). To test whether TRC clones behave more in vivo like in 3D culture, TRCs were 
cultured in a collagen-I gel (in collaboration with A. Tomei and M. Swartz, EPF Lausanne, Switzerland). 
TRCs contracted the collagen fibres leading to rapid size reduction of collagen gels strengthening the 
notion that these are myo-fibroblasts. This property makes long-term culture almost impossible (Link et 
al., 2007; Tomei et al., 2009b). To avoid gel contraction a macro-porous polyurethane sponge (pore size 
200-600µm) established by the group of M. Swartz was used as a stiff backbone comparable to the rigid 
LN capsule in vivo (figure 2.1.3a). This approach successfully prevented collagen contraction by the TRC 
clone (Tomei et al., 2009a, 2009b). The sponge culture also allows microscopical imaging although the 
sponge itself is slightly autofluorescent. TRC clones cultured in this 3D system were analysed by confocal 
microscopy. In contrast to their rather flattened morphology in 2D culture, they rapidly showed elongated 
and spindle-like morphology in 3D-culture, resembling their counterparts in vivo. Furthermore, within 3 
days after start of culture TRC networks had formed within the collagen matrix (Figure 2.1.3b). Cells 
could be re-isolated from the 3D cultures using a collagenase digest and analysed by different techniques, 
such as flow cytometry or RT-PCR. After 3D culture TRCs maintained their typical surface marker 
expression. However, 3D culture was not sufficient to restore CCL19, CCL21 and IL-7 production to 
physiological levels (not shown) (Tomei et al., 2009b). 
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Figure 2.1.3: TRC clone cultured in 3D shows in  v ivo  like morphology and network formation 
(a) Schematic depiction of polyurethane-sponge production (as published in (Tomei et al., 2009a)): alginate beads 
are filled into a cast-device (e.g. 96-well plate). Liquid polyurethane is pipetted on the beads and after addition of 
water polyurethane polymerizes. Alginate beads are removed by dissolving them using citric acid. Sponges are 
washed and autoclaved prior to use. For 3D culture cells are mixed with collagen-I solution and filled into the 
sponge. After polymerization of collagen complete medium is added on top of the sponge. (b) Confocal microscopy 
of the p53-/- TRC clone (GFP+, green) cultured in 2D (left) or 3D (middle and right). Cells were cultured for 3 days 
in chamber slides and then analyzed by confocal microscopy (inverted Leica SP2 microscope). Red shows secondary 
harmonics of collagen. Shown are z-projections of image stacks (done using ImageJ software). Scale-bar 100µm.  
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2.1.1.4. Flow induces Ccl21  expression in TRCs grown in a non-contractable 3D culture system 
In vivo slow interstitial flow of lymph is constantly present in LNs, moving from the afferent lymphatics 
into the SCS and within the conduits through the paracortex before reaching the medulla and exiting via 
the efferent lymphatics (Laemmermann and Sixt, 2008). Lymph flow is increased early during tissue injury 
or infection (He et al., 2002; Modi et al., 2007) and correlates with increased levels of CCL19 and CCL21 
levels in the LN during the first hours of the immune response (Scandella et al., 2008). As conduit-lining 
TRCs are constantly exposed to the incoming lymph, we hypothesized that the mechanical force of 
flowing lymph could contribute to the regulation of homeostatic chemokine expression.  
The experiments described in the following - to test the effects of interstitial flow on chemokine 
production by TRCs - were performed by A. Tomei (M. Swartz group, EPFL) and have been published 
(Tomei et al., 2009b). When TRCs were cultured in a mixture of collagen and Matrigel (ratio 9:1) in the 
above described polyurethane sponges and flow was applied, CCL21 protein expression was increased as 
assessed by immuno-histochemical analysis. These results were confirmed and extended in another 
culture model that allowed more precise control of the applied flow: TRC clones were cultured in a 
collagen-matrigel matrix surrounded by a polyethylene cylinder (figure 2.1.4a). After 7 days of culture, 
enhanced TRC proliferation could be observed, but only in presence of the highest tested flow rate 
(figure 2.1.4.b). Interestingly, although the highest flow rate induced the highest Ccl21 mRNA levels in 
TRCs, the lowest flow rate led to the highest secretion of CCL19 and CCL21 protein into the matrix as 
measured by ELISA on the digested matrix (figure 2.1.4c). But the detected chemokine transcript levels 
were still much lower than observed in ex vivo isolated TRCs (unpublished observation). To confirm the 
connection between lymph flow and CCL19/21 expression in vivo, afferent lymphatics of the inguinal LN 
were cut and 2 hours later CCL21 expression in the whole LN was measured. As predicted, blocking the 
flow to the LN decreased the CCL21 levels significantly, indicating a role of flow in CCL21 regulation. 
There was a trend, though not statistically significant, towards decreased CCL19 levels (figure 2.1.4e,f). 
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Figure 2.1.4: Fluid flow regulates CCL21 production by TRC clone 
(a-d). TRCs were cultured in a collagen matrix within a porous polyethylene ring to prevent cell contraction over 
time, and fluid flow rates through the TRC matrix were controlled by the pressure head applied. (a) Scheme of the 
simplified 3D flow chamber (b) Cell density increased with the highest flow velocity tested (23µmm/min) after 7 
days of culture. Data (n=3) were normalized to original cell densities (106 cells/ml). (c) Flow increased the secretion 
of CCL21 and CCL19 protein into the surrounding matrix, as compared with static controls and measured by 
ELISA on digested 3D cultures (n=12). (d) Flow in 3D induces an increase in the gene expression of Ccl2-ser as 
represented by quantitative real-time PCR (n=12). In mice two gene copies of Ccl21 exist: Ccl21-leu is expressed in 
lymphatics of non-lymphoid organs, while Ccl21-ser is expressed in lymphoid organs e.g. by TRCs in LNs (Förster et 
al., 2008). Ccl19-atg transcripts were not detectable (ND). Several Ccl19 transcribed gene copies exist, but only one 
the Ccl19-atg transcript encodes CCL19 protein (Luther et al., 2000). (e) Lymph flow through the inguinal LN was 
prevented by cutting the afferent and efferent lymphatic vessels. To visualize successful ablation of afferent lymph 
flow, FITC dextran uptake by the LN was measured in the case of ‘blocked flow’ and compared with the ‘normal 
flow’. Scale bars represent 1mm (left) or 2.5 mm (right). (f) After 2h of blocked lymph flow, expression of Ccl21-ser 
and Ccl19-atg transcripts was assessed in the LN and Ccl21-ser expression was found to be significantly decreased in 
the blocked LN (p < 0.05) compared with their corresponding control LN (n=7). Quantitative real-time PCR 
results are displayed as the ratio between normal flow and blocked flow. Data derived from (Tomei et al., 2009b).  
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2.1.2. TRC lines from lymph nodes of C57BL/6 mice 
The long-term goal of establishing a 3D system with TRCs was to re-construct the lymphoid T zone in 
vitro by the addition of T cells and DCs. However, as the established TRC clones were from LN of either 
p53-/- or p19arf-/- mice which are on a mixed C57BL/6 x 129 background (both H-2b, but differences 
in minor histocompatibility loci) (Fischer-Lindahl, 1997) the clones were not suitable for co-culture with 
polyclonal C57BL/6 T cells. To get around this limitation, TRC lines were established from pLN and 
mLN of naive C57BL/6 mice. In addition, lines from pLN of ubiquitin-GFP transgenic mice on a 
C57BL/6 background were generated to obtain fluorescent TRC lines, which are easily detectable in 
histology and provide a tool for time-lapse analysis.  
2.1.2.1. TRC lines resemble in  v ivo  TRCs, but lack CCL19, CCL21 and IL-7 expression 
Two entirely independent cell lines were established for each condition (C57BL/6 pLN, C57BL/6 mLN, 
Ubiquitin-GFP pLN). As for the generation of TRC clones, LN were collagenase-digested and TRCs 
enriched by panning. Initially, adherent cells grew very slowly and the morphology revealed heterogeneity 
among the cells. 2-3 months after start of culture the cells started to proliferate faster, and often became 
more homogeneous in their fibroblastic morphology. Flow cytometric analysis of cells at this time point 
showed that over 99% of cells were CD45- indicating that only non-hematopoietic cells had survived 
(figure 2.1.5a and 2.1.6a). Interestingly, after 3 months of culture the majority of mLN-derived cells were 
CD31int gp38+ resembling the phenotype of LECs, but not TRCs. However, when mLN cells were re-
analysed 2 months later, the majority of cells had a TRC-like surface phenotype (CD31- gp38+), although 
the gp38 expression level was lower than in pLN-derived TRC lines (figure 2.1.5a).  
 
Figure 2.1.5 Fibroblasts with TRC-like phenotype grow out of LN stromal cell cultures 
pLN or mLN from naive adult C57BL/6 mice were collagenase digested and adherent cells cultured in vitro. (a) 
Flow cytometric analysis of the lines mLN1 and pLN2. Dot plots show CD45 versus gp38 expression (1st column), 
or CD31 versus gp38 expression on CD45- cells after 3 (2nd column) or 5 months (3rd column) of culture. (b) 
Histograms show indicated markers on CD45- gp38+ CD31- mLN cells. Grey =no primary antibody control.  
 
This indicates that over time TRC-like fibroblasts grew out of the original mix of TRCs and LECs. As for 
this thesis the main interest was in pLN-derived TRCs, the mLN lines were not further characterized after 
the initial surface phenotype analysis (figure 2.1.5b). Much to our surprise, the obtained cell lines could be 
cultured for more than 50 passages; however, for experiments cells below passage 28 were used. In 
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conclusion, there was no need for using mice with a 'first hit' to generate long-lived primary fibroblast 
lines.  
The vast majority of pLN-derived cell lines were CD31- gp38+ and were negative for CD35, EpCAM, and 
MAdCAM-1, suggesting that these cells are probably not FDCs, epithelial cells nor MRCs (table 2.1.2 and 
figure 2.1.6a). Similar to the ex vivo TRCs, the pLN2-TRC lines expressed the adhesion molecules ICAM-1 
and VCAM-1 as well as PDGF-R and PDGF-R (table 2.1.2 and figure 2.1.6a,b). Only very little MHC-
II and no CD80 or CD86 expression was detected in the TRC line or ex vivo isolated TRCs (table 2.1.2 
and figure 2.1.6b). 
Surface 
marker 
ex v ivo  TRC pLN2 TRC line Surface 
marker 
ex v ivo  TRC pLN2 TRC line 
CD45 - - CD105 ++ ++ 
CD11b - - gp38 +++ +++ 
CD11c - - ICAM-1 ++ ++ 
CD31  - - VCAM-1 ++ +++ 
CD35 - - PDGF-R +++ +++ 
CD80 - - PDGF-R ++ + 
CD86 - - LTR ++ ++ 
CCR7 - - TNF-RI ++ + 
CTLA-4 n.d. - PD1 n.d. ++ 
MAdCAM-1 +/- - PD-L1 + +++ 
MHCII -/+ -/(+)    
BP-3 ++ -    
Table 2.1.2: Surface phenotype of pLN2-TRC line 
Flow cytometric analysis of ex vivo TRCs and the pLN2-TRC line analyzed between passage 18 and 25 (> 4 
months in culture) ‘-’ = no expression; ‘+’ peak shift below 0.5 log; ‘++’ peak shift between 0.5 and 1 log; 
‘+++’ peak shift above 1 log, all in relation to the no primary antibody control. n.d. = not done (analysis of ex 
vivo TRC phenotype, mostly done by A. Link and H.-Y. Huang) 
 
After the initial flow cytometric characterization of the different lines, the C57BL/6 pLN2 line was 
mostly used for further experiments. Labelling the cells with an antibody against gp38 and analysis by 
immunofluorescence microscopy revealed typical fibroblastic morphology. The majority of pLN2-TRCs 
express desmin+ intermediate filaments and alpha smooth-muscle actin (SMA)+ stress fibres confirming 
their myo-fibroblastic properties (figure 2.1.6c) (Link et al., 2007). Microscopic analysis of ECM secretion 
by pLN2-TRCs cultured in chamber slides revealed production of fibronectin, laminin and collagen I 
(figure 2.1.6d) assembled into fibres and remodelled by the cells. When GFP-pLN-TRC line cells were 
cultured in the 3D culture system (as described for the clones), their morphology was elongated and 
stellate resembling that of in vivo TRCs. As with the TRC clone, network formation in 3D culture could be 
observed (figure 2.1.6e and not shown). However, TRC lines expressed only very low levels of CCL19, 
CCL21 and IL-7, as explained below (figure 2.1.7a).   
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Figure 2.1.6: Phenotype of C57BL/6 pLN TRC lines  
(a,b) Flow cytometric analysis of TRC lines established from naïve WT C57BL/6 (‘pLN1’ and ‘pLN2’) or Ubiquitin-
GFP mice (‘GFP-pLN’) analyzed between passage 18-25 (>4 months of culture). (a) The first row shows CD45 
versus CD31 expression, while the following rows show histograms for the indicated markers on CD45- CD31- 
cells. (b) Shows additional markers on the pLN2 TRC line (CD45- CD31-). (c-e) Immunohistochemical analysis of 
the TRC line pLN2 and its secreted products. Nuclei (DAPI) are shown in blue. (c,d) Cells were cultured in 
chamber slides for 3 days: shown are (c) cell morphology (TRCs labelled with gp38 in red), SMA and desmin 
expression or (d) ECM molecules production. (e) GFP-pLN cells were cultured in the 3D culture system (as 
described in figure 2.1.3) for 2 days and analyzed by confocal microscopy. (c-e) Scale bar 50µm.  
 
2.1.2.2. Cytokine stimulation of TRC line modulates some surface markers, but does not restore 
cytokine expression 
During an immune response cytokines and other pro-inflammatory molecules such as TLR ligands are 
rapidly transported via lymph to the draining LN. As TRCs surround the conduits they will be exposed to 
these signals. To determine whether this induces changes in the TRC properties, pLN2-TRCs were 
cultured in the presence of different cytokines (TNF, LT3, IL-1, IFN or IFN), a cytokine receptor 
agonist (anti-LTR) or TLR-ligands (LPS or Poly I:C) for 24 hours. Various surface markers were 
analysed for potential changes. In addition, cells were counted but no difference in cell numbers was 
observed with or without stimulation. Stimulation with several cytokines (TNF, LT3, IL-1, IFN or 
IFN) increased the size of the TRCs, while their granularity was unchanged in comparison to un-
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stimulated cells (figure 2.1.7b). Interestingly, when cells were stimulated with TLR-ligands or a mix of 
TNF, IL-1 and IL-6 no size increase was observed, but rather a trend to decreased size. This might be 
due to overstimulation, when all three cytokines are present. None of the cytokines induced expression of 
CD35, CD31 or MAdCAM-1, indicating that the TRC line probably did not differentiate into another 
stromal cell type (data not shown). Furthermore, in contrast to a recent report using ex vivo isolated FRCs 
(Fletcher et al., 2010) the pLN2-TRCs did not increase MHCII, CD40, CD80 and CD86 expression upon 
stimulation of cytokines or TLR-ligands (not shown). Several tested stimuli increased gp38 expression 
with the highest increase being induced by IL-1 and TNF  (figure 2.1.7b). Some modulation of 
VCAM-1 expression levels could be observed: the combination of TNF with IL-1 and IL-6 led to a 4-
fold increase, while LPS stimulation to a 2-fold increase (Figure 2.1.7b). Interestingly, the stimulation with 
IFN and IFN dramatically increased PD-L1 expression on the pLN2-TRC, while only very little 
modulation of the LTR could be observed (Figure 2.1.7b). For other tested markers, such as CD71, 
PDGF-R, PDGF-R or CD44 no marked changes in expression level were observed (data not shown). 
These results indicate, that pLN2-TRCs are capable of responding to many different stimuli present 
during inflammatory responses, however, none of the tested cytokines nor LPS (TLR4-ligand) stimulation 
could induce CCL19, CCL21 or IL-7 expression (Figure 2.1.7a). 
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Figure 2.1.7: Cytokine stimulation of TRC-pLN2 line modulates some surface markers, but not cytokine 
expression 
pLN2-TRCs were stimulated with various cytokines or receptor agonists. TNF, LT3, TGF, IFN, IL-1, IL-
1 (all 10ng/ml), IL-6 (25ng/ml), IFN (500U/ml), anti-LTR (1µg/ml), LPS (0.5µg/ml), Poly I:C (20µ/ml)  
(a) Quantitative RT-PCR analysis of pLN2 line after 7h or 24h of stimulation. Shown is the expression level 
normalized to the average of the two housekeeping genes Hprt and Tbp. As published (Link et al., 2007) ex vivo 
TRCs show the following transcript levels Il-7  1, Ccl21  3500, Ccl19  200. (b) .Flow cytometric analysis of 
pLN2-TRC stimulated for 24h. Histograms show indicated markers, grey shows un-stimulated TRCs (‘-’). 
Separated panels show different experiments. Bar graphs show the expression level as ratio relative to un-
stimulated TRCs, as based on the median of fluorescence intensity. A relative expression level of 1 indicates no 
change in the fluorescence intensity. Relative expression level > 1 indicates increased, while < 1 indicates 
decreased expression levels or size/granularity. 
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2.1.2.3. Reconstruction of the lymphoid T zone in  v i t ro  
As mentioned before, the initial goal of establishing a 3D culture system with TRCs was to re-construct 
the lymphoid T zone, including T cells and DCs. This system should facilitate to analyse the role of TRCs 
in T cell priming. To this end, we first mixed ovalbumin (OVA)-specific CD8 T cells (OT-I) with 
polyclonal WT CD8 T cells in a ratio of 1:50 to mimic the in vivo situation, in which few antigen-specific T 
cells are intermingled with many polyclonal T cells. This T cell mix together with OVA-peptide-pulsed 
LPS-activated BMDCs (in a DC: T cell ratio of 1:10) was added on top of the 3D sponge culture system 
containing embedded TRCs or not. After 3-4 days of culture the cells were reisolated and the antigen-
specific T cell response analysed. In the absence of TRCs, a strong activation of OVA-specific CD8+ T 
cells was observed, as assessed by size increase, proliferation (CFSE dilution) and modulation of 
activation markers (CD44, CD62L) (figure 2.1.8). Surprisingly, when TRCs were present, the proliferation 
of antigen-specific T cells was strongly reduced (figure 2.1.8). However, in a pilot time-lapse analysis of 
the 3D co-culture containing TRCs, T cells and DCs, DCs and T cells were only found in proximity of 
the collagen-gel surface but not deep within the gel. Inclusion of recombinant CCL21 in the gel did not 
improve the penetration depth (data not shown). This might be due to lack of oxygen in deeper regions 
of this 3D system and may indicate the need of a more sophisticated culture and microscope set-up 
improving oxygen diffusion into the sponge. As we observed a similar inhibition of T cell proliferation 
when TRCs were cocultured with T cells and DCs in normal 2D systems, we continued to characterize 
this observation in detail only in 2D cultures (described and discussed in the second results part 2.2). This 
system is technically easier and allows testing more conditions within one experiment. 
 
Figure 2.1.8: Antigen-specific T cells get efficiently activated in the 3D culture system 
0.3 x 106 pLN2-TRC line cells were seeded in the 3D sponge culture system (as described in figure 2.1.2) and 
cultured for 2 days until TRC networks had formed. Then 0.2 x 106 LPS-activated and antigen-loaded BMDCs 
were added on top together with a total of 2 x 106 T cells, with T cells consisting of CFSE labelled OVA-specific 
CD8 T cells (= OT-I, red) mixed with polyclonal WT T cells (grey; 50% labelled with CFSE) in a ratio of 1:50. 
Cells were re-isolated after 3.5 days of co-culture and analyzed by flow-cytometry. Shown is the size of cells (FSC), 
their proliferation as assessed by CFSE dilution and the loss of CD62L as well as gain of CD44 as a measure of T 
cell activation. 
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2.1.2.4. Contributions by others 
M. Britschgi and A. Link, two former lab members, established the TRC clones, and M. Britschgi 
performed the initial characterization. A. Tomei – under supervision of M. Swartz (EPFL)- established 
the polyurethane sponge used for the 3D culture system, helped with the set-up of 3D cultures with the 
TRC clone, performed all experiments with the application of flow and the related in vivo experiment with 
blocked flow. H. Acha-Orbea (UNIL) contributed transgenic mice. 
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2.1.3. Discussion of results with newly established TRC clones and lines 
One difficulty in studying TRC function is their low percentage in LNs. Here I report the establishment 
of TRC clones and lines to obtain an abundant source of these cells as a basis for further characterization. 
Cell lines are widely used in research and their main advantage is that cells can be grown indefinitely and 
therefore large quantities can be easily obtained. However, to become immortalized cells undergo changes 
at the genomic and transcriptional level, which likely alter their behaviour compared to their in vivo 
counterparts. Cells can also de-differentiate in vitro during the several weeks of culture. Another advantage 
using cell lines or clones is that culture conditions can be precisely controlled and the identical cells are 
used in each experiment, which should improve reproducibility. However, results obtained with cell lines 
should, if possible, always be verified using ex vivo cells or ideally in an in vivo model.  
Both, the cell clones and lines express a very similar surface marker profile as that of ex vivo isolated 
TRCs. While TRC clones and lines still produce ECM molecules, the expression of Ccl19, Ccl21 and Il-7 is 
lost. So overall the phenotype of TRC clones and lines is very similar. To establish TRC clones mice 
lacking a tumorsuppressor gene (p53 or p19arf) were used, as initially we assumed that a first ‘hit’ toward 
tumorigenesis is needed to obtain immortalized clones. However, TRC lines could be easily established 
from WT mice by long-term culture and maintained in vitro for over 50 passages. This indicates that the 
first ‘hit’ towards tumorigenesis is not necessary to obtain TRC lines. During long-term culture of 
adherent LN cells we observed that cells first grew slowly and showed a heterogeneous phenotype, but 
after 2-3 months started to grow rapidly and became a homogenous population. It might be possible that 
the cells growing out after 2-3 months of culture are derived from one progenitor cell, which acquired 
genetic mutations that allowed rapid growth in vitro. Therefore we cannot exclude that our cell lines might 
represent a clonal population.  
FRC-like cell lines from murine LN or spleen, but also from human SLOs have been described by others 
and their basic phenotype characterization is summarized in table 2.1.3.(Katakai et al., 2004; Castro et al., 
1997; Vega et al., 2006; Amé-Thomas et al., 2007). T zone FRCs were shown the be present in the spleen 
(Nolte et al., 2003; Ngo et al., 2001) therefore the lines generated from spleen represent most likely a 
similar cell type as LN derived TRC clones/lines, which were characterized in this thesis. However, the 
lack of reliable stromal cell markers which are maintained in culture make it difficult to establish whether 
a cell is truly a TRC, a dedifferentiated form of a TRC or another type of FRC.  
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Our lines Katakai et 
al. 
Castro et al. Hou et al. Amé-
Thomas et 
al. 
Vega et al. 
Organism 
 
Mouse 
(C57BL/6) 
Mouse 
(Balb/c) 
Mouse 
(Balb/c) 
Mouse 
(C57BL/6) 
Human Human 
Organ 
pLN pLN Spleen Spleen Tonsil LN 
CD45 - - - - - - 
CD31 - - ND - ND - 
FDC marker - - - - ND - 
gp38 + + ND + ND ND 
MHCII -/+ - ND - ND ND 
VCAM-1 + + + + - ND 
ICAM-1 + -/+ - ND - ND 
MAdCAM-1 - -/+ ND - ND ND 
Mesenchymal 
markers 
PDGFR+  
PDGFR+ 
CD105+ 
ND ND ND CD90+ 
CD73+ 
CD105+ 
CD105+ 
LT-R + ND ND + + ND 
CCL19 -  - ND + - - 
CCL21 -  - ND - - - 
IL-7 - -/+ ND + ND - 
Detected by RT-PCR of 
RNA 
RT-PCR of 
RNA 
 RT-PCR of 
RNA 
RT-PCR of 
RNA 
Microarray 
of RNA 
P
he
no
ty
pe
 o
f u
ns
ti
m
ul
at
ed
 c
el
ls
 
ECM + + ND + + ND 
Most likely 
represent  
TRC TRC and 
MAdCAM-
1+ MRC  
Splenic TRC 
or red pulp 
stroma 
Splenic TRC Human TRC Human TRC 
Table 2.1.3 Phenotypic comparison of different FRC lines 
The table compares the basic characterization done on FRC lines established by others and us. The surface 
phenotype of cell lines from Hou and colleagues are also shown in supplementary figure 2.2.1. The phenotypic 
comparison here is for unstimulated cells and phenotypic changes after stimulation are described in the text. Surface 
marker expression was analyzed by flow cytometry, cytokine expression by RT-PCR or microarray as indicated in 
the table and ECM production by immunohistochemistry. In case of the Katakai lines ICAM-1, MAdCAM-1 and 
IL-7 were detected in MRC lines, but not TRC lines. FDC marker: CD35 or FDC-M1. ND = no data; ‘+’ detected; 
‘-’ not detected. (Katakai et al., 2004; Castro et al., 1997; Hou et al., 2010; Amé-Thomas et al., 2007; Vega et al., 
2006; Katakai et al., 2008).  
 
Surface marker profile and ECM production by TRC clones and lines  
TRC clones /lines are negative for the FDC marker CD35, as shown by others and us (table 2.1.3) 
(Katakai et al., 2004; Hou et al., 2010; Castro et al., 1997; Vega et al., 2006). However, in early attempts to 
generate FDC lines it was observed that upon in vitro culture FDCs rapidly lost the expression of FDC 
markers, such as CD35 (Kim et al., 1994; Clark et al., 1992; Tsunoda et al., 1990). Therefore, it cannot 
formerly be excluded that FDCs that were present after ex vivo isolation of adherent cells lost CD21/35 
expression and are still present in our TRC-like lines. However, two points argue against these cells being 
FDCs: 1) we have rarely observed CD35+ FDCs in our ex vivo isolates, 2) we see strong expression of 
ECM proteins what is typically not observed with FDCs.  
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Interestingly, ICAM-1 expression seems to vary on different lines (Katakai et al., 2004; Castro et al., 1997; 
Amé-Thomas et al., 2007). Only some of the lines reported by Katakai and colleagues showed 
constitutive ICAM-1 expression, while others only induced this marker after TNF stimulation (Katakai 
et al., 2004). Also lines reported by Castro and colleagues were found to be negative for ICAM-1,which 
could not be induced by treatment with IFN (Castro et al., 1997). In contrast, our TRC cell clones/lines 
all showed constitutive ICAM-1 expression, which was not increased upon stimulation with TNF or 
other tested cytokines such as IFN. It remains to be clarified whether ICAM-1 represents a marker that 
characterizes different TRC-subsets or activation states. Scandella and colleagues showed that short term-
cultures of splenic T zone stromal cells show high surface expression of VCAM-1 and gp38, but only 
little ICAM-1 expression. However, when these cells were infected with LCMV ICAM-1 expression was 
increased arguing for ICAM-1 as an activation marker (Scandella et al., 2008).  
TRCs constitutively express PD-L1, which was strongly increased on our TRC-lines in response to IFN 
and IFN stimulation, but not after stimulation with other cytokines or TLR-ligands. This is in 
accordance with results obtained by Khan and colleagues (Khan et al., 2011). In addition, consistent with 
these results, Fletcher and colleagues observed PD-L1 up-regulation on ex vivo TRCs isolated from mice 
that were challenged with the TLR3 ligand Poly I:C (Fletcher et al., 2010). Nevertheless, in their report 
the observed PD-L1 up-regulation might not be due to direct stimulation of TRCs by Poly I:C, but 
possibly due to pro-inflammatory mediators such as type I IFN which may be produced by Poly I:C 
stimulated DCs (Gauzzi et al., 2010). Interestingly, Mueller and colleagues reported that TRCs infected by 
LCMV (clone 13) up-regulate PD-L1 expression, which protects them from being killed by CD8+ T cells 
(Mueller et al., 2007). Together this suggests that PD-L1 might be an activation marker of TRCs, however 
its function on TRCs remains to be better defined.  
The Katakai-FRC lines were shown to produce ECM fibres as detected by the ER-TR7 antibody. The 
ER-TR7-antigen is not characterized, but was shown be an ECM component specific for murine 
fibroblasts (Van Vliet et al., 1986; Katakai et al., 2004). The ECM formation by the FRC-lines was 
strongly enhanced after co-culture with lymphocytes or the combined stimulation of the TNF-R (by 
TNF or LT3) and the LTR. ER-TR7 staining overlapped with laminin and fibronectin, but in 
contrast to ER-TR7, fibronectin secretion by FRCs seemed to be influenced very little or not at all by the 
presence of lymphocytes (Katakai et al., 2004). Here, we show collagen I, fibronectin and laminin 
production by our cell clones/lines. In preliminary experiments no enhanced ECM formation was 
observed after treatment with TNF + LT3 + anti-LTR (alone or combined). However, only 
secretion of fibronectin and collagen I was analysed and at this point we cannot exclude that ER-TR7 is 
regulated differently. 
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Cytokine expression by TRC clones and lines 
Katakai and colleagues reported the expression of several different chemokines by the FRC lines that 
were constitutively expressed: Ccl2, Cxcl12, Cx3cl1, Ccl4 and Ccl5. TNF stimulation increased Ccl4 and 
Ccl5 and furthermore induced Ccl20 and Cxcl10 expression. In a follow-up report, Katakai and colleagues 
showed that CXCL16 is induced in the TRC-line by different cytokines (IL-1, IFN and TNF) and 
LPS. CXCL16 expression by TRCs was confirmed in vivo and seems to be involved in adhesion of 
activated (CXCR6+) CD8 T cells to the TRC network (Hara et al., 2006). In a pilot experiment I analysed 
supernatant of the pLN2-TRC line by luminex technology, and CXCL10 (IP-10), CCL2 (MCP-1) and KC 
(CXCL1) could be detected as well as the cytokines IL-2, IL-5 and IL-6. However, similar to our cell 
clones/lines no Ccl19 or Ccl21 expression was detected in the Katakai-line with or without cytokine 
stimulation in the TRC line (Katakai et al., 2004). This is also consistent with the observation that TRCs 
cultured in vitro rapidly loose Ccl19 and Ccl21 expression (personal communication by T. Vogt). 
Nevertheless, in a follow-up report by Katakai and colleagues in which they describe the MRC subset, 
Ccl19 could be induced in a MRC line after TNF-R and LT-R stimulation (Katakai et al., 2008). So far 
we could not reproduce this with our cell lines.  
Together this shows, that TRCs cultured in vitro loose the Ccl19 and Ccl21 expression, which was not re-
stored by stimulation with the tested cytokines, while other cytokines are still expressed or can be induced 
by cytokine stimulation. During SLO organogenesis LT signals are crucial for CCL19 and CCL21 
induction (van de Pavert and Mebius, 2010). Furthermore, intra-peritoneal injection of the agonistic LT-
R antibody increases Ccl19 and Ccl21 expression in the spleen, suggesting that LT signals in adult mice 
directly or indirectly augments homeostatic chemokine expression (Dejardin et al., 2002). However, our 
results indicate that in adult TRCs LT signals are not sufficient to induce Ccl19 and Ccl21 expression. 
Still, other signals might be able to re-store the homeostatic chemokine expression in TRC lines and 
remain to be tested. It is likely that the regulation of CCL19 and CCL21 is complex and several signals 
need to be present, therefore complex mixtures such as lymph or cytokines cocktails should be tested. 
Furthermore, it might be interesting to co-culture TRC lines with other cells that are able to provide the 
appropriate signals. Scandella and colleagues showed that lymphoid tissues inducer (LTi) cells are 
important to restore the TRC network and the accompanying Ccl19 and Ccl21 expression, which are 
disturbed after LCMV infection. Furthermore, Ccl19 but not Ccl21 transcripts were maintained in ex vivo 
isolated splenic stromal cells (gp38+) when co-cultured with LTi for 4 days in vitro (Scandella et al., 2008). 
Therefore, LTi cells represent a potential candidate to restore chemokines expression in TRC 
clones/lines. A recent report showed that JAM-C (junctional adhesion molecule C) expressed on TRCs is 
implicated in the regulation of Ccl21 expression in vivo (Frontera et al., 2011). JAM-C was shown to be 
expressed on different cells types, such as endothelial cells or MSCs and to interact with itself, JAM-B, 
Mac-1 and CD11c (Zimmerli et al., 2009). It remains to be tested, whether TRC clones/lines express 
JAM-C and whether co-culture with cells expressing JAM-C ligands, for example endothelial cells, could 
restore CCL21 expression.  
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In a study in 2006 Vega and colleagues reported microarray analysis of humans FRC lines that they 
compared with human dermal fibroblasts (DF). Interestingly, Ccl2 as well as Il-1 and Il-6 expression were 
significantly higher in FRCs than DF. TNF up-regulated several chemokines (Ccl1, Ccl2, Ccl7, Ccl8, 
Ccl11, Ccl23, Cxcl1, Cxcl2, Cxcl3, Cxcl5, Cxcl8, Mip-1, and lymphotactin) in FRCs; however, a very similar 
response to TNF stimulation was seen in DF suggesting a common fibroblastic response to TNF. In 
contrast to our findings, IL-6 or IL-13 stimulation induced Ccl19 but not Ccl21 in human FRCs. 
However, Vega and colleagues studied FRCs derived from LNs that showed benign hyperplasia, were 
reactive or had lymphoma and therefore these FRCs may be altered (Vega et al., 2006). In a study from 
Amé-Thomas and colleagues, the establishment of human FRC lines derived from tonsils is reported. In 
contrast to previous results with murine FRCs but similar to the reported murine MRC line, Ccl19 was 
induced after combined TNF/LT12 stimulation for 3 days (Amé-Thomas et al., 2007; Katakai et al., 
2004; Vega et al., 2006). So FRCs from activated human tonsils might represent MRCs or behave 
differently than TRCs from naive murine LN or spleen. Nevertheless, it is possible that during the 
establishment of lines, cells grow out that do not produce or never produced CCL19 and CCL21. 
Therefore, the culture conditions during establishment of cell lines might be crucial to preserve 
chemokines expression. It remains to be tested whether continuous presence of stimuli, such as 
TNF and/or LT, in cultures of ex vivo isolated TRCs might preserve CCL19 and CCL21 expression. 
A characteristic feature of TRCs in vivo is the expression of Il-7 (Link et al., 2007), which was lost in our 
TRC lines. Il-7 was shown to be induced by LT signalling in MEFs (Vondenhoff et al., 2009). This was 
confirmed in TRC and MRC lines established by Katakai and colleagues, as LT3 or LTR stimulation 
increased Il-7 expression in an additive manner. Interestingly, while unstimulated TRC lines show no or 
very few Il-7 transcripts, MRC lines show some constitutive expression (Katakai et al., 2008). Besides LT 
signalling, IFN was shown to positively regulate Il-7 expression in human and murine intestinal epithelial 
cells (Shalapour et al., 2010; Oshima et al., 2004). However, in our hands none of the tested stimuli 
(LT3, TNF, agonistic anti-LTR, IL-1, F, IFN or LPS) restored Il-7 levels in TRC lines to 
physiological levels. The discrepancy of these results to the previous reports cannot be explained so far. I 
have only checked Il-7 transcripts after short-term stimulation (maximal 40h); maybe a longer stimulation 
is needed to see Il-7 upregulation.  
Culture of TRC clones and lines in a non-contractible 3D culture and the reconstruction of a 
lymphoid T zone in  v i t ro  
In recent years, the use of 3D cell culture systems has been more and more used to mimic in vivo like 
environments that nevertheless keep the advantages of in vitro culture. The reconstruction of lymphoid 
tissues is of great interest, for example for in vitro drug testing. Giese and colleagues reported the 
establishment of a human artificial LN, consisting of lymphocytes and DCs embedded in an agarose 
matrix. In this system an immune response to a Hepatitis A vaccine could be successfully reconstructed 
(Giese et al., 2010). However, the stromal cell compartment of SLO, FDCs as well as TRCs, is missing in 
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this human artificial LN. As both FDCs and TRCs strongly influence the immune response, it would be 
important to include them in such a system. In another approach, Kaminer-Israeli and colleagues report 
the co-culture of (murine) BMDCs together with a stromal cell line derived from murine bone marrow 
embedded in an alginate scaffold. Exogenously added T cells penetrated into the centre of the 3D culture 
system and T cell activation could be observed. Interestingly, similar to our results, presence of stromal 
cells inhibited T cell proliferation in vitro, but also in vivo, when this 3D system was transplanted under the 
kidney capsule (Kaminer-Israeli et al., 2010). 
In this thesis we report our approach to reconstruct a lymphoid T zone: we could successfully culture 
TRC clones/lines in a special 3D system, consisting of a collagen gel polymerized within a rigid 
polyurethane scaffold. TRCs in this system show in vivo like morphology and cell-networks are formed. 
The lacking cytokine expression in TRC clone/lines might be due to cell de-differentiation in long-term 
culture. It is known, that extracellular mechanical signals feed back to the cells by transducing it into 
intracellular signals (Tomasek et al., 2002; Kleinman et al., 2003) and that mechanical properties of the 
matrix in 3D culture systems greatly influence cell biology (Griffith and Swartz, 2006). In vivo almost all 
tissues are tethered in a way that cell contraction will lead to increased mechanical stress of the 
surrounding matrix, with this again influencing the cells within these tissues. Mechanical signals are 
important for cell function. For example, fibroblasts can only differentiate into myo-fibroblasts when they 
are cultured in mechanically loaded or restrained collagen gels (Tomasek et al., 2002). Therefore, free 
floating unrestrained collagen lattices are not an ideal model for mechano-regulated processes (Tomasek 
et al., 2002; Pedersen and Swartz, 2005). Here we embedded the mechanically weak collagen gel within a 
rigid polyurethane sponge. This allows the cells to remodel the collagen matrix, but the whole device is 
stiff enough to withstand the contraction forces by the cells (Tomei et al., 2009a, 2009b). We think this 
device resembles closely LNs as in these organs the ECM is anchored to the rigid capsule that is 
comparable to the polyurethane sponge in our 3D system (Tomei et al., 2009b). Considering this, we 
hypothesized initially that culturing TRC clones/lines in a 3D environment under mechanical stress might 
lead to differentiation and restoration of CCL19, CCL21 and IL-7 production. However, that was not the 
case, indicating that mechanical signals alone are not sufficient. Nevertheless, the application of fluid flow 
on the 3D system induced some CCL21 and CCL19 secretion by the p53-/- TRC clone, but did not reach 
physiological levels (Tomei et al., 2009b) indicating that there are still signals missing.  
In a recent report, Fletcher and colleagues reported the culture of ex vivo isolated TRCs in a collagen-
matrigel matrix (Fletcher et al., 2011a). Consistent with our results, TRCs contracted this gels leading to 
size reduction. Interestingly, when Fletcher and colleagues added BMDCs or splenocytes to this system, 
these cells used the TRC network in these 3D cultures for their migration (Fletcher et al., 2011a). In our 
approach to reconstruct the lymphoid T zone in vitro, we added antigen-specific T cells together with 
activated and antigen-pulsed DCs to the 3D culture system and could observe T cell activation. However, 
both cell types seemed to stay at the edges of the collagen gel, presumably due to the relative lack of 
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oxygen deep within the 3D system. Problems with limited exchange of nutrients and waste metabolites 
arise in 3D cultures with a thickness greater than 1-2mm, which is exceeded in our sponge system 
(Haycock, 2011; Pedersen and Swartz, 2005). Therefore, technical adjustments are needed to improve our 
3D culture system. Bioreactor systems have been established to overcome problems with oxygen and 
nutrient supply. Distinct systems exist to solve this issue, for example rotating vessel cultures or direct 
perfusion systems (Haycock, 2011; Pedersen and Swartz, 2005). However, in both systems cells would be 
cultured under flow conditions and so far it is not known how much flow or shear force T cells and DCs 
experience within the T zone parenchyma. As lymph is mostly canalled around the LN or in the conduit 
system, one might speculate that although TRCs experience flow through the conduits, T cells and DCs 
might be in an environment mostly free of flow and extracellular fluid (Kaldjian et al., 2001). This must 
be considered, if perfusion systems are used. An oxygen bubbling system, as reported (Kurata et al., 
2007), or the integration of hollow fibres in the 3D scaffold might be a solution (Haycock, 2011). In the 
human artificial lymph node from Giese and colleagues this problem was solved by the integration of 
membranes in the bioreactor that are continuously perfused with CO2 and O2 (Giese et al., 2010).  
There are several approaches that aim to reconstruct organs in vitro (Pampaloni et al., 2007; Kobayashi 
and Watanabe, 2010; Griffith and Swartz, 2006). Besides the in vitro application for research purposes, 
there is a lot of interest in the use of artificial organs for medical purposes. In 2007 Okamoto and 
colleagues reported that transplantation of a collagen sponge containing a LTproducing thymus 
derived stromal line under the kidney capsule of mice led to vascularisation and infiltration by 
lymphocytes as well as generation of FDC networks. Distinct T and B cell zones were also observed. 
Importantly, adaptive immune response could be elicited in this transplanted LN and even transferred 
into immune-deficient mice (Kobayashi and Watanabe, 2010; Okamoto et al., 2007). Polyurethane is a 
biocompatible material and is used in the clinics, for example in form of vascular grafts for heart patients 
(Santerre et al., 2005). Therefore, it should be possible to transplant our 3D TRC culture system into 
mice, for example under the kidney capsule. It would be interesting to test whether lymphocytes would 
infiltrate such transplants and whether adaptive immune responses could be induced. Furthermore, it 
would be worthwhile to investigate whether in this in vivo environment the TRC cell lines would restore 
their CCL21, CCL19 and IL-7 expression, and whether they can differentiate into other fibroblast types. 
Interestingly, in their report Amé-Thomas and colleagues showed that treatment of BM-derived-MSCs 
with TNF and LT12 for 7 days induced their differentiation into FRC-like cells as based on the 
expression of ICAM-1, VCAM-1, Ccl19 and ECM molecules (Amé-Thomas et al., 2007). This indicates 
that BM and possibly SLO contain MSCs and that these cells might be a precursor for FRCs. The 
transplantation of MSCs within the described 3D culture system might be a good way to test whether 
MSCs can also differentiate into FRCs in vivo. The use of GFP-tagged TRCs or MSCs would allow to fate-
map the transferred cells. 
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Though TRC clones and lines reported here lost the expression of Ccl19, Ccl21 and Il-7, many features of 
TRCs are preserved. Furthermore, 3D culture of these cells allows reconstructing an in vivo like lymphoid 
T zone in which recombinant cytokines such as CCL21 and IL-7 can be included. Therefore, the 
established clones/lines cultured in 2D but especially in 3D represent a valuable tool to study TRC 
biology.  
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2.2. Fibroblastic reticular cells attenuate T cell expansion by producing nitric 
oxide* 
 
 
Summary 
To define the precise role of TRCs in T cell priming an in vitro T cell activation assay was established. 
Activation of OVA-specific OT-I T cells by OVA-peptide presenting bone-marrow derived DCs 
(BMDCs) was studied in presence or absence of TRCs. Surprisingly, TRC lines and ex vivo TRCs inhibit T 
cell proliferation but not differentiation. TRCs share this feature with fibroblasts from non-lymphoid 
tissues as well as mesenchymal stromal cells. We identified FRC as strong source of nitric oxide (NO) 
thereby directly dampening T cell expansion as well as reducing the T cell priming capacity of DCs. The 
expression of inducible nitric oxide synthase (iNOS) was up-regulated in a subset of TRCs by both DC-
signals as well as interferon- produced by primed CD8+ T cells. Importantly, iNOS expression was 
induced during viral infection in vivo in both LN TRCs and DCs. As a consequence, the primary T cell 
response was found to be exaggerated in iNOS-/- mice. Our findings highlight that in addition to their 
established positive roles in T cell responses TRCs and DCs cooperate in a negative feedback loop to 
attenuate T cell expansion during acute inflammation. 
 
 
 
 
 
 
                                                      
* Based on: Siegert S, Huang HY, Yang CY, Scarpellino L, Carrie L, Essex S, Nelson PJ, Heikenwalder M, 
Acha-Orbea H, Buckley CD, Marsland, BJ, Zehn D, Luther SA (2011): Fibroblastic reticular cells from 
lymph nodes attenuate T cell expansion by producing nitric oxide; PLoS One 6 (11) e27618 
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2.2.1. Lymph node TRCs dampen T cell expansion 
To dissect the role of TRCs in T cell activation and differentiation, we initially adopted a reductionist 
approach: T cells were co-cultured with antigen-pulsed bone-marrow derived DCs (BMDCs), either in the 
presence or absence of TRCs. Given the difficulties in isolating pure TRC populations, several 
independent TRC cell lines were established from peripheral lymph nodes (pLN = pool of inguinal, 
axillary and brachial LN) of C57BL/6 wild-type (WT) mice (referred to as ‘pLN1’ and ‘pLN2’) or GFP-
expressing mice (‘GFP-pLN’). All these lines showed typical fibroblastic morphology and a uniform 
surface marker expression pattern comparable to ex vivo isolated TRCs (figure. 2.1.6 and table 2.1.2). In 
contrast to ex vivo TRCs (Link et al., 2007) cell lines expressed only low levels of Ccl19, Ccl21 and Il7 
transcripts (figure 2.1.7a). To circumvent this caveat, initial experiments included exogenously added 
CCL19, CCL21 and IL-7 protein with no difference in the outcome (data not shown).  
To study T cell priming CD45.1+ congenic ovalbumin (OVA)-specific OT-I T cell receptor (TCR) 
transgenic CD8+ T cells were labelled with the proliferation dye carboxyfluorescein succinimidyl ester 
(CFSE), mixed with unspecific WT T cells (CD45.2+) in a ratio of 1:50, and cultured together with 
antigen-pulsed BMDCs on top of an adherent layer of the TRC line. TRCs were previously irradiated to 
limit their proliferation and nutrient consumption. Surprisingly, the total OT-I cell number was strongly 
decreased in presence of the TRC line pLN2 (figure. 2.2.1a). Using CFSE dilution to measure T cell 
proliferation, both the percentage and number of dividing OT-I T cells were strongly reduced in the 
presence of pLN2 (figure. 2.2.1b). The increase in cell size (FSC) and CD44 expression (figure. 2.2.1c) as 
well as the loss of CD62L expression (figure.2.2.1d) occurred in presence of TRCs but to a reduced 
extent. The co-cultures were supplemented with IL-7 and IL-2, so a lack of known pro-survival factors 
for naïve and activated T cells is unlikely to be the cause. In line with that, the number of naïve, undivided 
OT-I T cells was not affected by the TRC presence, nor was the up-regulation of the high-affinity 
receptor chain for IL-2, CD25, on dividing T cells (figure 2.2.1e).  
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Figure 2.2.1: TRCs dampen the expansion of antigen-specific CD8+ T cells 
Flow cytometric analysis of T cell activation: CFSE-labelled OT-I T cells were mixed in a ratio of 1:50 with WT T 
cells (50% CFSE-labelled) and cultured with LPS-activated and OVA-peptide pulsed BMDCs. The assay was 
performed without stromal cells (‘no stroma’) or in the presence of TRCs from distinct sources (1:1:200 ratio of 
TRC to BMDCs, and to T cells). (a) Total OT-I numbers on day 2, 3 and 4 in absence or presence of the pLN2 
TRC line. (b) Proliferation of OT-I (black) or polyclonal T cells (gray) as assessed by CFSE dilution on day 3 or 4. 
Histograms (left) show the percentage (± standard deviation) of divided OT-I cells and bar graphs the absolute OT-
I cell numbers per CFSE dilution peak (right). (c) Dot plots (left) show CFSE dilution versus cell size (FSC) or 
CD44 expression of OT-I T cells after 3 days. Bar graphs (right) indicate the median FSC values or fluorescence 
intensity. (d) Histograms show CD62L expression and bar graphs the percentage of CD62Llow OT-I T cells. (e) As 
c, but showing CD25 expression on OT-I T cells after 4 days. (f,g) Bar graphs show the percentage inhibition of 
OT-I T cell proliferation as based on the proliferating OT-I cell numbers after 3 days of co-culture with different 
TRC lines (f) or ex vivo isolated and enriched TRC (g). The latter are derived from pLN of un-manipulated B6 mice 
or from mice s.c. injected with NP-CGG/Montanide 3 days prior to the TRC harvest (‘activated TRC’). Different 
symbols indicate different experiments. Data are representative of >10 (a-d), 3 (e-g), 2-3 (f) experiments; different 
symbols indicate different experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, p-values relate to ‘no stroma’ 
controls. 
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Importantly, several other fibroblast lines established independently from LN and spleen (Hou et al., 
2010) not only shared the same surface phenotype (figure. 2.1.6 and 2.2.2) but also the inhibitory effect 
on T cell expansion with a reduction in proliferating OT-I T cell numbers of 60-90% (figure. 2.2.1f). 
Importantly, primary TRCs isolated from naïve pLN limited T cell expansion at least as strongly as TRC 
lines (figure. 2.2.1g). Even TRCs isolated from pLN of mice immunized 3 days earlier with NP-CGG in 
Montanide adjuvant maintained these inhibitory properties (figure. 2.2.1g). 
 
 
Figure 2.2.2: Surface phenotype of ingLN and splenic TRC lines as well as ex v ivo  TRCs  
Flow cytometric analysis of the surface phenotype of (a) TRC lines from ingLN and (b) ex vivo isolated TRCs from 
pLN, used in the T cell activation assay shown in figure 2.2.1. (a) The first row shows dot plots for CD31 versus 
CD45 expression and the percentage of CD31- CD45- cells (± standard deviation). Following rows show 
histograms with the indicated surfaces markers on CD45- CD31- cells. Lines were established by S. Essex in the 
laboratory of C. Buckley, Birmingham, UK. (b) CD45- CD31- cells were analyzed in dot plots for CD31 versus gp38 
expression (first row). The following rows show the indicated surface markers on CD45- CD35- CD31- gp38+ cells 
Grey shadowed curves show the ‘no primary antibody control’. (a,b) representative for  3 experiments 
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Next, we examined the effect of TRCs on CD8+ T cell differentiation. OT-I T cells primed in the 
presence of TRCs expressed intracellular interferon gamma (IFN) protein (figure 2.2.3a) and killed target 
cells (figure 2.2.3b), although with markedly reduced efficiency. Together these results demonstrate that 
the presence of TRCs during T cell activation diminishes the expansion or survival of CD8+ T cells and 
to a lesser extent their differentiation into effector cells.  
 
Figure 2.2.3: CD8+ T cell primed in presence of TRCs still produce IFN  and kill target cells 
The T cell activation assay (see legend of figure. 2.2.1) was performed without stroma (‘no stroma’) or in presence 
of the pLN2 TRC line for 4 days followed by flow cytometric analysis of OT-I T cell effector function. (a) Dot 
plots (left) show intracellular IFNg versus CFSE dilution in OT-I T cells after in vitro re-stimulation with 1µM 
SIINFEKL peptide in presence of Brefeldin A. The right panel shows the median fluorescence intensity of IFNg 
expression in OT-I T cells. (b) The cytotoxic capacity of OT-I T cells was assessed by co-incubating OT-I T cells 
(= effector cells, E) from the T cell activation assay in the indicated E:T ratios with SIINFEKL-pulsed-
eFluor670high-labelled splenocytes (= target cells, T) mixed 1:1 with unpulsed-eFluor670low-labelled splenocytes 
(=internal control). After overnight culture the percentage of eFluor670high versus eFluor670low splenocytes was 
analysed and plotted as histograms. Indicated as percentage is the survival index for the target cells, as based on the 
ratio of peptide-pulsed eFluor670high relative to un-pulsed eFluor670low cells (± standard deviation). (a,b): n = 3, 
representative of 3 independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, p -values are relative to ‘no 
stroma’. 
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2.2.2. Fibroblasts from non-lymphoid organs also attenuate T cell proliferation  
It has been reported that murine and human fibroblasts can have anti-proliferative effects on activated T 
cells, similar to mesenchymal stem cells (MSCs) and certain tumour lines (Jones et al., 2007; Haniffa et al., 
2009, 2007; Bouffi et al., 2011; Nauta and Fibbe, 2007; Uccelli et al., 2008). Therefore we tested in our 
system the inhibitory potential of several fibroblastic cell lines established de novo from different non-
lymphoid organs, as well as their ex vivo equivalents (CD45-CD35-CD31-EpCAM-gp38+; figure 2.2.4), and 
compared them to our pLN2 line. In addition, epithelial-like cells from the epidermis and kidney, a MSC 
line and two tumour cell lines (MC38 colon carcinoma and B16-F10 melanoma) were tested.  
Figure 2.2.4: Surface phenotype of non-lymphoid cell lines as well as ex v ivo  stromal cells from non-
lymphoid organs 
Flow cytometric analysis of the surface phenotype of (a) non-lymphoid cell lines or (b) ex vivo stromal cells isolated 
from dermis, epidermis and kidney used in the T cell activation assay shown in figure 2.2.5. (a) The first row shows 
dot plots for CD31 versus CD45 expression and the percentage of CD31- CD45- cells (± standard deviation). 
Following rows show histograms with the indicated surfaces markers on CD45- CD31- cells. Lines from lung were 
established by S. Essex in the laboratory of C. Buckley, Birmingham, UK. MEFs were a kind gift from M. 
Heikenwalder, Munich, Germany. The MC38 and B16-F10 lines were a kind gift from A. Donda, Lausanne, 
Switzerland. All other lines were de novo established. (b) CD45- CD31- cells were analyzed in dot plots for CD31 
versus gp38 expression (first row). The following rows show the indicated surface markers on CD45- CD35- CD31- 
gp38+ cells as black line, and gp38- CD31- cells as dotted line (includes epithelial cells). Grey shadowed curves show 
the ‘no primary antibody control’. (a,b) representative for 2-3 experiments 
 
All cell lines inhibited OT-1 T cell proliferation to an extent comparable with pLN2 (figure. 2.2.5), 
highlighting that inhibition of T cell expansion is a property common to many cell types, including 
fibroblasts from various non-lymphoid organs.  
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Figure 2.2.5: Stromal cells from various non-lymphoid organs decrease antigen-specific T cell 
proliferation 
The T cell activation assay (see legend of figure. 2.2.1) was performed in presence of either stromal cell lines 
(a,b,d) or ex vivo isolated stromal cells (c). OT-I T cells co-cultured for 3 days were analyzed for CFSE dilution 
using flow cytometry. Representative histograms of CFSE dilution (left panel) and the number of proliferating 
OT-I cells as percentage inhibition are presented (right panel, as in figure. 2.2.1). Shown are assays with a (a) 
mouse embryonic fibroblast line (MEFs) and lung fibroblast line, (b) lines derived from different non-lymphoid 
organs (dermis, heart, femoral muscle, kidney), (c) ex vivo isolated adherent cells from the dermis, epidermis or 
kidney, (d) Mesenchymal stem/stromal cell (MSC) line and the tumour cell lines B16-F10 (melanoma) and MC-38 
(colon carcinoma). (a-d) n  3, representative for  2 experiments. Different symbols indicate different 
experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, if not indicated otherwise p-values are relative to ‘no stroma’. 
The dotted line indicates the inhibition observed by pLN2 cells within the same experiment 
 
2.2.3. TRCs directly inhibit T cell proliferation and render DCs less stimulatory 
MSCs have been shown to inhibit T cell proliferation by intracellular expression of enzymes such as 
indoleamine 2,3-dioxygenase (IDO) and arginase-1, surface expression of PD-L1 or by secretion of 
molecules like NO, prostaglandin E2 (PGE2), IL-10 and TGF- and (Nauta and Fibbe, 2007; Uccelli et 
al., 2008). The proposed pathways included direct inhibition of T cell proliferation or conversion of DCs 
to a non-stimulatory or suppressive phenotype (Svensson and Kaye, 2006; Uccelli et al., 2008). To 
examine whether TRCs can directly interfere with T cell proliferation pLN2 were co-cultured with anti-
CD3/CD28 bead-stimulated T cells. Clearly, TRCs diminished the number of dividing T cells but the 
inhibitory effect was only half of what we had observed in the BMDC-induced T cell activation assay 
(figure. 2.2.6a). Next, potential effects of TRCs on the stimulatory capacity of antigen-pulsed BMDCs 
were investigated by co-culturing first pLN2 with BMDCs before incubating these ‘TRC-conditioned’ 
BMDCs alone with T cells. The capacity to stimulate T cell proliferation was reduced by half in 
conditioned relative to unconditioned BMDCs (figure. 2.2.6b). Together these results indicate that TRCs 
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limit T cell expansion in two additive ways, by making DCs less immunogenic and by directly inhibiting T 
cell proliferation or survival.  
 
Figure 2.2.6. TRCs dampen T cell proliferation by modifying both T cells as well as BMDCs 
(a) Flow cytometric analysis of T cell proliferation induced by anti-CD3/CD28 beads as based on CFSE dilution 
after 3 days of culture. WT T cells were cultured with beads and in presence of the pLN2 TRC line (T cell to TRC 
ratio of 100:1) or their absence (‘no stroma’). Representative histograms  (top) show the percentage (± standard 
deviation) of divided CD8+ T cells and bar graphs (bottom) the absolute CD8+ T cell numbers per division. The 
bar graph (right) shows percentage of inhibition (as in figure. 2.2.1). Similar data were obtained for CD4+ T cells 
suggesting TRCs may also suppress their expansion (data not shown). (b) Flow cytometric analysis of cell 
proliferation induced by TRC-conditioned BMDCs. LPS-activated and SIINFEKL-pulsed BMDCs were co-
cultured with pLN2 TRCs at a ratio of 1:1, or cultured alone. After overnight culture TRC-conditioned-BMDCs 
were re-isolated by MACS, counted and subsequently co-cultured for 3 days with CFSE labelled OT-I cells mixed 
1:50 with unspecific WT T cells (of which 50% are CFSE labelled). Representative histograms (top) show the 
percentage (± standard deviation) of divided OT-I cells and bar graphs (bottom) the absolute cell numbers per 
CFSE dilution peak. Percentage of inhibition (as in figure. 2.2.1) is shown in the bar graph on the right. (a,b) n = 
3, (a) representative for  3 experiments, (b) representative for 2 experiments. * p < 0.05, ** p < 0.01, *** p < 
0.001, if not indicated otherwise p-values are relative to ‘no stroma’. 
 
2.2.4. TRCs limit T cell expansion by producing NO  
To gain insight into the nature of the TRC-derived inhibitory factor T cells and BMDCs were either 
separated from the pLN2 by a permeable-membrane (transwell) or simply incubated with supernatant 
(SN) from pLN2. Both settings led to a decrease in T cell expansion, but this was smaller than in co-
cultures where all the three cell types are intermingled (figure. 2.2.7a). These results suggest a role for 
either a soluble factor which acts only efficiently at short distance, or for at least two inhibitory factors, 
one being soluble and the other being cell-cell contact dependent. It also argues against a role for TRCs in 
presenting antigen to T cells and thereby inhibiting T cell proliferation. To identify the molecules 
responsible for suppressing T cell expansion in our assay several candidates or their synthesis pathway 
were blocked, including PD-L1, TGF, IL-10, IDO and arginase-1 but none of them neutralized the 
TRC-mediated inhibition (figure 2.2.7b). 
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However, blocking the enzymatic activity of iNOS (NOS2) or cyclooxygenase (Cox) -1 and -2 partially 
rescued T cell proliferation with the effects of the two pharmacological inhibitors used being partially 
additive (figure. 2.2.8a). This result demonstrates that iNOS-dependent NO and COX-1/2 dependant 
factors are responsible for most of the inhibitory effect observed. We focused our attention on iNOS as 
transcripts for Inos but not Cox2 were enhanced in stimulated TRCs (as shown later). Strikingly, Inos-/- 
TRCs had lost all suppressive activity and showed even an enhancement of T cell proliferation, in 
contrast to the inhibitor 1400W that partially abolished the suppressive effect of ex vivo WT TRCs (figure. 
2.2.8b), reminiscent of the effects seen for the pLN2 line (figure. 2.2.8a). To show directly the expression 
of iNOS protein in TRCs and assess the frequency of iNOS-expressing cells, antibodies to iNOS were 
used in immunofluorescence microscopy. iNOS protein could only be detected in pLN2 co-cultures with 
BMDCs and activated T cells. However, iNOS was only detected in a small fraction of gp38+ TRCs 
(figure. 2.2.8c). Occasionally, iNOS protein staining was observed in BMDCs-like cells (gp38-) but never 
in lymphocytes (not shown). These experiments establish that TRCs are a source of iNOS that inhibits T 
cell proliferation. They also demonstrate that the inhibitory activity of TRCs on T cell expansion is not 
due to metabolic effects of co-culture. 
 
Figure 2.2.7: Inhibition of T cell 
proliferation by TRCs is mediated by a 
soluble factor 
Flow cytometric analysis of the T cell activation 
assay (as described in figure. 2.2.1): bar graphs 
show percentage of inhibition. (a) pLN2-TRCs 
in the assay were present in the same well 
(‘control’) or separated by a permeable 
membrane (transwell). Or 30% pLN2-TRC-
conditioned- supernatant taken after 72h from 
subconfluent irradiated cultures was added to 
the cultures (b) Pharmacological inhibitors 
against IDO (1MT, 1mM), arginase-1 (BEC, 
200µM) or blocking antibodies against PDL1 
(20µg/ml), TGF (30µg/ml) or IL-10 
(20µg/ml) were added to co-cultures. One out 
of several tested inhibitor concentrations is 
shown along with the percentage of inhibition. 
The dotted line shows the average inhibition by 
pLN2 TRCs without inhibitor/blocking 
antibodies.  (a,b) n 3; representative for 2 
experiments. * p < 0.05, ** p < 0.01, *** p < 
0.001, if not indicated otherwise p-values are 
relative to ‘no stroma’ 
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Figure 2.2.8: Inhibition by TRCs is mediated via NO and COX-1/2 dependant factors 
Flow cytometric analysis of the T cell activation assay (as described in figure. 2.2.1): (a) Pharmacological inhibitors 
against iNOS (1400W, 1 µM) and/or COX-1/2 (indomethacin, 10 µM) were added to the co-cultures after 
optimization of their concentrations (tested range for 1400W: 1-10 µM; for indomethacin: 1-10 µM). The 
histograms show the percentage of divided OT-I cells (± standard deviation) and the bar graph (right) shows the 
percentage of inhibition. (b) T cell activation assay was carried out in the presence of ex vivo isolated enriched TRCs 
from WT or Inos-/- mice along with the indicated inhibitors. The histograms show the percentage of divided OT-I 
cells (± standard deviation) and the bar graph (middle) shows the percentage of inhibition. (c) 
Immunohistochemical analysis of iNOS expression in pLN2 TRC lines. pLN2 cells were cultured alone (top) or in 
presence of OT-I and WT T cells together with LPS activated, SIINFEKL-pulsed BMDCs (ratios as in figure. 2.2.1) 
(bottom). Insets of higher resolution images are shown to indicate the generally increased iNOS expression level in 
pLN2 cocultured with BMDCs, antigen and T cells. (d) Bar graph showing NO2- levels in the co-culture supernatant 
from the T cell activation assay shown in (b,c) as determined using a Griess assay. (a-d) n  3, (a) representative for 
 3 experiments, (b,d) representative for 2, (c) 1 experiment; * p < 0.05, ** p < 0.01, *** p < 0.001, if not indicated 
otherwise p-values are relative ’no stroma’. 
As readout of iNOS activity, we measured extracellular nitrite levels in the SN. In absence of TRCs the 
SN of T cells activated by BMDCs contained very low levels of nitrite. Presence of pLN2 or ex vivo TRCs 
in this assay increased the NO2- concentration 2- and 5-fold, respectively (figure. 2.2.8d), further 
strengthening the notion that NO production by TRCs leads to inhibition of T cell proliferation or 
survival. In the case of ex vivo TRCs approximately half of the nitrite was due to iNOS activity in TRCs as 
suggested by the use of 1400W or Inos-/- TRCs. They also suggest a contribution of NO production by 
one of the two other NOS isoforms which are insensitive to concentrations of 1400W used and possibly 
expressed in TRCs or in the few endothelial cells found within the adherent cell fraction. As the levels of 
iNOS protein correlate better with NO-mediated inhibition of T cell expansion than those of extracellular 
nitrite, the subsequent analysis was focused on the factors inducing iNOS expression in TRCs. 
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2.2.5. IFN  and other T cell derived cytokines induce iNOS protein expression in TRCs 
To look at the role of T cells in inducing iNOS protein in TRCs, pLN2 were co-cultured with T cells and 
fixed cells analysed for intracellular iNOS protein by immunohistology. Non-activated T cells induced 
iNOS in only a few TRCs whereas T cells activated with anti-CD3/CD28 beads up-regulated iNOS in a 
large proportion of TRCs (figure. 2.2.9a). This suggests that most TRCs have the potential to express 
iNOS upon activation but typically only a small proportion shows detectable protein. IFN is a T cell-
derived cytokine known to induce iNOS expression in various cell types (Lavnikova and Laskin, 1995; 
Bogdan et al., 2000; Bogdan, 2001; Ren et al., 2008). Indeed, adding recombinant IFN was sufficient to 
induce iNOS expression in a fraction of pLN2 (figure. 2.2.9a). Comparable results were obtained with ex 
vivo LN cells when the adherent cells enriched for gp38+CD31- TRCs were used in presence of naïve or 
activated T cells or IFN (figure. 2.2.9a). Consistent with these data a significant increase in nitrite was 
observed in the SN of TRC lines or ex vivo TRCs upon IFN stimulation or upon addition of T cells with 
or without anti-CD3/28 activation (figure. 2.2.9b).  
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Figure 2.2.9: IFN  or activated T cells induce iNOS expression in TRCs 
Immunohistochemical analysis of iNOS expression in pLN2 TRC lines (a) or ex vivo (b). pLN2 TRCs or TRC-
enriched cells from pLN of WT mice were cultured for 2 days either alone (first row), in the presence of WT T cells 
without (2nd row), with anti-CD3/28 beads (3rd row), or in the presence of 10ng/ml recombinant IFN (4th row). (a) 
iNOS is shown in red and gp38 TRCs in green. Blue shows DAPI+ nuclei. Tiny nuclei are from T cells, larger nuclei 
from BMDCs and pLN2. (b) The first column shows iNOS in red and DAPI in blue, except the last row that shows 
the ‘no primary antibody’ control in red. The second column shows gp38+ CD31- TRCs and gp38+ CD31+ 
lymphatic cells. Arrows show examples of gp38+ CD31- TRCs expressing iNOS. Scale bar 50µm. (c) Analysis of the 
NO2- concentration in the supernatants from co-cultures shown in a and b. (a-c) n= 3-5, representative for 2 
experiments. * * p < 0.05, ** p < 0.01, *** p < 0.001 
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To obtain a more quantitative assessment of iNOS-expressing TRCs, iNOS-expressing cells were 
measured using intracellular staining and flow cytometry. This analysis showed that while IFN induced 
few TRCs to become iNOS-positive, there was a strong synergistic effect when both IFN and BMDCs 
were present in the co-culture with up to 25% TRCs being positive (figure. 2.2.10a). Given that BMDCs 
were occasionally observed to express iNOS in the co-cultures, we assessed the influence of IFN and 
TRCs on the ability of BMDCs to express iNOS. Interestingly, both IFN and TRCs induced iNOS 
protein expression in around 3% of BMDCs, but having both IFN and TRCs in the co-culture led to a 
strong synergistic iNOS expression in up to 30% of BMDCs (figure. 2.2.10a). This synergy was reflected 
in the almost 10-fold increase in extracellular nitrite levels detectable in the SN (figure. 2.2.10b). 
Interestingly, more than 50% of the nitrite seemed to be due to iNOS expression in TRCs rather than 
BMDCs as assessed using Inos-/- BMDCs. At present, a contribution by the two other NOS isoforms to 
nitrite production can not be excluded. 
Figure 2.2.10: iNOS and NO production is highest when TRCs, BMDCs and IFN  are present 
(a) Flow cytometric analysis of intracellular iNOS expression in pLN2 TRCs or BMDCs, cultured for 2 days either 
alone or together and with or without 10ng/ml recombinant IFN. The histograms show the percentage of iNOS-
expressing TRCs (gp38+ CD45- CD31-; panel on the left) or BMDCs (CD45+; panel on the right) (± standard 
deviation). (b) NO2- concentration in the supernatant from the co-cultures in a; (a,b) n= 2, representative for 2 
experiments.  
Next we analyzed the speed of iNOS induction in pLN2 by looking at transcript levels. Already 7h after 
IFN stimulation Inos mRNA was induced 10-fold and further increased after 24h indicating direct 
transcriptional regulation of the Inos promoter (figure. 2.2.11). Interestingly, several pro-inflammatory 
cytokines (IFN, TNF, LT3) or LPS showed a similarly rapid and strong induction of Inos transcripts 
while their maintenance at 24h differed. TRCs constitutively expressed Cox2, which was slightly elevated 
after stimulation with IL-1, TNF, LT3 or LPS. In summary, these results demonstrate that a subset 
of both TRCs and BMDCs can be triggered to express Inos transcripts and proteins leading to the release 
of NO. Various pro-inflammatory signals can serve as triggers in TRCs, including signals derived from 
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newly primed T cells suggesting the possibility of a negative feedback loop leading to inhibition of T cell 
expansion in our in vitro co-culture assay.  
 
Figure 2.2.11: Various pro-inflammatory cytokines induce iNOS expression in TRC line 
Quantitative RT-PCR analysis for Inos mRNA (a) or Cox2 mRNA (b) of pLN2 cells stimulated with various 
cytokines, the agonistic anti-LTR (LTR) or the TLR4 ligand LPS for 7h or 24h. The expression levels relative 
to two housekeeping (Hprt and Tbp) genes are shown. Different symbols indicate different experiments. (a,b) n=2-
3, representative for 2 experiments. * p < 0.05, ** p < 0.01, *** p < 0.001 
 
2.2.6. Inos  deficiency leads to exaggerated CD8+ T cell responses in v ivo  
To characterize the expression of iNOS during immune response in vivo, mice adoptively transferred with 
OT-I T cells were immunized with OVA-expressing vesicular stomatitis virus (VSV-OVA) and draining 
LN analyzed. By pressing LN across a 40 µm mesh a soluble fraction containing most hematopoietic cells 
was obtained as well as a non-soluble stromal cell fraction, including TRCs and part of the DCs (Luther et 
al., 2000; Link et al., 2007). Interestingly, one day after immunization Inos transcripts were induced in both 
fractions and dropped back to pre-immunization levels on day 2 and 4 (figure. 2.2.12a). These levels were 
always 5-10-fold higher in the fraction enriched in stromal relative to hematopoietic cells. To identify 
more precisely the cell type and frequency of iNOS expressing cells in the draining LN intracellular iNOS 
protein expression was analyzed by flow cytometry along with lineage markers. A subset of at least 2.6% 
TRCs were identified as major iNOS source appearing on day 1 and being again undetectable on day 2 
and 4 post infection (figure. 2.2.12b). DCs showed a weak induction of iNOS expression on day 1 
without reaching statistical significance relative to day 0. Few macrophages (CD11b+ CD11c-) were also 
found to express iNOS protein (data not shown). This result emphasizes the inducible and transient 
activation of iNOS both at the mRNA and protein level, consistent with pro-inflammatory molecules 
inducing it. It also strengthens the notion of more than one cell type expressing iNOS within the T zone 
of draining LN, most notably TRCs and DCs. Our attempts to identify and localize iNOS protein-
expressing cells in situ were not successful (data not shown), consistent with the low iNOS expression 
detected by flow cytometry.  
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Figure 2.2.12: Lack of iNOS in  v ivo  leads to an increased primary T cell response after viral infection 
WT or Inos-/- mice were retro-orbitally grafted with 100'000 splenocytes from OT-I transgenic mice one day prior 
to subcutaneous infection with VSV-OVA. (a,b) Regional pLN from infected mice were harvested 1, 2 or 4 days 
after infection. (a) Normalized Inos mRNA levels as analyzed by quantitative real time-PCR on crude fractions of 
LN. (b) Intracellular iNOS protein expression in TRCs (gp38+CD45-CD31-CD35-) or DCs 
(CD11c+MHCII+CD45+) as analysed by flow cytometry on collagenase-digested LN. Representative histograms 
show the percentage (± standard deviation) of iNOS expressing TRCs (top) and DCs (bottom) in WT versus Inos-
/- mice. (c) A pool of 6 draining pLN harvested after 4, 6 or 8 days after infection were homogenized and analyzed 
by flow cytometry. The graph on the left side shows the total CD8+ T cell numbers in pLN, the graph in the 
middle the percentage of OT-I T cells among the CD8+ T cells and the graph on the right side the total OT-I 
number. No significant difference was observed in total CD8+ T cell numbers between immunized WT and Inos-/- 
mice. (d,e) Blood of VSV infected mice collected 4, 6 and 8 days after infection (d) and spleen harvested on day 8 
(e) were analyzed by flow cytometry for the presence of OT-I T cells. (d) shows the percentage of OT-I T cells 
among the CD8+ T cells in the blood, (e) shows the total number of OT-I T cells in the spleen. (a-e) n  3. (b-e) 
1 out of 2 independent experiments is shown. * p < 0.05, ** p < 0.01, *** p < 0.001 
As a next step the impact of Inos-deficiency on OVA-specific T cell expansion and survival was measured 
in the LN draining the site of VSV-OVA injection. While on day 4 after immunization the total CD8+ T 
cell number was similar in both mouse strains the percentage and number of OT-I T cells was 2-fold 
higher in Inos-/- relative to WT mice (figure. 2.2.12c). On day 6 and 8 after immunization, the difference in 
OT-I T cell numbers was minimal between the two strains presumably due to many effector cells having 
left the LN between day 5 and 8. This scenario is supported by the strong increase in OT-I cells in blood 
between day 4 and 6 as well as by the significantly higher frequency of OT-I cells in blood of Inos-/- 
relative to WT mice (figure. 2.2.12d). As a consequence 2-fold more effector OT-I T cells accumulated 
within day 8 spleen in Inos-/- relative to WT mice (figure. 2.2.12e). Interestingly, the differentiation into 
effector cells occurred efficiently in the absence of iNOS, as based on the analysis of IFN expression 
and in vitro killing activity of effector CD8+ T cells from LN and spleen (figure. 2.2.13).  
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Figure 2.2.13: CD8 effector cells generated in VSV-OVA infected WT or Inos -/-  mice show no difference 
in killing ability or IFN  expression 
WT or Inos-/- mice received 0.1 x 106 OT-I splenocytes by retro-orbital injection 1 day prior to infection with VSV-
OVA. Draining pLN and spleen were harvested on day 4 and 6 after infection, homogenized and analyzed for 
IFN protein expression in OT-I T cells using flow cytometry (a) or for killing activity (b). (a) Histograms show the 
percentage of OT-I T cells (standard deviation) expressing intracellular IFN. Bar graphs show the fluorescence 
intensity of the IFN staining within OT-I T cells. (b) Cells from day 6 were used in an in vitro killing assay. The 
specific lysis of target cells is shown for the respective effector to target ratios. (a,b) n= 3. (a) representative for 2 
experiments. (b) 1 experiment (but similar data were obtained for day 8 LN and spleen, not shown) 
 
To address whether iNOS expression is critical in hematopoietic or non-hematopoietic cells bone marrow 
chimeras were generated. Unfortunately, a cell trapping defect was observed in inflamed LN if the 
stromal cell compartment was Inos-deficient, presumable due to a role of NO in vasodilatation in 
irradiated mice but not straight Inos-/- mice (figure 2.2.14). Therefore, no conclusions could be drawn from 
these experiments. In summary, the in vivo data indicate that acute inflammation associated with a viral 
infection leads to the transient expression of NO by TRCs and BMDCs found within the LN T zone, 
which slows down and lowers the antigen-specific T cell expansion but does not seem to impact on the 
differentiation and migration of effector T cells. 
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Figure 2.2.14: Bone marrow chimeras lacking Inos  in the 
non-hematopoietic system show a lymphocyte trapping 
defect in immunized lymph nodes 
To assess the relative contribution of hematopoietic versus 
non-hematopoietic cells as iNOS source, BM chimeras were 
generated having Inos-deficiency in either the hematopoietic 
system (Inos-/- BM into WT hosts) or non-hematopoietic system 
(WT in Inos-/-) and were compared with control chimeras (WT 
into WT). 2 month after reconstitution, BM-chimeras were 
infected with VSV-OVA (as described in figure 2.2.12) and 4 
days after infection pLN were collected, single cell suspensions 
counted and stained before analysis using flow cytometry. As 
comparison non-immunized BM-chimeras are shown. Inos-/- 
into Inos-/- chimeras have not been made. Surprisingly, none of 
the chimeras showed an increased OT-I expansion. Rather, 
Inos-deficiency in either the hematopoietic or the non-
hematopoietic system led to a strong decreased OT-I 
expansion. Surprisingly, lymphocyte trapping did not occur in 
the case of Inos-deficiency in the non-hematopoietic 
compartment, in contrast to the other two groups and the non-
chimeric Inos-/- mice (figure 2.2.12). Therefore, the expansion of 
OT-I T cells cannot be interpreted for that group of mice. The 
lack of OT-I expansion in the group of mice having Inos 
deleted in the hematopoietic system indicates also a positive 
role of Inos in T cell proliferation, presumably in a low but not 
high concentration, as previously suggested (Niedbala et al., 
2006). In all BM chimeras the chimerism was >85% as assessed 
by measuring ratio’s of CD45.1 (WT) versus CD45.1 (Inos-/- or 
WT) expression on total LN cells using flow cytometry. 2-4 
mice per group, one experiment. 
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of  the manuscript; Alena Donda, Greta Guarda, Catherine Ronet, Carl Ware and Anne Wilson with 
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2.2.8. Discussion 
Inflamed LN as well as the TRC network are generally considered as strongly immune-stimulatory for T 
cell immunity. Surprisingly, we obtained several lines of evidence demonstrating an inhibitory role of 
TRCs in early T cell activation: 1) In vitro TRCs limit the expansion of CD8+ T cells primed by antigen-
pulsed BMDCs or anti-CD3/28 beads at TRC-T cell ratio’s as low as 1:100 with T cell effector function 
being reduced as well. 2) TRCs reduce the T cell activation potential of antigen-loaded BMDCs. 3) TRCs 
constitutively express transcripts for Cox-2, the enzyme required for the synthesis of PGE2 and related 
factors (Tsatsanis et al., 2006). Inhibition of Cox-1/2 markedly reduces this suppressive effect. 4) When 
exposed to pro-inflammatory cytokines pLN2 and ex vivo TRCs transiently express iNOS protein leading 
to NO2- synthesis. This correlates with rapid induction of Inos transcripts in activated pLN2. Inhibition of 
iNOS or use of Inos-deficient TRCs markedly reduces the suppression with this effect being enhanced by 
a Cox-2-inhibitor. 5) Upon immunization, iNOS protein gets transiently expressed in TRCs and DCs 
within the draining LN. 6) Absence of iNOS in vivo correlates with an exaggerated primary CD8+ T cell 
response, consistent with the previous observation of an exaggerated memory T cell response in Inos-/- 
mice (Vig et al., 2004). Thus, while TRCs may have several ways of enhancing T cell activation, our assays 
have only revealed attenuating effects.  
Attenuating effects of TRCs on T cell immunity have been reported recently based on the expression of 
self-antigen in the context of MHC I as well as PD-L1 expression on TRCs leading to modulation of 
CD8+ T cell responses (Mueller et al., 2007; Lee et al., 2007; Fletcher et al., 2010). Here we have used 
fibroblasts of the LN T zone to show that they are a source of soluble immunomodulators such as NO 
and COX-1/2 dependent factors strongly inhibiting T cell expansion in response to a foreign antigen, 
with no role observed for PD-L1. Another study had noted iNOS expression in reticular LN fibroblasts 
upon infection with Leishmania major parasites, but the precise nature and localization of these cells have 
remained unclear. In addition, NO was in that case shown to be important for the control of the parasite 
rather than for adaptive immunity (Bogdan et al., 2000). Together these data suggest TRCs may help 
control CD8+ T cell responses to both self- and foreign-antigens. Whether they also modulate the 
deletion of self-reactive T cells still needs to be tested. 
Two previous reports have highlighted the capacity of spleen-derived stromal cells in inhibiting T cell 
activation. A mix of adherent stromal cells, possibly including TRCs, was shown to promote development 
of BM-derived progenitor cells into IL-10+ regulatory DCs (Svensson et al., 2004) or the conversion of 
mature BMDCs into NO+ regulatory DCs (Zhang et al., 2004). We did not observe consistent changes in 
the surface phenotype of TRC-conditioned DCs, possibly because our co-cultures were less than 16h 
allowing only short-term changes. In contrast, the previous reports were based on co-cultures of 1-2 
weeks allowing developmental changes. While we have not yet identified the reason for the decreased 
stimulatory capacity of TRC-conditioned DCs it may be due to the rapid induction of iNOS in BMDCs.  
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Our results are reminiscent of observations with MSCs known to modulate many aspects of innate and 
adaptive immunity, including T cell proliferation (Nauta and Fibbe, 2007; Uccelli et al., 2008). In vitro BM-
derived MSCs were shown to block mitogen- and DC-induced T cell proliferation by many different 
pathways, including NO and PGE2 production (Aggarwal and Pittenger, 2005; Sato et al., 2007; Ren et al., 
2008). In settings of allografts and autoimmune disease large numbers of injected MSCs strongly suppress 
T cell responses due to their anti-inflammatory properties, and due to their efficient homing to 
inflammatory sites and lymphoid tissues (Von Luttichau et al., 2005; Nauta and Fibbe, 2007; Uccelli et al., 
2008). Interestingly, mature mesenchymal cells such as fibroblasts from various non-lymphoid tissues also 
dampen T cell expansion (Jones et al., 2007; Haniffa et al., 2007; Uccelli et al., 2008; Bouffi et al., 2011) 
suggesting mesenchymal cells at several maturation stages share this property. Alternatively, MSCs and 
fibroblasts may be hard to distinguish (Haniffa et al., 2009). We propose that LN and spleen TRCs have 
conserved this immunosuppressive property that they share with MSCs and fibroblasts from non-
lymphoid tissues. The extent of inhibition was highly dependent on the number of TRCs being present in 
the culture (unpublished observation) which may explain the difference in the extent of NO-mediated 
suppression observed in vitro versus in vivo. Our preliminary results suggest that this inhibitory effect not 
only affects CD8+ but also CD4+ T cells. Besides affecting T cell expansion and possibly apoptosis, TRC 
presence partially reduced effector differentiation in vitro but not in vivo. While the reason for this 
difference is not known, it may be explained by the presence of lower NO concentrations or additional 
factors found in vivo that positively influence CD8+ T cell differentiation. Given that TRCs and non-
lymphoid fibroblasts can be grown easily from many accessible tissues in humans, such as tonsils or skin, 
they may represent an interesting source of immunomodulatory cells. A very recent study using skin 
fibroblasts has established their potential in efficiently suppressing the clinical signs of experimental 
arthritis in mice (Bouffi et al., 2011). 
Different mechanisms of suppression have been described for MSCs: they can either directly inhibit T cell 
activation or reduce the stimulatory capacity of DCs by various means (Nauta and Fibbe, 2007; Uccelli et 
al., 2008). MSCs can produce high amounts of NO upon contact with T cells which interferes with 
STAT-5 phosphorylation and therefore IL-2 signalling. MSC-mediated T cell suppression could be 
partially neutralized using inhibitors of iNOS or COX-2, or using Inos-/- MSCs (Sato et al., 2007; Ren et 
al., 2008) thus showing clear parallels in MSC- and TRC-mediated T cell mechanisms. In our in vitro 
experiments we have obtained evidence for an additive inhibitory effect of NO and COX-1/2 dependent 
factors (possibly PGE2), but additional factor(s) probably remain to be identified to explain the entire 
inhibitory effect. Blocking TGF, PD-L1, IL-10, arginase-1 and IDO activity did not influence TRC 
mediated inhibition, however additional studies will be necessary to fully rule out their contribution. 
Furthermore, we cannot exclude that the other two NOS isoforms - eNOS and nNOS - are expressed in 
TRCs and contribute to the TRC mediated inhibition.  
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The expression and activity of iNOS is tightly controlled at several levels with the best-characterized 
positive regulators being IFN,  IFN-/, TNF,  IL-1 and LPS (Bogdan, 2001). Indeed, iNOS 
expression in TRCs was induced by all of these pro-inflammatory cytokines confirming and extending 
previous data using LN fibroblasts, MEFs and MSCs (Lavnikova and Laskin, 1995; Bogdan et al., 2000; 
Bogdan, 2001; Ren et al., 2008). Interestingly, only a subset of IFN-stimulated TRCs expressed iNOS, 
even when a TRC clone was used (data not shown), in line with previous reports on other fibroblast types 
(Lavnikova and Laskin, 1995; Bogdan et al., 2000) as well as our observation on BMDCs reported here. 
Whether these are distinct cell subsets or whether iNOS expression by some cells prevents expression by 
others remains to be investigated. Recent results suggest that IFN is not restricted to immune synapses 
but more widely accessible throughout the T zone (Perona-Wright et al., 2010) which may explain why 
TRCs obtain this signal in the absence of cognate interaction with primed T cells. Several reports showed 
that IFN during T cell priming influences the degree of CD8+ T cell contraction (Haring et al., 2006). 
While IFN signalling within T cells may lead to this outcome (Haring et al., 2006), our results suggest 
that IFN signalling in TRCs and DCs leading to NO production early after infection might not only 
control the expansion, but also the contraction phase of CD8+ T cells, such as by nitrosylating and 
thereby altering key proteins of the IL-2 or TCR signalling pathway (Bogdan, 2011; Kasic et al., 2011). 
More experiments will be necessary to test this hypothesis and to understand the underlying mechanism.  
Strikingly, iNOS induction and NO2- production was highest when TRCs, activated DCs and IFN were 
present together suggesting only adjacent TRCs become licensed to suppress T cell expansion with this 
being a highly controlled and transient process. The DC-derived signals leading to iNOS expression in 
TRCs remain to be identified. Good candidates are IL-1/ and TNF which may act synergistically 
with IFN, similar to iNOS expression in MSCs (Ren et al., 2008). NO effects are known to be highly 
dose-dependent. Low NO doses can enhance T cell proliferation, as possibly suggested by the decreased 
T cell expansion in some of the BM chimera experiments (Inos-/- into WT).  Higher NO doses are known 
to induce cell-cycle arrest and apoptosis of T cells (Bogdan, 2001; Niedbala et al., 2006) indicating that the 
reduced expansion seen in presence of TRCs may represent a combined effect of reduced proliferation 
and increased apoptosis of T cells. The dual role of NO may also explain the only two-fold higher 
expansion of T cells in absence of iNOS. Given that NO is a highly reactive gas close proximity to TRCs 
is likely to be critical in inhibiting T cells and DC activation. To further improve this process cytokine-
stimulated TRCs could actively recruit or retain primed T cells, as suggested for MSCs (Ren et al., 2008). 
Interestingly, TNF-stimulated TRCs were shown to express the IFN-inducible chemokine CXCL10 
that attracts activated but not naïve T cells (Katakai et al., 2004).  
Both in vitro and in vivo, we found not only TRCs but also DCs to express iNOS and produce NO2-. It is 
possible that the iNOS+ DC subset identified in vivo represents the inflammatory tipDC 
(TNF+iNOS+CCR2+) which are recruited into the splenic T zone early during infection with Listeria 
monocytogenes a (Serbina et al., 2003) or other pathogens (Dominguez and Ardavin, 2010) as they were also 
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CD11cint in our analysis (unpublished observation). Interestingly, increased T cell proliferation was also 
reported for Ccr2-/- mice lacking tipDCs (Serbina et al., 2003). In vitro we found iNOS expression in 
BMDCs to be induced in a synergistic manner by IFN and TRC presence, similar to synergistic effects 
of IFN and BMDCs on iNOS expression by TRCs. While the factors involved in the cellular crosstalk 
remain to be identified these findings point to the interdependence of these two cell types in inhibition of 
T cell expansion, an observation which needs further in vivo studies with cell-type specific Inos deletion. 
Our attempts to distinguish between stromal versus hematopoietic sources of iNOS using bone marrow 
chimeras were unsuccessful due to a cell trapping defect in inflamed LN if the stromal cell compartment 
was Inos-deficient, presumably due to a role of NO in vasodilatation in irradiated mice but not straight 
Inos-/- mice. Based on our current results we propose the following working model (figure 2.2.15): Low 
levels of iNOS expression are induced in both immigrating DCs and TRCs when they meet in the T zone 
early during the immune response. This may increase the threshold required for T cell priming and 
thereby prevent the activation of low-affinity T cells that are often self-reactive. Alternatively, it may help 
in T cell priming. Once the first T cells are primed and produce IFN they may boost iNOS expression in 
both cell types in a transient fashion thereby inducing a negative feedback loop dampening T cell 
expansion by either slowing down their proliferation or diminishing their survival. This feedback loop 
may be activated mainly during a very strong immune response. 
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Figure 2.2.15: Model showing how inflammatory cytokines may induce iNOS expression in TRCs and 
create a negative feedback loop limiting antigen-specific T cell expansion 
During the early phase of immune response antigen –specific CD8+ T cells interact with antigen-bearing DCs 
within the context of the TRCs network within the T zone of the draining LN. Upon prolonged cognate 
interactions T cells start to produce IFN and possible other cytokines that induce strong but transient iNOS 
expression in the neighbouring TRCs as well as DCs. The local production of NO creates a negative feedback loop 
in which NO and possibly other inhibitory factors limit the expansion of neighbouring antigen-specific T cells. This 
effect is due in part to direct inhibition of T cell proliferation or survival, in part to a decrease in the stimulatory 
capacity of DCs. NO is known to lead to nitrosylation of cysteine- and tyrosine-containing proteins thereby altering 
their function, including in T cells where reduced T cell proliferation was reported in presence of NO (Bogdan, 
2011). High NO concentrations may also reduce T cell survival. An alternative model is that in vivo innate immune 
cells, such as NK cells, become activated early during the response and release IFN that induces iNOS in TRCs 
and DCs. Together, these processes may prevent overshooting antigen-specific T cell expansion while affecting 
much less T cell differentiation. This selective negative regulation of T cell numbers by TRCs and DCs may allow 
gradual organ and stromal cell growth thereby achieving a compromise between preservation of functional organ 
structure and fast effector T cell differentiation. It is reminiscent of the role of TRCs in controlling naive T cell 
numbers (Link et al., 2007; Zeng et al., 2011). The early and transient induction of iNOS may have also an impact 
on later aspects of the immune response, such as the contraction phase and memory T cell generation, as they are 
thought to be controlled by conditions encountered during T cell priming phase (Williams and Bevan, 2007; Haring 
et al., 2006).  
 
The immunosuppressive feature of mesenchymal cells is intriguing. It raises the question of why these 
cells have this function, especially when considering TRCs localize to the T zone of SLO where inhibitory 
effects are less expected but well known from TipDCs and regulatory T cells. We would like to propose 
two possible reasons: 1) Keeping the LN in a slightly suppressive state might be a mechanism to limit the 
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activation of potentially auto-reactive cells while allowing strong immune responses to foreign antigens to 
occur. In line with this hypothesis we found Cox-2 transcripts to be highly expressed in naïve LN. Others 
showed that high iNOS and NO2- levels are frequently associated with Th1-mediated inflammation, but 
sometimes also with autoimmune disease (Bogdan, 2001; Niedbala et al., 2006) Consistent with a 
protective role of this pathway in certain autoimmune diseases, Inos-/- and Ifn-/- mice have a higher 
incidence, increased severity and less relapses of experimental autoimmune encephalitis that correlate with 
increased proliferation of auto-reactive T cells relative to WT mice (Fenyk-Melody et al., 1998; Xiao et al., 
2008) Similarly, in a mouse model for myasthenia gravis Inos-/- mice develop more self-reactive T and B 
cells, including epitope spreading (Shi et al., 2001). 2) In contrast to recirculating hematopoietic cells 
fibroblasts resident in lymphoid and non-lymphoid organs have a function for the organ itself: ensure its 
integrity and functionality. During injury, such as infection or inflammation, fibroblasts perform tissue 
repair to re-establish homeostasis. LN swelling during immune response can be viewed as a threat to the 
organ as it is characterized by the dramatic increase in organ size due to the influx of many naïve 
lymphocytes as well as the rapid expansion of antigen-specific lymphocytes. The strong increase in 
lymphocyte numbers within the T zone may be harmful for the existing TRC network that functions as 
the structural platform for T cell priming and probably also T cell differentiation. Destruction of the TRC 
architecture, such as after LCMV infection, correlates well with immunodeficiency (Scandella et al., 2008; 
Mueller and Germain, 2009; Svensson and Kaye, 2006). Limiting T cell expansion early in the immune 
response might be necessary to give TRCs the time to adjust step-wise to the new space demands and to 
start proliferating thereby increasing the scaffold size accommodating T cells and DCs. Such a process 
may ensure continuous functionality of the growing organ which is finally also to the benefit of efficient 
effector T cell generation 
.
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Overview over the major findings 
In the first results part of this thesis, I have described the establishment and characterization of LN TRC 
clones and lines, the establishment of a special 3D cell culture system for TRCs in which T cells and 
antigen-bearing DCs can be included. Therefore, I was able for the first time to reproduce a functional T 
zone microenvironment in vitro in which T cell activation could be induced. Much to our surprise, the 
presence of TRCs appeared to reduce rather than enhance T cell proliferation. 
In the second results part of this thesis I have dissected in detail the surprising negative effect of TRCs on 
T cell activation by antigen-presenting DCs using 2D cultures. I have obtained in vitro and in vivo evidence 
for prominent iNOS expression in activated TRCs along with a key role for NO in the attenuation of T 
cell responses. Therefore, we propose that TRCs act not only as positive but also as negative regulators of 
T cell immunity within draining LN.  
3.1. Establishment and characterization of TRC clones / lines and the reconstruction of 
the lymphoid T zone in v i tro 
Culturing adherent cells from digested murine LN led to the outgrowth of fibroblastic cells with a 
morphological and surface phenotype comparable to ex vivo isolated TRCs. However, the production of 
Ccl19, Ccl21 and Il-7 is lost and could not be re-stored by stimulation with various cytokines or TLR 
ligands. One possibility explaining the lack of CCL19, CCL21 and IL-7 expression, might a partial de-
differentiation of TRCs in vitro and it remains to be clarified whether TRC clones and lines still have the 
capability to produce these cytokines. Preliminary experiments by Chen-Ying Yang in the lab failed to 
recover TRCs upon intravenous or subcutaneous cell transfer. It would be interesting to test whether 
injection of these cells via afferent lymphatic vessels would lead to their re-integration into the stromal 
network of the draining LN and whether their cytokine expression is restored in the in vivo 
microenvironment.  
We have established a 3D culture system for TRCs that corresponds much more to a 3D network 
forming cell type than conventional 2D cultures. When collagen-only gels were used strong contraction of 
these was observed (Tomei et al., 2009b; Link et al., 2007), similar to a recent report by Fletcher and 
colleagues, who cultured ex vivo isolated TRCs in a collagen-matrigel matrix. They added the pan Src 
tyrosine kinase inhibitor PP2 to prevent gel contraction (Fletcher et al., 2011a). As this inhibitor blocks 
several Src tyrosine kinases including Lck and Fyn it interferes with TCR signalling and would not be 
appropriate for studies on T cell activation (Salmond et al., 2009; Hanke et al., 1996). To that end, a rigid 
poly-urethane sponge like used in our experiments appears more appropriate (Tomei et al., 2009a, 2009b). 
In both studies, TRCs cultured in 3D show in vivo like morphology and form 3D networks (Tomei et al., 
2009b; Fletcher et al., 2011a). When we added antigen specific T cells and antigen loaded BMDCs to this 
3D culture system, antigen-specific T cell activation was observed. Preliminary microscopical analysis, 
however, indicated that T cells and DCs did not penetrate into the deeper regions of the sponge-collagen 
culture, which was not altered by embedding CCL19 and CCL21 in the collagen matrix. Therefore, this 
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likely arises from insufficient oxygen and nutrient transport due to the thickness of our 3D culture system 
(Haycock, 2011). When Fletcher and colleagues added T cells and DCs to their 3D cultured TRCs, 
migration of T cells along TRC networks was observed (Fletcher et al., 2011a). In contrast to our 3D 
culture, they cultured TRCs in thin gels, in which no problems with oxygen or nutrient supply should 
occur. However, TRCs rapidly contract these matrices, making long-term culture and imaging of T cell 
activation almost impossible. The integration of an oxygen-supply into our 3D culture system should 
allow to perform long-term culture with good gel penetration of cells. An alternative approach to study T 
cell activation in vitro in a more physiological system, would be the use of live vibratome sections, used for 
example by Aspertini-Boursin and colleagues (Asperti-Boursin et al., 2007). However, in such a system 
the composition of the slice, for example the presence of certain chemokines, cannot be as easily 
controlled as in the 3D culture system. More importantly, as no TRC-knock out model is yet described, T 
cell activation could not be observed in the complete absence of TRCs.  
3.2. TRC attenuate T cell proliferation mediated by nitric oxide production 
The presence of TRCs in our in vitro T cell activation assay strongly reduced T cell proliferation and 
partially reduced cytotoxic T cell differentiation into effector cells. It was hypothesized that the TRC 
network helps T cells to efficiently encounter many antigen presenting DCs and in this way positively 
influences T cell activation (Junt et al., 2008; Mueller and Germain, 2009). However, the T cell activation 
assay was conducted in 2D co-cultures in which it should be easier for antigen-specific T cells to find 
antigen-presenting DCs than in 3D, making the described positive influence from TRCs less important in 
that system. To this end, preliminary experiments were conducted in the 3D culture system where in vivo 
like TRC networks were present but T cell proliferation was similarly inhibited compared to the ‘no 
stroma’ control that showed efficient T cell activation. However, as discussed above, the 3D culture 
system still needs optimization in terms of oxygen supply and it remains to be tested, whether the access 
of T cells and DCs to the deeper regions of the sponge might change the outcome of T cell activation.  
Nevertheless, in accordance with our results, Kaminer-Israeli and colleagues reported that presence of a 
murine BM-derived stromal cell line inhibits T cell proliferation induced by antigen-pulsed BMDC in a 
3D culture system in vitro (Kaminer-Israeli et al., 2010). In their report stromal cells were embedded in an 
alginate scaffold along with BMDC, while proteolipid-protein (PLP) specific T cells were added 
exogenously. Addition of stromal cells markedly inhibited T cell proliferation and development into Th1 
or Th17 cells, possibly due to the high levels of IL-10 and TGF- found in the system. Furthermore, the 
BMDC or BMDC/stromal cell seeded alginate constructs could be successfully transplanted under the 
kidney capsule and were shown to maintain PLP antigen in vivo. Transplanted constructs in PLP-TCR 
transgenic mice were infiltrated by T cells, which subsequently proliferated. Also in the in vivo situation, 
presence of stromal cells inhibited T cell proliferation (Kaminer-Israeli et al., 2010). These findings 
suggest that upon optimization of our 3D culture system similar results may be obtained.  
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TRCs in vivo are a major source of the three cytokines IL-7, CCL19 and CCL21, which was taken as 
evidence that TRCs positively regulate T cell responses. In contrast, TRC lines used for most of the 
experiments lack the production of CCL19, CCL21 and IL-7. For this reason, in initial experiments 
recombinant CCL19, CCL21 and IL-7 were added without altering the dampened T cell activation 
observed in presence of TRC lines. Furthermore, freshly isolated ex vivo TRCs, which still produce 
CCL21, CCL19 and IL-7 (Link et al., 2007) (personal communication with T. Vogt) equally inhibited T 
cell proliferation. In summary, we conclude that it is most likely not the lack of the homeostatic 
chemokines or IL-7 production by TRC lines that mediates inhibition of T cell proliferation. However, in 
initial T cell activation assays a considerable number of dying T cells was observed which was ameliorated 
by addition of low doses of recombinant IL-7 and IL-2. None of the two cytokines had obvious effects 
on the TRC-mediated inhibition of T cell proliferation and therefore they were routinely added in further 
experiments to ensure good survival of T cells. This is consistent with previous observations that IL-7 
enhances T cell responses to influenza A infection in vivo, without having effects on T cell activation in 
vitro (Saini et al., 2009; Pellegrini et al., 2011). 
The situation is different for the chemokines CCL21 and CCL19 that are also presented by HEVs and 
LECs (Förster et al., 2008) thereby guiding both lymphocytes and mature DCs into the LN T zone. As a 
consequence, immune responses in LN of CCR7-deficient or plt/plt (paucity of lymph node T cell) mouse 
mutants is delayed (Förster et al., 2008; Cyster, 2005). In our in vitro assay, this role of CCR7 ligands is not 
necessary. It may, as suggested by several in vitro studies, simply increase somewhat T cell motility 
(Asperti-Boursin et al., 2007) and T cell co-stimulation (Friedman et al., 2006; Flanagan et al., 2004; 
Gollmer et al., 2009) besides enhancing DC maturation (Sanchez-Sanchez et al., 2006; Marsland et al., 
2005). However, CCL19 is completely dispensable for effective T cell activation in vivo under the 
conditions tested (Britschgi et al., 2010). Furthermore, viral infection of CCR7-/- mice still results in 
efficient formation of cytotoxic T cells (Junt et al., 2004). It is possible that the effects of CCL19 and 
CCL21 on T cell priming only become detectable in settings of suboptimal stimulation which may not be 
the case in our co-culture systems where we used relatively high OT-I T cell frequencies and fully 
matured BMDCs loaded with saturating doses of peptide.  
An early working hypothesis was that inhibition of T cell proliferation by TRCs might only occur in naïve 
mice and in this way represent a mechanism to prevent activation of auto-reactive T cells. Accordingly, 
stimulation of TRCs with pro-inflammatory signals produced in infections could lead to a functional 
switch in TRCs and make them non-inhibitory. To this end, various cytokines were added to the T cell 
activation assay. None of the tested cytokines or agonists (IL-1, IL-1, IL-6, IL-13, RANKL, TNF, 
LT3, anti-LTR) significantly decreased the inhibition of T cell proliferation, or stimulation led to 
unspecific effects. To draw a definitive conclusion more experiments will be necessary. MSCs were 
reported to express TLR3 and TLR4 and triggering of these receptors abrogated their ability to suppress 
T cell proliferation (Liotta et al., 2008). In our hands, stimulation with the TLR ligands Poly I:C (TLR3 
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ligand), CpG or LPS (TLR9 and TLR4 ligand, respectively) slightly (up to 50% less inhibition) decreased 
the inhibition of T cell proliferation, but direct effects on DCs could not be excluded. To this end TRCs 
were pre-stimulated with various cytokines or TLR ligands for 24 hours prior to addition of T cells and 
DCs. Again, none of the tested cytokines significantly changed T cell proliferation in presence of TRCs. 
While no effect of LPS pre-stimulation could be observed, pre-stimulation with Poly I:C seemed to 
reduce the TRCs mediated inhibition (50-100% less inhibition in 3 independent experiments). But 
considerable variations were observed in different experiments and no definitive conclusion could be 
drawn. These results are rather puzzling, as LPS stimulation of TRCs induced Inos expression and LPS is 
known to be a strong inducer of Inos expression in macrophages and DCs (Bogdan, 2001). However, 
freshly isolated ex vivo TRCs from immunized mice inhibited T cell proliferation to similar extent as ex vivo 
TRCs from naïve LN, rather arguing against a functional switch of TRCs during inflammation. Still, mice 
in these experiments were immunized with NP-CGG in Montanide, the latter being a water-in-oil-
emulsion adjuvant. Although pro-inflammatory cytokines should be produced, no known TLR ligands 
were added. Therefore, regulation of the inhibitory features of TRCs by TLR-ligands might still represent 
a possible control mechanism. Experiments with TLR3- and/or TLR4-deficient TRCs would be useful to 
gain more insight into the role of these pathways.  
We show here that indomethacin, a COX inhibitor, and 1400W, an iNOS specific inhibitor, restored 
partially the T cell activation in presence of TRCs. Interestingly, Cox-2 is constitutively expressed in TRCs 
while Inos was induced by IFN as well as other cytokines such as IL-1 and was highest when IFN and 
activated BMDCs were present. TRC-conditioned supernatant inhibited T cell activation but the extent 
was significantly decreased compared to physical presence of TRCs. This is most likely not due to NO as 
TRC conditioned supernatant was derived from TRCs cultured alone and no iNOS expression was 
detectable without cytokine stimulation. Moreover, NO is a short-lived molecule, which is most likely not 
stable in cell culture supernatant. Therefore, we attribute the weak inhibitory features of TRC conditioned 
supernatant mostly to COX-1/2 dependent factors. However, it should be mentioned that also Cox-2 
transcription was enhanced after stimulation with pro-inflammatory stimuli such as IL-1. This might be 
partially a consequence of Inos induction, as NO is known to positively regulate Cox-2 transcription 
(Tsatsanis et al., 2006; Harizi and Gualde, 2006). 
Constitutive expression of Cox-2 in TRCs might be a mechanism to keep the LN in a slightly suppressive 
state during homeostasis and to prevent activation of auto-reactive T cells by setting an ‘activation 
threshold’ (figure 3.1). In that sense it would be interesting to test whether TRC-specific COX-2 deficient 
mice are more prone to develop auto-immunity compared to WT mice. Interestingly, Cox-2 was found to 
be constitutively expressed in thymic stromal cells and seems to be implicated in tolerance induction 
(Rocca and FitzGerald, 2002). Furthermore similar to thymic stromal cells, TRCs were shown to express 
peripheral-tissue antigens and to promote peripheral tolerance (Fletcher et al., 2011b). Therefore, it seems 
worthwhile to test whether COX-2 activity in TRCs contributes to peripheral tolerance induction. In 
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addition, the transient induction of Inos during infection might be a mechanism to increase the ‘activation 
threshold’ for T cells to prevent bystander activation of autoreactive T cells during acute inflammation 
and T cell activation (figure 3.1). If this model were correct, then TRC-specific Cox-2/Inos double 
knockout mice should be more susceptible to experimentally induced autoimmunity than single knockout 
mice, or even develop spontaneous autoimmune disease. 
 
Figure 3.1: Model showing how COX-2 and iNOS expression in TRCs could set a threshold for T cell 
activation 
TRCs constitutively express Cox-2, which might keep the LN in a slightly suppressive state during homeostasis. 
Upon infection, iNOS is transiently induced in TRCs (and DCs), which may increase the threshold for T cell 
activation. This might be an important mechanism to prevent bystander activation of autoreactive T cells during 
inflammatory responses.  
 
Upon viral infection of WT mice, Inos was transiently induced in a subset of TRCs and DCs. In 
accordance with previous reports showing that the outcome of a CD8 T cell response is programmed 
within the first few days after infection (Williams and Bevan, 2007; Haring et al., 2006), this was sufficient 
to limit T cell expansion, as it was significantly increased in iNOS-/- mice. Unfortunately, it was not 
possible to dissect the role of iNOS expression in DCs versus TRCs. Experiments with BM-chimeras of 
WT in iNOS-/- and vice versa were conducted. However, chimeras showed defective cell trapping upon 
infection and results were therefore not conclusive. Cell type specific iNOS-/- mice will be needed to 
answer this question more conclusively. To this end, the establishment of mice carrying a floxed iNOS is 
necessary (ES cells containing floxed Inos are available from the Wellcome Trust Sanger Institute, UK) 
which can then to be crossed with DC or TRC specific cre-recombinase mice. Though DC specific 
CD11c-cre mice exist (Caton et al., 2007), no such mouse model is available yet for TRCs. One difficulty 
is that no highly TRC-specific promoter is known. Very recently Onder and colleagues reported the 
generation of a BAC transgenic mouse expressing the cre-recombinase under the gp38 promoter, but 
only 15% of LN FRCs were shown to express the transgene. In addition the transgene was also expressed 
in a subset of LECs (Onder et al., 2011). For this reasons this mouse model is not the ideal to dissect the 
TRC-specific role of iNOS. Nevertheless, in collaboration with our laboratory B. Ludewig (St. Gallen, 
Switzerland) has established a transgenic mouse expressing cre-recombinase under control of the CCL19 
promoter (abstract, Swiss Immunology meeting, Lugano, 2011), which might prove to be a valuable tool 
for future experiments.  
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Although primary T cell expansion was significantly increased in iNOS-/- mice, the magnitude of this 
effect seems to be smaller compared to the difference in T cell proliferation observed in vitro with or 
without TRCs or 1400W. One major difference is that TRCs were completely absent in our negative 
control of the in vitro assay, while these cells were still present in Inos-/- LN, and therefore capable of 
expressing other suppressive factors such as such as COX-1/2 dependent molecules. It remains to be 
tested whether blockage of PGE2 production in vivo and/or genetic disruption of the Cox2 gene will lead 
to increased primary T cell responses. Furthermore, if the production of PGE2 partially compensates for 
the lack of Inos in our in vivo model, then primary T cell responses should be even more enhanced in 
Cox2-Inos double knock out mice. However, as both iNOS and COX-2 are known to be expressed by 
DCs and not only TRCs (Harizi and Gualde, 2006; Gualde and Harizi, 2004), again the question will arise 
about the contribution of DCs and TRCs to this effect in vivo. It remains to be tested how much COX-
1/2 is expressed by TRCs compared to DCs. More important evidence may be obtained by analysing cell-
specific COX-2 knock out mice. PGE2 is an interesting molecule as it was shown to have anti- and pro-
inflammatory features depending on the context. It modulates DC function: While it is co-stimulatory for 
naïve DCs in the periphery it seems to be suppressive for mature DCs (Gualde and Harizi, 2004). We 
show that co-culture of TRCs with activated BMDCs reduces the stimulatory capacity of DCs. It is likely 
that this is mediated by COX-1/2 derived factors, as Cox-2 is constitutively expressed in TRCs and NO2- 
levels were not elevated in supernatant from TRC BMDC co-cultures in absence of IFN. However other 
factors or cell-cell contact as reported by Zhang and colleagues (Zhang et al., 2004) might play a role as 
well. Therefore, co-cultures of TRCs and BMDCs in a transwell setting would be useful to further dissect 
this question. Or to condition BMDCs with supernatant derived from TRCs cultured in presence of the 
COX-1/2 inhibitor indomethacin. 
Strengthening the relevance of the negative regulation of T cell activation by TRCs, two other 
publications were recently published showing very similar results (Lukacs-Kornek et al., 2011; Khan et al., 
2011) (table 3.1).  
  
Siegert  Khan  Lukacs-Kornek 
Read-out for proliferation based on Number of 
proliferating T cells 
% T blasts Number of 
divisions and % of 
divided T cells 
DC : OT-I 
TRC : OT-I 
OT-I :WT 
1:4 
1:4 
1:50 
1:10 
1:20/40/100 
No WT T cells 
1:1  
= 1:1/5/10 
No WT T cells 
BMDC 
stimulated T 
cells 
Reduction of T cell 
proliferation by TRC 
80% 50-100% (dose-
dependent) 
50-100% (dose-
dependent) 
TRC : T 1: 100 1 : 1/5/10/20  1 : 20 Anti-CD3/28 
stimulated T 
cells  
Reduction of T cell 
proliferation by TRC 
40-50% 0-90% (dose-
dependent) 
30% 
Stimulation of T cells 
by 
BMDC  BMDC  Anti-CD3/28  further 
characterization 
of in vitro T cell 
proliferation in 
presence of 
T cells activation 
markers 
CD69 no difference  
() CD44, CD25;  
 CD62L 
CD69 and CD25 no 
difference 
CD69 and CD25 no 
difference 
General discussion and perspectives 
94 
Differentiation into 
effector T cells 
Slightly reduced No data No data TRC 
T Cell cycle 
progression 
No data Blocked by TRC No data 
Transwell Reduction of T cell 
proliferation by TRC 
50-60% No reduction No reduction 
TRC 
supernatant 
Reduction of T cell 
proliferation by TRC 
40% No data No data 
Not responsible  Lack of IL-2 
PD-L1, Il-10 
TGF, IDO, 
Arginase-1,  
Lack of IL-2 
PD-L1, CD80 
CD86, IL-4, IL-12 
Lack of IL-2 
PD-L1, IDO, 
Arginase-1 
Block of iNOS 
activity 
1400W rescues 
about 50% of T cell 
proliferation 
Complete rescue by 
1400W and L-
NMMA 
Complete rescue by 
L-NMMA 
iNOS induction in 
TRC 
By IFN and other 
pro-inflammatory 
cytokines; highest in 
presence of DC and 
IFN 
Highest in presence 
of DC and IFN 
Induced by IFN 
and TNF;  
Block of IFN activity No data Complete rescue Complete rescue, 
IFN is derived 
from T cells and 
reacts on TRC 
Mechanism of 
inhibition 
Block of Cox2 activity Indomethacin 
recues about 50% 
of T cell 
proliferation 
No data No data 
In vivo relevance Model Transfer of OT-I 
cells and VSV-OVA 
infection 
Antigen-loaded DC 
injection or antigen-
targeting via anti-
DEC205 
Transfer of OT-I 
cells into iFABP-
tOVA mice 
 iNOS expression Transient in TRC 
and DC 
No data In TRC and LEC 
 iNOS-/- mice  Primary T cell 
expansion 
(inflammatory 
conditions) 
 Primary T cell 
expansion with 
inflammatory DC 
 Primary T cell 
expansion in non-
inflammatory 
condition 
 OT-I proliferation 
in response to 
antigen presented 
by TRC in non-
inflammatory 
condition 
Reduced T cell proliferation in presence 
of other stromal cells 
Various fibroblasts 
lines, MSC and 
tumour cells 
MEF, NIH-3T3, 
BEC, LEC 
LEC 
Table 3.1: comparison of our results to two similar reports 
All three publications report that TRC presence inhibits T cell proliferation in vitro. This is mediated by NO 
production of TRCs induced by IFN. Despite remarkable resemblance of the results, some difference exist 
between the different reports, which might be largely explained by different ratios of TRCs to T cells, 
stimulating methods and reads-outs used to assess T cell proliferation. Interestingly, in all three reports the 
primary T cell response was about 2 times increased in Inos-deficient mice. Also the decrease of the primary T 
cell response in Inos-/- mice in non-inflammatory conditions reported by Khan and colleagues was in this range. 
(Khan et al., 2011; Lukacs-Kornek et al., 2011).  
 
Both reports show that presence of TRC lines but also ex vivo isolated TRCs dampens T cell proliferation 
stimulated by peptide-loaded DC or anti-CD3/28 in a dose-dependent manner. This inhibition is 
mediated via NO production by iNOS, which is induced in TRCs by IFN (figure 3.2a) (Lukacs-Kornek 
et al., 2011; Khan et al., 2011). Similar to our results, Khan and colleagues show that other fibroblasts – 
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MEFs and NIH-3T3 cells - inhibited T cell proliferation, but also endothelial cells –BEC and LEC lines - 
had the same effects, the later confirmed by Lucas-Kornek and colleagues (Lukacs-Kornek et al., 2011). 
This substantiates our findings that inhibition of T cell proliferation seems to be a common fibroblastic 
feature and extends this observation to endothelial cells found in LN. In addition, endothelial cell seem to 
suppress T cell activation as well via an IFN/NO dependant mechanism (Khan et al., 2011; Lukacs-
Kornek et al., 2011). This is an interesting finding as MSCs and adult fibroblasts from non-lymphoid 
tissues were shown to be strongly immune-suppressive in murine disease models or human patients 
(Haniffa et al., 2007; Jones et al., 2007; Uccelli et al., 2008; Sato et al., 2010). As TRCs display very similar 
feature and as they are easy to obtain from tonsils (Amé-Thomas et al., 2007) and to maintain in culture 
they might provide another source of cells that could be used for that purpose. The established TRC lines 
would be a valuable tool to test how long TRCs infused in mice stay alive, where they home and whether 
their presence could ameliorate graft-versus-host disease, auto-immune diseases such as EAE or chronic 
inflammation such as arthritis. An intriguing aspect of MSCs is that allogeneic cells have been successfully 
used to ameliorate graft-versus-host disease in human patients (Sato et al., 2010). It would be interesting 
to test whether the same holds true for TRCs. This could be tested by infusion of the TRC lines that 
originate from C57BL/6 mice into BALB/c mice. The GFP-expressing TRC lines would thereby provide 
a tool for easy tracking of infused TRCs in mice.  
Both, Khan and Lukacs-Kornek show that IFN is needed for TRC-mediated inhibition (figure 3.2). In a 
series of experiments using IFN-/- T cells or IFNR-/- TRCs, Lukacs-Kornek and colleagues establish 
that in their in vitro co-culture IFN is produced by T cells and acts on the TRCs (figure 3.2a) (Lukacs-
Kornek et al., 2011). Consistent with our results, inhibition of T cell proliferation by TRCs was not 
mediated by PD-L1, IL-4, IL-12, IDO or arginase but blocking of iNOS activity restored T cell 
proliferation (Lukacs-Kornek et al., 2011; Khan et al., 2011). Unlike the two reports, we did not observe 
complete rescue of T cell proliferation by blocking iNOS activity. This might be explained by the use of 
different read-outs: while we used absolute numbers of proliferated T cells to assess the amount of 
inhibition, both other groups used only the percentage of proliferated T cells (table 3.1). If we only took 
the percentage of proliferated T cells into account, we would as well see a complete rescue of T cell 
proliferation by blocking iNOS; however, the absolute numbers were still reduced. Besides different 
presentation and interpretation of the data, another reason for this discrepancy might be the use of 
different assay conditions (table 3.1). By increasing the iNOS inhibitor concentration we could completely 
restore T cell proliferation, but unspecific effects in the ‘no stroma’ control were observed making these 
data non-conclusive (data not shown). Similarly to our results, when Lukacs-Kornek used iNOS-/- TRCs 
the inhibition of T cell proliferation was not only ablated but CD8 T cell proliferation was even increased. 
The reason for this phenomenon is unknown. One may speculate that in the absence of iNOS/NO 
factors are induced in TRCs that positive regulate T cell activation. To elaborate on this, a large screening 
of factors produced by WT versus iNOS-/- would be interesting. Furthermore, it should be tested whether 
and how TRCs respond to NO themselves leading potentially to inactivation of positive regulators. In 
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contrast to our results, both Khan and Lukacs-Kornek do not mention experiments in which COX-2 
activity was blocked. Nevertheless, in a recent report from Fletcher and colleagues reporting microarray 
analysis of ex vivo sorted TRCs, Cox-2 (also named Ptgs-2) was found to be expressed in TRCs (Fletcher et 
al., 2011a). 
 
Figure 3.2: Mechanism of TRC mediated inhibition of T cell proliferation 
(a) Interaction between TRCs and T cells: upon polyclonal TCR triggering T cells produce IFN and TNF, 
which together induce Inos expression in TRCs. Cox-2 is constitutively expressed in TRCs. NO and COX-2 
dependent factors, such as PGE2, decrease T cell proliferation. (b) Interactions between TRCs, DCs and T cells: T 
cells primed by antigen-presenting DCs produce IFN that stimulates Inos expression and NO production in DCs 
and TRCs. Also other factors, such as IL-1 or LPS can induce Inos expression in TRCs and possibly DC (Khan 
et al., 2011; Lukacs-Kornek et al., 2011; Siegert et al., 2011).  In addition, TRCs decrease the stimulatory capacity 
of DCs, (Siegert et al., 2011), most likely at least in part by COX-1/2 dependent factors. It is likely that NO here 
also negatively influences DCs (Bogdan, 2011) and possibly also TRCs. 
 
To confirm the in vitro findings in a more physiological setting, both reports show experiments comparing 
WT with iNOS-/- mice (table 3.1). Similar to our observations, Khan and colleagues report unexpected 
defects in the lymphoid compartment of BM chimeras (iNOS-/-- into WT) and results were therefore not 
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conclusive. However, when iNOS-/- mice were immunized with peptide loaded BMDC, a significant 
increase in antigen-specific T cells could be observed in comparison to WT mice three days after 
immunization (Khan et al., 2011). This is consistent with our unpublished observations using the same 
system. In contrast, when OVA was directly targeted to LN resident non-inflammatory DC using the 
anti-DEC205 antibody, a decrease in antigen-specific T cell expansion was observed (Khan et al., 2011). 
This shows that TRC mediated inhibition might only be relevant in specific types of immune responses, 
for example in which very large amounts of IFN are produced. Lukacs-Kornek and colleagues used the 
iFABP-tOVA model in which a truncated form of OVA is expressed under the control of the intestinal 
fatty acid binding promoter. In a previous report, Fletcher and colleagues showed that TRCs in pLN 
express tOVA, leading to peripheral tolerance induction by clonal deletion (Fletcher et al., 2010). After 
transfer of OT-I T cells into iNOS-/-- iFABP-tOVA mice the T cells expanded and proliferated more 
than in WT iFABP-tOVA mice. It was accompanied by increased iNOS expression in TRCs and LECs, 
but probably not in DCs (Lukacs-Kornek et al., 2011). The discrepancy to our results is very likely due to 
the use of different model systems. While Lukacs-Kornek and colleagues use a model, in which antigen is 
presented by TRCs and no inflammation is induced, we use a viral infection model in which antigen 
should be mainly presented by DCs and which should be accompanied by massive inflammation (table 
3.1). This leads to activation of DCs and possibly other myeloid cells and induces iNOS expression in 
these cells (figure 3.2b). In contrast to Lukacs-Kornek and colleagues, Khan and colleagues observed 
decreased T cell expansion under non-inflammatory conditions, when iNOS was absent. This discrepancy 
might be explained be the different cell types that present antigen in the two different models: While 
Khan and colleagues target antigen to non-inflammatory DCs, Lukacs-Kornek and colleagues use a 
model in which antigen is presented by TRCs themselves. The observations by us and Khan et al. 
suggests a role in trans for TRCs with no evidence for antigen presentation by TRCs. Furthermore, Khan 
and colleagues evaluated the proliferation of endogenous T cells in response to the OVA-SL8 peptide and 
did, in contrast to us or Lukacs-Kornek and colleagues, not adoptively transfer OT-I T cells (Lukacs-
Kornek et al., 2011; Khan et al., 2011). Therefore, the percentage of antigen-specific cells should be much 
lower for Khan and colleagues. In addition, it was shown, that naïve OT-I T cells very rapidly produce 
TNF upon TCR triggering and IFN after entering cell cycle (Denton et al., 2011). Therefore, one can 
assume that in the anti-DEC205 model used by Khan and colleagues, much less TNF and IFN are 
present in the LN leading to less iNOS expression in TRCs (figure 3.2). 
Together, these three reports (Lukacs-Kornek et al., 2011; Khan et al., 2011) show that TRCs have 
besides their established positive role a negative influence on T cell proliferation. However, the different 
in vivo systems suggest that the dampening of T cell proliferation might be only important in certain type 
of immune responses. TRCs mediated attenuation may be particularly important when high amounts of 
IFN are produced. Traditionally, IFN is regarded as a pro-inflammatory cytokine, and it plays an 
essential role in various aspects of the immune response, such as for the activation of macrophages, 
clearance of intracellular pathogens or the promotion of TH1 responses. However, IFN was shown to 
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have immune-regulatory features, thereby limiting tissue damage associated with inflammation. 
Interestingly, depending on the context IFN can augment or suppress auto-immunity, such as in 
experimental autoimmune encephalomyelitis (EAE) (Hu and Ivashkiv, 2009; Kelchtermans et al., 2008). 
Several mechanisms have been shown to play a role: IFN modulates expression of tissue-destructive 
enzymes, alters the recruitment of inflammatory cells, such as neutrophils, suppresses TH17 differentiation 
and positively regulates TREG differentiation (Hu and Ivashkiv, 2009; Kelchtermans et al., 2008). 
Interestingly in an EAE model, in which disease is enhanced in IFN-/- mice, an increase of proliferating 
T cells was shown in spleen and the central nervous system when IFN was absent (Chu et al., 2000). In 
addition, Feurer and colleagues showed that IFN produced by TH1 T cells limits their own expansion in 
the later phase of the immune response dependent on NO production by host cells (Feuerer et al., 2006). 
We propose that TRC-produced NO is at least partially responsible for inhibition of T cell expansion in 
IFN-/- mice. Therefore, it would be worthwhile to test whether TRC-specific IFN-R-/- mice show 
similar results after EAE induction as reported for complete IFN-/- mice. Interestingly, another inducer 
of Inos in TRCs, TNF, was also shown to have a dual role in autoimmunity: it promotes autoimmune 
disease, such as in rheumatoid arthritis or multiple sclerosis, but surprisingly anti-TNF therapy in MS 
patients aggravates disease and consistent with this finding, several autoimmune mouse models show 
higher incidence and severity when TNF is absent (Kassiotis and Kollias, 2001a, 2001b; Campbell et al., 
2001). Another positive regulator of Inos in TRCs is IL-1, which is known to promote the development 
of autoimmune disease (Lachmann et al., 2011). However, unlike IFN or TNF no dual role has been 
described for IL-1 in autoimmunity.  
Nevertheless, the biological reason of TRC mediated inhibition of T cell proliferation is only speculative 
so far. We assume that this is a mechanism to prevent overshooting T cell responses and the potentially 
accompanied tissue disruption. During an immune response the LN size increases dramatically. T. Vogt 
and CY. Yang observed that at the peak of the immune response, the TRC network is still intact and that 
this is achieved by extensive TRC proliferation after immunization. Interestingly, TRC proliferation only 
starts 3 days after immunization, when the total LN cellularity is already increased. This might indicate 
that TRCs need some time to adapt to the new situation and slowing down the T cell proliferation might 
be mechanism to buy this time preventing disruption of the TRC network (poster CY Yang and S Luther, 
Swiss Society for Allergology and Immunology, Lugano 2011). In addition, it should be stressed that 
iNOS induction in TRCs is only very transient which indicates a tight regulation of this 
immunoregulatory mechanism. It is also intriguing that iNOS was only induced in a subset of TRCs. This 
might be an evidence for the existence of a special “regulatory” TRC subset, similar to TREG or regulatory 
DCs. Another possibility is that within the T zone special “regulatory” niches are induced in which T cell 
proliferation is inhibited. This might be a mechanism to facilitate tight control the T cell proliferation 
within the LN. It would be interesting to further characterize the immune response in TRC-specific Inos-/-
mice after VSV-infections when treated or not with Cox-2 inhibitors. If our assumption is true, these 
mice should show disruption of the stromal cell network in the pLN. Scandella and colleagues showed 
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that destruction of the TRC network leads to infection-associated immunodeficiency (Scandella et al., 
2008). Therefore one should investigate whether this is also the case in TRC-specific Inos/Cox2 double 
knockout mice.  
The summary of results obtained during this thesis clearly show that TRCs are far from being only inert 
structural cells in the LN. In contrast, these cells influence the immune response in several ways and are 
implicated in tolerance induction. The further characterization of these cells, especially in the context of 
tolerance induction, will be of great interest, as these cells might prove to be a potential target in the 
therapy of auto-immune disease and chronic inflammation. In addition, the new tools established during 
my thesis work, the TRC lines and co-culture systems, should be of great help to advance our knowledge 
on these still poorly defined LN fibroblasts. 
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4.1. Mice and immunizations 
C57BL/6 (B6, CD45.2+) mice were from Janvier (France). B6 OT-I CD45.1+, Ubiquitin-gfp transgenic and 
Inos-/- mice were from the Jackson laboratories. p19arf-/- and p53-/- mice were previously described (Kamijo 
et al., 1997; Zheng et al., 2002). Immunizations: For both -the NP-CGG immunization and the VSV-
infection model- mice were subcutaneously (s.c.) injected at six sites in the back to target six peripheral 
lymph nodes (pLN; 2x axillary, 2x brachial, 2x inguinal). NP-CGG model: 25µg NP-CGG (Biosearch 
Technology) diluted in PBS and Montanide ISA 25 (25%; Seppic) were injected per site. VSV infection 
model: 0.1 x 106 OT-I splenocytes were retro-orbitally grafted into mice 1-3 days prior to viral infection. 
Per site 0.33 x 106 pfu VSV-OVA (Kim et al., 1998) were injected. Bone marrow (BM)-chimeras: BM 
from donor-mice was obtained from femur and tibia by crushing bones with a mortar. 15 x 106 BM cells 
were injected retro-orbitally into recipient mice irradiated twice with 450 rad in a 4h interval. The 
following 4 weeks mice received the antibiotic ‘Baytril 10%’ (1/1000) in the drinking water. WT mice 
used were either CD45.2+ or CD45.1+ while Inos mice were CD45.1+. All mice were maintained in specific 
pathogen-free conditions. All mouse experiments were authorized by the Swiss Federal Veterinary Office 
(Bern, Switzerland).  
4.2. Flow cytometry 
Groups of 1 x 105 to 2 x 106 cells were stained in 96-well V-bottom plates (Falcon). Cells were blocked 
with 2% normal mouse serum (Sigma) or Fc-receptor block (anti-CD16/32 antibodies from the 
hybridoma 2.4G2) for 20 min on ice and then stained with antibodies in 25 µl FACS buffer (PBS 
containing 2% fetal calf serum (FCS; PAA), 2 mM EDTA and 0.1% NaN3) for 30 min on ice. After 2 
times washing, cells were incubated with secondary reagents in 25µl FACS buffer. Antibodies and 
secondary reagents used are listed in the table 4.1. OT-I T cells were identified as CD8+B220- cells 
expressing CD45.1 (and in some cases TCR V2 and V5). Dead cells were excluded using 7-AAD (7-
Aminoactinomycin D) or DAPI (4,6-diamidino-2-phenylindole), or using Aqua (all from Invitrogen) in 
case of 4% paraformaldehyde (PFA)-fixed cells from VSV-infected mice. Intracellular IFN staining: cells 
were re-stimulated in vitro with 1µM SIINFEKL peptide in the presence of Brefeldin-A (10 µg/ml, 
AppliChem) for 3-4h at 37°C. Then cells were fixed with BD-cytofix (BectonDickinson) for 10 min at 
RT. After permeabilization with BD-Permwash (BectonDickinson) for 30 min, cells were incubated 45 
min with the anti-IFN antibody (XMG1.2) diluted in BD-Permwash at RT. In case of VSV-infected 
tissues, cells were fixed in 4% PFA followed by permeabilization with 0.1% saponin (Sigma). Intracellular 
iNOS staining: Cells fixed with 4% PFA were washed, permeabilized with FACS buffer containing 0.1% 
saponin, then anti-iNOS antibody (rabbit antibody; Millipore) or as a control anti-LYVE-1 antibody 
(RELIAtech) was added followed by donkey-anti-rabbit IgG coupled to Alexa488 (Molecular Probes). 
For cell cycle analysis cells were fixed and permeabilized, then incubated with Hoechst 33342 (20 µg/ml; 
Invitrogen) for 5 min at RT. Data were acquired on a FACSCanto or LSR II flow cytometer (both 
BectonDickinson) and were analysed with FlowJo software (TreeStar).  
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Primary reagents 
Target Species Clone or 
designation 
Conjugate Supplier  
CD105 (Endoglin) Rat MJ7/18 FITC Hybridoma 
CD106 (VCAM-1) Rat 429 eFluor450 or biotin or FITC eBioscience or hybridoma 
CD11b Rat M1/70 Alexa700 or FITC or biotin eBioscience or bioLegend 
CD11c Rat N418 PE-Cy5.5 or FITC eBioscience or hybridoma 
CD140a (PDGFR) Rat APA5 FITC or biotin Hybridoma 
CD140b (PDGFR) Rat APB5 FITC or biotin Hybridoma 
CD120a (TNF-R1) A. Hamster 55R-170 Biotin BioLegend 
CD157 (BP-3) Mouse BP-3 Biotin or PE BD Pharmingen 
CD19  Rat ID3 FITC Hybridoma 
CD25 Rat PC61 Biotin eBioscience 
CD31 (PECAM1) Rat 390 PE or PerCP-eFluor710 BioLegend/eBioscience 
CD326 (EpCAM) Rat G8.8 Biotin BioLegend 
CD35/21 Rat 7E9 PE-Cy7 BioLegend 
CD4 Rat RM-4-6 PE-Cy5.5 or eFluor450 eBioscience 
CD40 Rat FGK-45 FITC Hybridoma 
CD44 Rat IM7 Biotin eBioscience 
CD45 Rat 30-F11 PE-Cy7 eBioscience 
CD45.1 Mouse A20.1 Alexa647 hybridoma 
CD45R (B220) Rat RA3-6B2 PE-Texas Red BD Pharmingen 
CD54 (ICAM-1) Rat YN1/1.7.4 FITC or biotin Hybridoma 
CD62L (L-selectin) Rat MEL-14 Alexa700 eBioscience 
CD71 Rat R17217 PE eBioscience 
CD80 (B7-1) A. Hamster 16-10A1 Biotin BioLegend 
CD86 (B7-2) Rat GL-1 PE eBioscience 
CD8 Rat 53-6.7 PE-Cy7 BioLegend 
IFN Rat XMG1.2 PE eBioscience 
iNOS Rabbit Polyclonal, cat 
nbr. 06-573 
Purified Millipore 
gp38 (podoplanin) S. hamster 8.1.1 Alexa647 Hybridoma 
LYVE-1  Rabbit Polyclonal Purified RELIATech 
LTR rat 3C8 Biotin eBioscience 
MAdCAM-1 Rat Meca-89 FITC Hybridoma 
MHCI (H-2kb) Mouse AF6 Biotin eBioscience 
MHCI-SIINFEKL Mouse eBio25-D1.16 PE eBioscience 
MHCII I-A/I-E Rat M5/114.15.2 Alexa647 Hybridoma 
PD-1 (CD279) A. Hamster J43 Biotin eBioscience 
PD-L1 (CD274) Rat MIH5 biotin eBioscience 
TCR V2 Rat B20.1 FITC Hybridoma 
TCR V5 Mouse MR9-4 PE BD Pharmingen 
Secondary reagents 
Streptavidin   PE or APC-Cy7 or  APC-
eFluor780 
eBioscience 
Streptavidin   Alexa700 Invitrogen 
Rabbit IgG donkey  Alexa488 Molecular Probes 
Table 4.1: Primary and secondary reagents used for flow cytometry 
A. =Armenian; S. = Syrian  
 
4.3. Ex vivo  stromal cell isolation 
To isolate stromal cells from LN, axillary, brachial and inguinal LN were isolated from CO2-killed mice, 
their capsule opened with a 26-gauge needle and the organs digested for 30 minutes at 37°C in DMEM 
(Invitrogen) containing collagenase IV (3mg/ml; Worthington), DNAse I (40mg/ml; Roche), 2.5% 
(vol/vol) FCS, 1.2 mM CaCl2, 10 mM HEPES and 50IU/ml Penicillin, 50µg/ml streptomycin. 
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Subsequently, EDTA was added (5mM final) and remaining clumps dissolved by pipetting, passed 
through a 40-µm mesh, washed twice, and re-suspended in complete RPMI. Complete RPMI contained: 
RPMI 1640 plus GlutaMAX-I (Invitrogen) supplemented with 10% FCS (PAA), 10mM HEPES (Sigma), 
50IU/ml penicillin, 50µg/ml streptomycin (Sigma) and 50µM -mercaptoethanol (Sigma). For stromal 
cell isolation from femoral muscle, kidney and heart, the respective organs were dissected, then cut into 
small pieces using razor blades and digested as described above for 1h at 37°C. For stromal cell isolation 
from ears: Ears were split with forceps and incubated in phosphate-buffered saline (PBS) with 0.5% 
trypsin (Sigma-Aldrich) and 5mM EDTA for 20 minutes at 37°C to separate dermal and epidermal sheets. 
The separation was done under a stereomicroscope using forceps. Then both sheets were cut into small 
pieces using razor blades and digested for 2h with collagenase IV as described above. After digestion, 
stromal cells were enriched by panning on 10 or 15cm dishes coated with antibodies against CD45 
(5µg/ml; clone M1/9.4.3), CD31 (1.5µg/ml; clone GC-51), CD11c (1µg/ml; clone N418) and CD11b 
(1µg/ml; clone M1/70). Cells were added on the panning plates in 5ml (for 10cm dish) or in 10ml (for 
15cm dish) complete RPMI and incubated for 30 min at 4°C. Panning was done 2 times. Live cells were 
counted by using trypan blue dye to exclude dead cells and using an automated cell counter (Countess, 
Invitrogen). 
4.4. TRC clone generation 
Peripheral LNs (pool of axillary, brachial, and inguinal) were isolated from adult p53-/- mice or p19-/-(mix 
of C57BL/6 and 129 background) (Zheng et al., 2002), digested as previously described (Link et al., 
2007), and cultured at 37°C with 4.5% CO2 in complete RPMI. After 24 h, non-adherent cells were 
removed and the adherent fibroblastic cells were cultured for several weeks and then subcloned using 
limited dilution. Outgrowth over 2–3 months yielded only CD45- CD31- podoplanin+ clones.  
4.5. Fibroblastic cell line generation 
To generate stromal cell lines stromal cells were isolated by collagenase digest (described above) of pLN, 
mLN heart, dermis, epidermis and kidney of naïve B6 mice and from pLN of naïve Ubiquitin-gfp mice. 
After overnight culture in complete RPMI non-adherent cells were washed away. Adherent cells were 
cultured at 37°C with 4.5% CO2 until they reached confluency, then split on new dishes. Cells were used 
between passage 8 and 25. Other cell lines used: B16-F10 and MC-38 tumour lines (kindly provided by 
A.Donda, Lausanne), spleen and lung fibroblasts (C.Buckley (Hou et al., 2010)) MEF (M.Heikenwälder, 
Munich), MSC (P.Nelson, Munich (Zischek et al., 2009). 
4.6. 3D cell culture 
Polyurethane sponges were prepared as previously described (Tomei et al., 2009a). Briefly, alginate beads, 
with diameters of 50–500 µm, were prepared by extruding a solution of 2% sodium alginate (Fluka) in 
distilled water through a 25-gauge needle fitted with a syringe into a solution of 102 mM CaCl2 in 0.9% 
NaCl (Sigma). After 1 h the beads were vacuum filtered and air-dried. Dried beads were packed in a 
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scaffold-casting device (chamber slides or 96-well plates) and a 25mg/ml solution of polyurethane 
(Pellethane 2363-80A; Dow Plastics) in N-methylpyrrolidon (Sigma) was poured onto the beads and 
allowed to penetrate into the spaces between the packed beads. After 90 min, the N-methylpyrrolidone 
solvent was removed from the polyurethane solution by solvent exchange with distilled water. The 
alginate beads were then dissolved with 0.5 M citric acid (Sigma) solution. The resulting polyurethane 
scaffold or sponge was rinsed in distilled water and autoclaved in PBS. 
For 3D cultures in the Polyurethane-sponge, the collagen-solution was prepared as flowing: 1mg/ml type 
I collagen (Rat tail collagen, Cat.nbr.: 354249 BD Biosciences) was re-suspended in 10xPBS, 7.5% 
NaHCO3  and complete RPMI medium. The pH was adjusted to 7.3-7.5. TRC cells (clone or line) were 
re-suspended at a concentration of 106 cells/ml in the collagen solution. Polyurethane sponges were 
placed in non-treated 24-wells (Nunc) and TRCs in the collagen solution were poured on top, until the 
macropores of the scaffold were completely filled. Collagen was allowed to polymerize at 37°C with 5% 
CO2 for 2-4h and complete RPMI was added until the whole sponge-collagen culture was completely 
covered. All cultures were maintained in a humidified 37°C, 5% CO2 incubator for the duration of the 
culture. To re-isolate TRCs from the 3D cultures, they were cut into small pieces using scissors and 
digested with 1mg/ml collagenase D (Roche) for 30-60min at 37°C. 
4.7. Cytokine stimulation of TRC clones/lines 
TRC cells were seeded in 6-wells (0.05 x 106 per well) or chamber slides (3000 cells per well). After 
overnight culture after overnight culture 10ng/ml IFN, 10ng/ml IL-1, 10ng/ml TNF, 10ng/ml 
LT3, 25ng/ml IL-6, 5 or 50ng/ml IL-13, 0.2 or 10ng/ml IL-1, 0.5 or 10ng/ml TGF, 1 or 20ng/ml 
PDGF-BB, (all from Peprotech), 0.5µg/ml LPS (Sigma), 2 or 20µg/ml Poly I:C (kind gift from J. 
Tschopp), 500 U/ml IFN (PBL Interferon Source) or 1µg/ml of the agonistic antibody against LTR 
(LTR; clone 4H8 WH2; provided by C.Ware) were added to stromal cells for indicated times (7h - 
24h).  
4.8. Generation of bone-marrow-derived dendritic cells (BMDCs) 
Bone-marrow (BM) cells were obtained from femur and tibia of B6 mice by crushing bones with a 
mortar. After filtering through a 40 µm mesh, BM cells were cultured for 7 days in complete IMDM 
(Invitrogen) containing HEPES (10mM), penicillin (50IU/mL), streptomycin (50µg/mL), -
mercaptoethanol (50µM), 10% FCS, and 10% (vol/vol) GM-CSF–containing culture supernatant (COS 
line donated by F. Tacchini-Cottier, Lausanne) in untreated 100 mm plastic dishes (Falcon, Petri dish). 
Medium was changed on days 3 and 6 of culture. BMDCs were harvested on day 7 by adding PBS 
containing 2 mM EDTA and gentle pipetting. Cells were subsequently frozen in aliquots using standard 
procedures. For experiments BMDCs were thawed one day prior to use and cultivated overnight in 
complete IMDM. 
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4.9. T cell activation assay 
Stromal cells: 1x104 cells in complete RPMI were seeded in 24-wells and after overnight culture irradiated 
with 1000rad. Initially, experiments with non-irradiated or irradiated pLN2 were performed with no 
difference in the outcome (not shown) Ex vivo cells were isolated as described above, then non-adherent 
cells were gently washed away after overnight culture and complete RPMI was added. BMDCs: They were 
activated with 0.5µg/ml LPS (Sigma) for 6h at 37°C. 2h after LPS addition 1µM SIINFEKL peptide was 
added. Activated BMDCs were harvested by adding PBS containing 2mM EDTA and gentle pipetting. 
After washing two times, cells were counted using trypan blue to exclude dead cells and 1x104 cells were 
added per 24-well. T cells: spleen and pLN were dissected from CO2-killed B6 and OT-I transgenic mice. 
The organs were suspended by passing them across a 40µm mesh. After washing, cells were re-suspended 
in red blood cell lysis buffer (Tris-Ammonium chloride based) for 30 seconds at room temperature and 
washed again. CD8 cells were enriched by panning on Petri dishes coated with antibodies against B220 
(3µg/ml; clone RA3-6B2), CD4 (2µg/ml; clone H129.19.6), CD11b (1µg/ml; clone M1/70) and CD11c 
(1µg/ml; clone N418). Cells were re-suspended in 5ml (10cm dish; surface 56cm2) or 10ml (15cm dish; 
surface 151cm2) in complete RPMI in a concentration of 1.5 – 2.5x106 cells per cm2 (=16.8 -28 x 106 
cells/ml). Panning was done two times for 30 min at 4°C. The OT-I cells and 50% of the B6 WT cells 
were labelled with 2µM CFSE (Invitrogen) and counted again. Per 24-well 0.04 x 106 CFSE+ OT-I cells 
together with 0.98 x 106 unlabelled B6 WT cells and 0.98 x 106 CFSE+ B6 WT cells were added. The assay 
was performed in complete RPMI enriched with 1x MEM (Invitrogen), 3ng/ml recombinant murine IL-7 
(Peprotech) and 10U/ml recombinant human IL-2 (Merck Serono). Cells were harvested by gently 
pipetting 2-4 days after start of co-culture. Cells were counted on an automated cell counter using trypan 
blue to exclude dead cells and analysed by flow cytometry. To better compare the decrease of T cell 
proliferation between experiments the attenuating effect by the stromal cells was defined as percentage of 
inhibition in divided OT-I T cell numbers relative to the ‘no stroma’ control: {1-(number of proliferated 
cells)stroma / (number of proliferated cells)no stroma}*100). Transwell assay: Stromal cells were seeded in the 
lower chamber, while T cells and DCs were cultured in the upper chamber of a 0.4µm transwell chamber 
(HTS 24-well, Vitaris). For blocking experiments the following reagents and concentrations were used: 
10µM indomethacin (Sigma), 1µM 1400W (= dihydrochloride; Sigma), 10µM 1-Methyl-L-tryptophan (1-
MT; Sigma), 200µM (S)-(2-Boronoethyl)-L-cysteine (BEC, Calbiochem), 10µg/ml anti-PD-L1 (MIH5, 
eBioscience), 20µg/ml anti-IL-10 (kind gift from F. Tacchini-Cottier, Lausanne, Switzerland) and 
30µg/ml anti-TGF (clone 1D11.16.8; BioXCell). 
4.10. T cell activation by anti-CD3 and anti-28 beads 
2500 stromal cells were seeded in 96-wells and after overnight culture irradiated with 1000rad. A total of 
2.5 x 105 T cells mixed with 1.25 x 105 anti-CD3/28 beads (Dynabeads, Invitrogen) were added on top. 
After 2-3 days of co-culture cells were harvested by gentle pipetting. Live cells were counted on an 
automated cell counter and analysed by flow cytometry.  
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4.11. T cell activation by TRC-conditioned BMDCs 
10000 pLN2 TRC lines were seeded per 24-well and after overnight culture LPS-activated and 
SIINFEKL-pulsed BMDCs (see T cell activation assay) were added in a ratio of 1:1. After overnight 
culture BMDCs were separated from stromal cells by magnetic cell sorting (MACS): Cells were stained 
with biotinylated anti-gp38- antibody (clone 8.1.1) and followed by magnetic-beads coupled streptavidin 
(Miltenyi) in MACS buffer (PBS containing 2% FCS and 2mM EDTA). Cells were separated using MS-
columns (Miltenyi) according to the manufactures instructions. For the T cell activation assay 2500 TRC 
conditioned DCs were co-cultured with 0.01 x 106 CFSE labelled OT-I cells mixed with 0.48 x 106 
unspecific WT T cells (of which 50% were CFSE labelled) per 96-well for 3 days (Ratios are the same as 
for the T cell activation assay described above). 
4.12. T cell activation in chamber slides 
Stromal cells were seeded a density of 3000 cells / well in 8-well chamber slides (Falcon). Co-culture 
experiments: After overnight culture 0.25 x 106 WT T cells and 0.125 x 106 anti-CD3/28 beads were 
added or 5000 CFSE-labelled OT-I T cells mixed with 0.245 x 106 WT T cells together with 5000 LPS-
activated and SIINFEKL-pulsed BMDCs (as described above) were added.  
4.13. In vi tro  cytotoxicity assay 
Target cells: The spleen was dissected from CO2-killed WT mice and meshed through a 40 µm-mesh. Red 
blood cells were removed by re-suspending the cells in red blood cell lysis buffer for 30 seconds at room 
temperature. Half of the cells were labelled with 0.16µM proliferation dye eFluor670 (eBioscience) 
(eFluor670low) and the other half with 0.5µM proliferation dye eFluor670 (eFluor670high). The 
eFluro670high population was pulsed with 1 µM SIINFEKL peptide for 1h at 37°C. Per 96-well 5 x 103 
eFluor670high and 5 x 103 eFluor670low cells were added. Effector cells: They were harvested from the T 
cell activation assay after 4 days of co-culture. Alternatively, they were isolated from homogenized spleen 
or pLN from VSV-infected mice. Effector cells were added to target cells in different ratios and 
incubated overnight. The ratio of target cells was analysed by flow cytometry, as were the input numbers 
of OT-I effector T cells allowing the calculation of the effective E/T ratio. Percentage specific lysis = {1-
(specific survival)sample/(specific survival)control}*100 with specific survival = eFluor670high/eFluorlow, 
(control: target cells only). 
4.14. Nitrite detection 
NO2- as read out for NO in cell culture supernatants was measured using the Griess assay. Briefly, 0.1% 
N-1-naphtylethylenediamine dihydrochloride (Sigma) was mixed with p-aminobenzensulfonamide 
(Sigma) in 5% phosphoric acid and 100µl of this mixture were incubated with 100µl cell culture 
supernatant. After 10min incubation at RT absorbance was measured at 550nm and background 
absorbance at 690nm was subtracted. The absorbance of complete RPMI was also subtracted. In each 
measurement a NO2- -standard series (100-0.1µM NaNO2; Sigma) was included to assess the absolute 
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NO2- concentration in the supernatant. Only values above 0.5µM were considered to be above 
background. pLN2 cells were free of mycoplasma that can contribute to NO2- production. 
4.15. Immunofluorescence microscopy 
Lymph nodes dissected from CO2-killed WT mice were fixed at 4°C in 4% (weight/vol) PFA and 
saturated for 3 h at 4°C in 30% (weight/vol) sucrose before being embedded in Tissue-Tek optimum 
cutting temperature compound (OCT, Sakura) followed by freezing in an ethanol dry ice bath. Cryostat 
sections (8µm thickness) collected on Superfrost/Plus glass slides (Fisher Scientific) were air-dried 
overnight. For cells cultured in chamber slides: chambers were removed according to the manufactures 
description. Then sections/cells were fixed for 10min in ice-cold acetone. After rehydration, sections 
were ‘quenched’ with 0.3% (vol/vol) H2O2, if tyramide amplification was used, then were blocked with 
0.1% (weight/vol) BSA and 1–4% (vol/vol) normal mouse and donkey serum, followed by treatment 
with a homemade streptavidin-biotin blocking kit. Immunofluorescence staining was done with 
antibodies (table 4.2.) diluted in PBS containing 0.1% (weight/vol) BSA and 1% (vol/vol) normal mouse 
serum. For gp38, primary antibodies were visualized with secondary antibodies coupled to horseradish 
peroxidase, followed by treatment with the Tyramide Signal Amplification Kit #22 (Molecular Probes) 
according to the manufacturer’s instructions, but with a borate buffer (0.1M boric acid (Applichem) in 
PBS, pH 8.5) for tyramide dilution.  Images were acquired with a Zeiss Axioplan microscope and treated 
with ImageJ (http://rsbweb.nih.gov/ij/) and Photoshop software (Adobe). 
Primary reagents 
Target Species Clone or 
designation 
Conjugate Supplier  
iNOS Rabbit Polyclonal purified Millipore 
gp38 Syrian 
hamster 
8.1.1 purified Hybridoma 
CD31 Rat GC-51 purified Hybridoma 
Alpha Smooth-muscle actin  Mouse 1A4 Cy3 Sigma 
Collagen I Goat  Purified Southern Biotech 
Desmin Rabbit Polyclonal Purified Progen 
Fibronectin Rabbit  Purified Sigma 
Laminin Rabbit Polyclonal Purified Progen 
Secondary reagents 
Rat IgG Donkey  APC Jackson 
Immunoresearch 
Rat IgG Donkey  Cy3 Jackson 
Immunoresearch 
Syrian Hamster IgG Goat  Biotin or Cy3 Jackson 
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Immunoresearch 
Rabbit IgG Donkey  Cy3 Jackson 
Immunoresearch 
Rabbit IgG Donkey  Alexa488 Molecular Probes 
Rabbit IgG Donkey  Alexa647 Molecular Probes 
Goat IgG Donkey  Alexa488 Molecular Probes 
Streptavidin   Alexa488 Molecular Probes 
Table 4.2: Primary and secondary reagents used for Immunofluorescence 
4.16. Transcript analysis 
RNA isolation (using Trizol, Invitrogen), reverse transcription and quantitative real-time PCR (using 
SYBR-Green and LightCycler, Roche Diagnostics) was performed as described previously (Link et al., 
2007), including the primers for amplification of Ccl19, Ccl21 and the two housekeeping genes 
Hypoxanthine guanine phosphoribosyl transferase 1 (Hprt 1) and TATA-binding protein (Tbp). Additional primers 
used: Inos-F: gttctcagcccaacaatacaaga, Inos-R: gtggacgggtcgatgtcac. Cox2-F: tggtgcctggtctgatgatg, Cox2-R:  
gtggtaaccgctcaggtgttg. Efficiency-corrected expression of Inos, Cox2, Ccl19 and Ccl21 was normalized by 
dividing with the geometric mean of expression of the two housekeeping genes. 
4.17. Statistical analysis 
A F-test was performed to determine whether equal or unequal variance in the t-test should be used. For 
the F-test p < 0.05 was considered as unequal variance. Statistical significance was determined with a 
student’s t-test 
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